Skin transplantation in a mouse model of naïve T-cell deficiency by Gumienny, Aleksandra Maria
 
 
 
 
 
 
SKIN TRANSPLANTATION IN A MOUSE MODEL 
OF NAÏVE T-CELL DEFICIENCY 
 
 
 
 
 
 
 
Inauguraldissertation 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
 
von 
 
 
 
Aleksandra Maria Gumienny 
aus Polen 
 
 
Basel, 2018 
Originaldokument	gespeichert	auf	dem	Dokumentenserver	der	Universität	Basel	edoc.unibas.ch
	Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät  
auf Antrag von 
 
Prof. Dr. Jean Pieters 
Prof. Dr. Antonius Rolink 
 
 
 
 
 
 
 
 
Basel, den 18.10.2016 
 
 
 
       Prof. Dr. Jörg Schibler
	 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my Father, who showed me how to be a GOOD person, which I hope I became. 
	 
 
  
	 
 
 
I seem to have been only like a boy playing on the seashore, (…) finding a smoother 
pebble or a prettier shell than ordinary, whilst the great ocean of truth lay all 
undiscovered before me.  
– Isaac Newton –  
	 	 	 	
	 7	
 
Acknowledgements 
 
Galileo once said: You cannot teach a man anything; you can only help him discover it in himself, 
therefore I would like to thank my mentors who guided me through my years of education. 
First of all I would like to thank the person without whom I would not be here – my Father, he showed 
me that even a dull Polish poem can teach you something as long as you keep asking question. 
I would like to express my special thanks to Beatrice Bolinger, the best ‘thing’ that happen to me 
during my PhD. I owe her everything I know, from designing the experiment to multicolour staining 
and analysis. Moreover, she became my great friend and support during the best time of my life – 
parenthood. 
I would like to express my deepest gratitude to Simona Rossi Girard who was always there for me 
when I needed an advice, Ed Palmer for cheering me up and keeping his fingers crossed, and Ton 
Rolink who joined my committee as a fresh air and new hopes. They were not only my scientific 
advisors but also shoulders on which I could stand on. I would also like to thank them for their time 
and effort put into reviewing this work. 
I am grateful to current and past members of Pieters’ Lab. Thank to Helene and Julie for the ‘mouse’ 
help, without it my work would be impossible. Thanks Michi, Adrien, Stefan, Samantha, Vera, 
Somdeb, Sebi for sharing with me their skills and knowledge, and for everyday company. Special 
thanks to Paula, Saumya and Francesco for making even my greyest days much funnier and becoming 
my best friends. Also, many thanks to Mathias for semi-scientific conversations and all the support in 
the lab. Special thank to Mathias Schmaler for teaching me the art of surgery. I would like to express 
my gratitude to Maja Güntensperger-Heckel for the great and hard job she makes on administrative site 
thereby making our life much easier. My work would be impossible without FACS Core Facility. 
Thus, I would like to thank Janine Zankl for endless patience in helping me with the experiments and 
questions.  
Last but not least I would like to thank my husband Rafał, for all his support and encouragement. 
Without him I would never reach this far. I am really thankful to my parents and brother who gave me 
all possible support I could think of. The same gratitude I have for my parents-, brothers-, and sister-in-
low.  
Thank you! 
	 8	
  
 	 	 	 	
	
Table of contents 
	
	 	
9	
 
Table of contents 
 
Acknowledgements ............................................................................................................ 7 
Table of contents ................................................................................................................ 9 
List of tables ..................................................................................................................... 12 
List of figures ................................................................................................................... 12 
Abbreviations ................................................................................................................... 17 
1 Summary ............................................................................................................................... 21 
2 Introduction .......................................................................................................................... 23 2.1	 Coronin	protein	family	....................................................................................................................	23	
2.1.1 Discovery, general features and function of Coronin 1 ....................................................... 25 
2.1.2 Coronin 1 and T lymphocytes .............................................................................................. 27 
2.1.3 Coronin 1 mutations effect in humans ................................................................................. 29 2.2	 Principles	of	immune	activation	.................................................................................................	31	
2.2.1 T cell development and activation ....................................................................................... 33 
2.2.2 T cell tolerance (central and peripheral tolerance) .............................................................. 35 2.3	 Transplantations	...............................................................................................................................	38	
2.3.1 Alloreactivity ....................................................................................................................... 39 
2.3.2 Major histocompatibility complexes ................................................................................... 40 
2.3.3 Allograft rejection ................................................................................................................ 42 
2.3.3.1 Hyperacute rejection .................................................................................................... 46 
2.3.3.2 Acute rejection ............................................................................................................. 46 
2.3.3.3 Chronic rejection .......................................................................................................... 47 
2.3.4 Therapy of allograft rejection .............................................................................................. 47 
2.3.5 Tolerance induction in transplantation – the role of CD4+CD25+Foxp3+ T cells ............. 48 2.4	 Survival	and	homeostasis	of	naïve	T	cells	..............................................................................	49	
3 Aim of the study ................................................................................................................... 53 
4 Results ................................................................................................................................... 55 4.1	 Skin	transplantation	models:	major	and	minor	mismatch	..............................................	55	
4.1.1 Rejection of major mismatched grafts in coronin 1-deficient recipients ............................. 56 
4.1.2 Survival of minor mismatched grafts in wild type and coronin 1-deficient mice ............... 60 
 	 	 	 	
	
Table of contents 
	
	 	
10	
4.2	 CD4+	T	cell-mediated	allograft	rejection	(MHC	class	II	mismatched	transplantations)	...........................................................................................................................................	63	4.3	 Analysis	of	differences	in	T	cell	numbers	between	wild	type	and	coronin	1-deficient	mice	and	their	influence	on	graft	rejection	....................................................................	66	4.4	 Study	of	T	cell	function	in	coronin	1-deficient	compared	to	wild	type	mice	...........	68	
4.4.1 Mixed lymphocyte reaction experiment in the study of proliferation of T cells ................. 68 
4.4.2 Proliferation and survival of wild type and coronin 1-deficient T cells upon allorecognition 
……….. ............................................................................................................................................. 69 
4.4.3 Survival of wild type and coronin 1-deficient T cells ......................................................... 72 
4.4.4 Analysis of concentration dependence in survival of coronin 1-deficient T cells in vitro .. 73 
4.4.5 Concentration dependence of the survival of coronin 1-deficient T cells in vivo ............... 74 
4.4.6 Characterization of cell proliferation in co-culture of coronin 1-deficient with wild type T 
cells ….. ............................................................................................................................................ 78 
4.4.7 Cytokine production by coronin 1-deficient and wild type T cells ..................................... 79 
4.4.8 Expression of specific markers by coronin 1-deficient T cells ............................................ 82 
4.4.9 Numbers of T cell subsets in coronin 1-deficient mice ....................................................... 86 4.5	 Analysis	of	tolerance	induction	after	skin	transplantation	in	coronin	1-deficient	recipients	..........................................................................................................................................................	89	
4.5.1 Regulatory T cells in coronin 1-deficient mice ................................................................... 89 
4.5.2 Tolerance maintenance after skin graft transplantation ....................................................... 90 
4.5.3 Induction of graft rejection in coronin 1-deficient recipients .............................................. 92 
4.5.4 Induction of rejection in immunodeficient recipients .......................................................... 93 
4.5.5 Analysis of graft rejection in CD25-depleted skin transplantation model ........................... 94 
4.5.6 In vitro induction of regulatory T cells from wild type and coronin 1-deficient cCD4+ T 
cells …. ............................................................................................................................................. 96 
4.5.7 In vivo regulatory T cells numbers after skin transplantation .............................................. 97 
4.5.8 Analysis of the suppression capacity of coronin 1-deficient and wild type regulatory T cells 
in vitro   ........................................................................................................................................... 101 
4.5.9 Proliferation of CD4+ T cells in the absence of CD4+CD25+ T cells .............................. 101 
4.5.10 Analysis of suppressive abilities of conventional coronin 1-deficient CD4+ T cells ........ 102 
5 Discussion ............................................................................................................................ 107 5.1	 Is	the	delayed	rejection	due	to	the	lower	number	of	T	cells	in	the	coronin	1-	deficient	mice?	..............................................................................................................................................	108	5.2	 Are	coronin	1-deficient	T	cells	impaired	in	their	functionality?	.................................	109	5.3	 Is	the	prolonged	acceptance	of	the	graft	due	to	induction	of	tolerance	in	coronin	1-deficient	recipients?	..............................................................................................................................	113	5.4	 Conclusions	........................................................................................................................................	115	
 	 	 	 	
	
Table of contents 
	
	 	
11	
6 Materials and Methods ...................................................................................................... 117 6.1	 Buffers	and	media	...........................................................................................................................	117	6.2	 Antibody	list	......................................................................................................................................	118	6.3	 Mouse	lines	........................................................................................................................................	120	6.4	 Transplantation	procedure	and	graft	scoring	.....................................................................	121	
6.4.1 Rejection score ................................................................................................................... 122 6.5	 Organ	harvesting	and	processing	for	analysis	....................................................................	122	6.6	 FACS	staining	of	cells	.....................................................................................................................	123	6.7	 Cell	enrichment	procedure	(total	T	cells,	CD4+,	CD8+	T	cells)	....................................	124	6.8	 Cell	sorting	by	FACS	sorter	for	CD25-	and	CD25+CD4+	T	cells	...................................	124	6.9	 Adoptive	transfer	of	cells	into	mouse	recipients	...............................................................	125	6.10	 Blood	test	............................................................................................................................................	125	6.11	 CD25-depletion	................................................................................................................................	125	6.12	 CD25	(PC61)	monoclonal	antibody	production	from	hybridoma	cells	...................	126	6.13	 CD25	(PC61)	antibody	purification	from	culture	supernatant	...................................	126	6.14	 Dendritic	cells	differentiation	and	culture	...........................................................................	127	6.15	 Plate	coating	and	stimulation	with	antibodies	...................................................................	128	6.16	 Cell	Trace	Violet	(CTV)	labeling	................................................................................................	128	6.17	 Proliferation	assay	..........................................................................................................................	129	6.18	 In	vitro	cytokine	analysis	.............................................................................................................	130	6.19	 In	vitro	generation	of	regulatory	T	cells	from	CD4+CD25-	T	cells	.............................	130	6.20	 Mixed	lymphocyte	reaction	(MLR)	..........................................................................................	131	6.21	 In	vitro	suppression	assays	.........................................................................................................	132	6.22	 In	vivo	suppression	assay	.............................................................................................................	132	6.23	 Statistical	analysis	...........................................................................................................................	132	6.24	 Software	used	....................................................................................................................................	133	
7 Appendix ............................................................................................................................. 135 7.1	 Supplementary	Figures	.................................................................................................................	135	7.2	 Contribution	...........................................................................	Error!	Bookmark	not	defined.	7.3	 Bibliography	......................................................................................................................................	146	7.4	 Curriculum	Vitae	..............................................................................................................................	162	
 
 	 	 	 	
	
List of tables and figures 
	
	 	
12	
List of tables 
Table 1. Mammalian coronin isoforms. ............................................................................. 23	
Table 2. Summary comparison of cytokine (IFN-gamma, TNF-alpha, IL-2) and LAMP-1 
production in BL/6 wild type and Cor1-/- mice after stimulation with dendritic cells 
(DC), CD3/CD28 or PMA/I over time. ..................................................................... 81	
Table 3. Summary of cell markers expression. .................................................................. 85	
Table 4.  Antibody list. ..................................................................................................... 120	
 
List of figures 
Figure 1. Structure of coronins. ......................................................................................... 24	
Figure 2. Model of mycobacterial entry into macrophage and coronin 1 function. .......... 26	
Figure 3. The impaired survival of coronin 1-deficient T cells in the periphery.. ............. 29	
Figure 4. Innate and adaptive immune responses.. ........................................................... 33	
Figure 5. Immune activation and tolerance induction by dendritic cells. ......................... 37	
Figure 6. Conventional recognition and models of allorecognition of allogeneic-MHC 
complexes by T cells. ................................................................................................. 40	
Figure 7. Panel A. Different mechanisms of graft rejection process. Panel B. Major and 
minor mismatch model. .............................................................................................. 45	
Figure 8. CD4+ and CD8+ T cell role in graft survival. .................................................. 46	
Figure 9. Homeostatic maintenance of naïve T cells. ........................................................ 51	
Figure 10. Rejection score (A) and skin graft survival (B) in BL/6 wild type and coronin 1-
deficient recipients of Balb/c tail skin grafts. ............................................................ 56	
Figure 11. Immune cells in lymph nodes of BL/6 wild type and coronin 1-deficient 
recipients of Balb/c skin grafts. ................................................................................. 58	
Figure 12. Immune cells in spleen of BL/6 wild type and coronin 1-deficient mice 
transplanted with Balb/c tail skin (major mismatch) or mock controls. ................... 59	
Figure 13. A – B. Rejection score (A) and skin graft survival (B) in BL/6 wild type or 
coronin 1-deficient recipients of 6.25% Balb/c in BL/6 tail skin grafts (minor 
mismatch). .................................................................................................................. 61	
 	 	 	 	
	
List of tables and figures 
	
	 	
13	
Figure 14. Rejection score (A) and graft survival (B) in BL/6 wild type and coronin 1-
deficient recipients of bm12Rag2-/- tail skin. ............................................................ 63	
Figure 15. CD4+ T cells in lymph nodes of BL/6 wild type and coronin 1-deficient mice 
with and without bm12Rag2-/- skin grafts. ............................................................... 64	
Figure 16. Graft survival after CD8+ T cells-dependent (bm1) skin transplantations. .... 65	
Figure 17. Survival of bm12Rag2-/- skin grafts in Rag2-/- recipients after transfer of BL/6 
wild type and coronin 1-deficient CD4+ T lymphocytes. .......................................... 67	
Figure 18. Mixed lymphocyte reaction (MLR) experiments with major mismatch antigens 
(Balb/c) for total (A), CD4+ (B) and CD8+ (C) T cells from BL/6 wild type or 
coronin 1-deficient mice. ........................................................................................... 69	
Figure 19. CD4+ T cells proliferation analysis in a mixed lymphocyte reaction (MLR) for 
total T cells from BL/6 wild type and coronin 1-deficient mice as responders and 
different concentrations of Balb/c splenocytes as stimulators. ................................. 71	
Figure 20. Survival of CD4+ (A-D) and CD8+ (E-H) T cells in vitro without (A and E) or 
with stimulation with anti-CD3 and anti-CD28 (B and F), PMA and ionomycin (C 
and G), or dendritic cells (D and H). ........................................................................ 72	
Figure 21. CD4+ T cells proliferation analysis in a mixed lymphocyte reaction (MLR) for 
total T cells from BL/6 wild type and coronin 1-deficient mice as responders and 
different concentrations of Balb/c splenocytes as stimulators. ................................. 74	
Figure 22. Survival of CD4+ T cells from BL/6 wild type and coronin 1-deficient mice 
after adoptive transfer into tail vein of Rag2-/- mice. ............................................... 77	
Figure 23. Co-culture of BL/6 wild type and coronin 1-deficient T cells after stimulation 
with either MHC mismatched splenocytes (A) or autologous dendritic cells, anti-
CD3 and anti-CD28, and PMA/I (B). ........................................................................ 79	
Figure 24. Different T cells subsets in BL/6 wild type compared with coronin 1-deficient 
mice. ........................................................................................................................... 87	
Figure 25. Percentage (A) and numbers (B) of different T cells subsets in the thymus of 
BL/6 wt and Cor1-/- mice. ......................................................................................... 88	
Figure 26. Frequencies and numbers of regulatory T cells (Tregs) in naïve (A) and mice 
transplanted with bm12Rag2-/- skin (B). .................................................................. 90	
Figure 27. Adoptive transfer of BL/6 wt CD4+ T cells into Cor1-/- mice transplanted with 
bm12Rag2-/- skin. ...................................................................................................... 92	
 	 	 	 	
	
List of tables and figures 
	
	 	
14	
Figure 28. Adoptive transfer of ABM cells into Cor1-/- mice transplanted with bm12Rag2-
/- skin. ........................................................................................................................ 93	
Figure 29. Transfer of BL/6 wild type and coronin 1-deficient CD4+ T cells into Rag2-/- 
mice transplanted with bm12Rag2-/- skin and additional challenge with ABM cells.
 ................................................................................................................................... 94	
Figure 30. Rejection score (A) and graft survival (B) after transplantation of bm12 Rag2-
/- skin grafts onto BL/6 wild type and Cor1-/- mice depleted or not of CD25+ cells.
 ................................................................................................................................... 95	
Figure 31. In vitro generation of Tregs from CD25- CD4+ T cells. ................................. 97	
Figure 32. Regulatory T cells generation after skin transplantation in bm12Rag2-/- 
recipients. .................................................................................................................. 99	
Figure 33. Mock skin transplantations (BL/6 wild type onto BL/6 wild type and Cor1-/- 
onto Cor1-/-) and cell quantities 3, 5 and 7 days after surgeries. .......................... 100	
Figure 34. In vitro (A and B) and in vivo (C and D) competition assay of conventional 
CD4+ T cells (CD4+CD25-) from BL/6 wt and Cor1-/- mice. ............................... 105 
Figure 35. Scoring for the health and rejection of skin grafts after the transplantation.. 122 
Figure 36. Test of dendritic cell culture obtained from bone marrow of BL/6 wild type 
mice after one-week culture in the presence of GM-CSF (10ng/ml). ...................... 128		
Supplementary Fig. 1. Major histocompatibility complexes (MHC) staining for 6.25% 
Balb/c in BL/6 mice.. ............................................................................................... 135	
Supplementary Fig. 2. Analysis of CD8+ T cells in a mixed lymphocyte reaction (MLR) 
for total T cells from BL/6 wild type and coronin 1-deficient mice as responders and 
Balb/c splenocytes as stimulators (plated in different concentrations). .................. 136	
Supplementary Fig. 3. Analysis of CD8+ T cells in a mixed lymphocyte reaction (MLR) 
for total T cells from BL/6 wild type and coronin 1-deficient mice as responders and 
Balb/c splenocytes as stimulators (plated in different concentrations). .................. 137	
Supplementary Fig. 4. CD8+ T cells from BL/6 wild type and coronin 1-deficient mice 
analyzed for cytokine secretion in a culture without (medium) and with stimulation 
with dendritic cells (DC), anti-CD3 and anti-CD28 (CD3/CD28), and PMA and 
ionomycin (PMA/I).. ................................................................................................ 138	
 	 	 	 	
	
List of tables and figures 
	
	 	
15	
Supplementary Fig. 5. CD4+ T cells from BL/6 wild type and coronin 1-deficient mice 
analyzed for cytokine secretion in a culture without (medium) and with stimulation 
with dendritic cells (DC), anti-CD3 and anti-CD28 (CD3/CD28), and PMA and 
ionomycin (PMA/I). ................................................................................................. 139	
Supplementary Fig. 6. Expression of different cell markers in BL/6 wild type compared to 
coronin 1-deficient T cells from spleens.. ................................................................ 140	
Supplementary Fig. 7. Expression of different cell markers in BL/6 wild type compared to 
coronin 1-deficient T cells from lymph nodes.. ....................................................... 141	
Supplementary Fig. 8. Expression of different cell markers in BL/6 wild type compared to 
coronin 1-deficient T cells from thymus.. ................................................................ 142	
Supplementary Fig. 9. CD4+Foxp3+CD25+ (regulatory T) cells in blood of BL/6 wild 
type and Cor1-/- recipients of bm12Rag2-/- skin treated or not with PC61 antibody 
(CD25 depletion). .................................................................................................... 143	
Supplementary Fig. 10. Regulatory T cells studies. A. Suppression assay comparing Tregs 
from BL/6 wt and Cor1-/- mice.. .............................................................................. 144		
 
 	 	 	 	
	
List of tables and figures 
	
	 	
16	
 	 	 	 	
	
Abbreviations 
	
	 	
17	
Abbreviations 
 
Ab Antibody 
ABM Antigen-specific CD4+ T cells towards the I-Abm12 
ACK Ammonium-Chloride-Potassium 
ADCC Antibody-dependent cell-mediated cytotoxicity 
Ag Antigen 
AICD Activation-induced cell death 
APC Allophycocyanin 
APC Antigen-presenting cell 
Bcl-2 B cell lymphoma 2 
BL/6 or B6 C57BL/6 mouse 
BrdU 5-bromo-2’-deoxyuridine 
Ca2+ Calcium ions 
CC Coiled-coil 
CCR7 C-C chemokine receptor type 7 
CD Cluster of differentiation 
cCD4 Conventional CD4+ T cells 
CD40L CD40 ligand 
CD62L CD62 L-selectin 
CICD Cytokine-induced cell death 
Cor1-/- Coronin 1-deficient mouse 
CRAC Calcium release activated channel 
CTL Cytotoxic T lymphocytes 
CTLA-4 	 Cytotoxic T-lymphocyte antigen 4	
CTV Cell trace violet 
DC Dendritic cells 
DMSO Dimethyl sulfoxide 
DN Double negative 
DNA Deoxyribonucleic acid 
DP Double positive 
 	 	 	 	
	
Abbreviations 
	
	 	
18	
EAE Experimental autoimmune encephalomyelitis 
EBV Epstein-Barr Virus 
EC Endothelial cell 
EDTA Ethylenediaminetetraacetic acid 
ER Endoplasmic reticulum 
EtOH Ethanol 
FACS Fluorescence-activated cell sorting 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanat 
Foxp3 Forkhead box protein 3 
GM-CSF Granulocyte macrophage colony-stimulating factor 
IFN Interferon 
ICAM Intercellular adhesion molecule 
Ig Immunoglobulin 
IL Interleukin 
IP3 Inositol-1,4,5-triphosphate 
IP3R Inositol-1,4,5-triphosphate receptor 
kDa Kilodalton 
Lamp-1 Lysosomal associated membrane protein 1 (CD107a) 
LCMV Lymphocytic Choriomeningitis Virus 
LEAF Low Endotoxin, Azide-Free 
LFA-1 Lymphocyte-function-associated antigen 1 
LN Lymph node 
mAB Monoclonal antibody 
Mac-1 Macrophage-1 antigen (αMβ2 integrin) 
MHC Major histocompatibility complex 
MLR Mixed lymphocyte reaction 
mTECs Medullary thymic epithelial cells 
Na-Py Sodium Pyruvate 
NEAA Non-essential Amino Acid Solution 
NFAT Nuclear factor of activated T cells 
 	 	 	 	
	
Abbreviations 
	
	 	
19	
NK Natural Killer cells 
OD Optical density 
PBS Phosphate buffer saline 
PD-1 Programmed cell death protein 1 
PE Phycoerithrin  
PE/Cy7 Phycoerithrin/Cyanine 7 
PerCp Peridinin Chlorophyll protein 
PerCp/Cy5.5 Peridinin Chlorophyll/Cyanine 5.5 
PLCγ1 Phospholipase Cγ1 
PMA/I Phorbol-12-myristate-13-acetate and Ionomycin stimulation 
Rag2 Recombinase-2 gene 
RPMI Roswell Park Memorial Institute 
RTE Recent thymic emigrants 
SCID Severe combined immunodeficiency 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SDS-PAGE  Sodium dodecyl sulfate - polyacrylamide gel electrophoresis 
SF-IMDM Serum-Free Iscove's Modified Dulbecco's Medium 
SNP Single-nucleotide polymorphism 
SP Single positive 
SPF Specific pathogen free 
STIM1 Stromal interaction molecule 1 
TACO Tryptophan-Aspartate containing coat protein 
TCR T-cell receptor 
TGF-β Transforming growth factor beta 
TH T helper cell 
TNF Tumor necrosis factor 
TNFR Tumor necrosis factor receptor 
Treg Regulatory T cell 
TSAs Tissue specific antigens 
UD Unique domain 
 	 	 	 	
	
Abbreviations 
	
	 	
20	
WD Tryptophan/aspartate 
Wt Wild type 
VCAM-1 Vascular cell adhesion molecule 1 
VLA-4 Very late antigen 4 (α4-integrin) 
VSV Vesicular stomatitis virus 
 	 	 	 	
	
Summary 
	
	 	
21	
	
1 Summary 
 
Coronin 1 is one of seven mammalian coronin family members that is preferentially 
expressed in hematopoietic cells and brain tissue (Ferrari et al. 1999; Jayachandran et al. 
2014). It was initially discovered in macrophages where it is involved in Mycobacterium 
tuberculosis pathogenesis and survival (Ferrari et al. 1999). Interestingly, analysis of 
coronin 1-deficient mice showed a drastic reduction in the numbers of T cells in the 
periphery (Föger et al. 2006; Shiow et al. 2008; Haraldsson et al. 2008; Mueller et al. 
2008). However, segregation and development of T cells in the thymus showed no 
significant changes when compared with wild type mice (Mueller et al. 2008). Recent 
data demonstrate that despite the paucity in naïve T cells, coronin 1-deficient mice are 
resistant to infections but fail to induce autoimmune diseases (Tchang et al. 2013; 
Haraldsson et al. 2008; Shiow et al. 2008; Siegmund et al. 2011). The physiological 
relevance of coronin 1 deficiency in allorejection is yet to be discovered, however, the 
importance of T cells in this process suggests a critical role for coronin 1. When organs 
are transplanted between members of the same species, an immune response to such a 
graft develops alloreactivity. It consists of the same mechanism as an immune response 
for defense against pathogens but it is mediated against differences in major 
histocompatibility complexes (MHC) class I and II molecules between the host and the 
donor (Goldsby et al. 2002).  
The goal of my project was to dissect the ability of coronin 1-deficient T cells to 
recognize foreign MHC complexes and to reject the allograft. I focused on finding the 
mechanisms that allow coronin 1-deficent mice to keep the graft while at the same time 
drive the immunity against infection. To this end, I combined skin transplantation 
experiments with in-depth in vitro analysis. 
Interestingly, we found prolonged survival of Balb/c skin transplanted onto coronin 1-
deficient BL/6 recipients. Further investigations showed tolerance induction in a minor 
mismatch setting where BL/6 skin presenting minor histocompatibility antigens from 
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Balb/c were transplanted onto coronin 1-deficient mice. This could be the outcome of 
reduced frequency and/or impaired activation of T cells in the absence of coronin 1. 
However, despite increasing coronin 1-deficient CD4+ T cells numbers, we could not 
induce rejection in Rag2-/- mice transplanted with bm12Rag2-/- skin. Although the 
retained lower counts of CD4+ T cells could indicate a defect in proliferation or antigen 
recognition after skin transplantation, further in vitro experiments suggested that coronin 
1-deficient T cells were able to recognize antigen through the T cell receptor (TCR) and 
respond, could become activated and could proliferate. Furthermore, cytokines and cell 
markers analysis suggest that coronin 1-deficient T cells were under the stress of high 
activation (IFNγhi, CD5hi, IL-7Rlo) and intense proliferation (Ki-67hi) that could cause 
exhaustion (PD-1hi) and consequently lead to their death (FasL). As the same markers 
were not changed in the thymus of coronin 1-deficient mice and the mice could produce 
recent thymic emigrants this can provide insight into the time point at which coronin 1 is 
essential for T cells’ survival. In-depth analysis of T cells in vitro and in vivo confirmed 
the different impact of coronin 1-deficiency in CD8+ and CD4+ T cells, as the prolonged 
graft survival resembled the depletion of CD4+ T cells in skin transplantation model 
(Goldsby et al. 2002). In a CD4+ T cell-dependent model, where bm12Rag2-/- skin was 
transplanted onto coronin 1-deficient mice, we observed acceptance of the graft. What is 
more, the bm1 (CD8-dependent) skin was rejected in coronin 1-deficient recipients upon 
transplantation. This absence or delay in rejection in coronin 1-deficient mice caused by 
induction of tolerance may be due to elevated rate of regulatory T cells (Tregs), the 
suppressive abilities of conventional CD4+ T cells or combination of these. Finding 
increased frequencies of Tregs in the coronin 1-deficient mice, compared to wild type 
mice, supported this statement. In-depth analysis of regulatory T cells in coronin 1-
deficient mice showed no difference in suppressive abilities compared with wild type 
cells. Moreover, we demonstrated that the cells did not generate or proliferate better in 
coronin 1-deficient mice. Nevertheless, their superior survival over conventional coronin 
1-deficient CD4+ T cells in vitro could explain their higher frequencies and could be 
linked to enhanced expression of PD-1. This, in turn, promotes apoptosis in antigen-
specific T cells while increasing survival of Tregs (Francisco, Sage, and Sharpe 2010). 
Overall, the data suggests a critical role of coronin 1 in T cell-mediated allograft rejection. 
However, its precise function and mechanistic details are subject for further study. 
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2 Introduction 
 
2.1  Coronin protein family 
Coronins constitute an evolutionary conserved family of proteins widely expressed from 
yeast to human (Eckert, Hammesfahr, and Kollmar 2011; Jean Pieters, Müller, and 
Jayachandran 2013). Lower eukaryotes, such as yeast Saccharomyces cerevisiae and 
Dictyostelium discoideum, have only single coronin gene, called Crn and Coronin A 
(Clemen, Rybakin, and Eichinger 2008), respectively, while mammalian cells can co-
express several coronin molecules. Seven coronin isoforms have been identified in 
mammalians so far (Jean Pieters, Müller, and Jayachandran 2013; Okumura et al. 1998). 
Interestingly, gene expression suggests that most of the mammalian coronins are 
expressed in immune cells and the nervous system (Jean Pieters, Müller, and 
Jayachandran 2013).  
Coronin Alternative names Expression Chromosomal localization Protein length Human Mice Human Mice 
Coronin 1 
CORO1A, p57, 
TACO, CLIPINA, 
CRN 4, CLABP 
Immune cells, 
neurons 16p11.2 7F3 461 461 
Coronin 2 CORO1B, Coroninse, p66, CRN1 
Immune cells, 
neurons 11q13.2 19A 489 484 
Coronin 3 CORO1C, HCRNN4, CRN2 Ubiquitous 12q24.1 5F 474 474 
Coronin 4 
CORO2A, IR10, 
CLIPINB, WDR2, 
CRN5 
Brain 9q22.3 4B1 525 524 
Coronin 5 CORO2B, CLIPINC, CRN6 Brain 15q23 9B 480 480 
Coronin 6 CLIPONE Ubiquitous 17q11.2 11B5 472 471 
Coronin 7 POD1, p70 Immune cells, brain, fibroblasts 16p13.3 16A1 925 922 
Table 1. Mammalian coronin isoforms. Table presents alternative names, expression, localization in the 
chromosome and protein length of different mammalian coronin isoforms [adapted from (Jean Pieters, 
Müller, and Jayachandran 2013)]. 
The coronin protein structure is characterized by an amino-terminal tryptophan/aspartate 
(WD) repeat-containing domain followed by a unique region of variable length connected 
 	 	 	 	
	
Introduction 
	
	 	
24	
to a coiled-coil (CC) carboxy-terminal domain, which is essential for oligomerization (de 
Hostos 1999; John Gatfield et al. 2005). The mammalian coronin family can be divided 
into two groups based on their structure (Fig. 1). Coronin 1 to coronin 6, coronin of D. 
discoideum and S. cerevisiae share the classical coronin structure described above 
(Kammerer et al. 2005). Coronin 7 presents a tandem repetition of the core WD-repeats 
region and lacks the coiled-coil domain (Rybakin et al. 2004; Yuan et al. 2014). 
Biophysical analysis of the coronin 1 C-terminal domain demonstrated that this protein 
forms a trimeric structure (Kammerer et al. 2005; Appleton, Wu, and Wiesmann 2006). 
Although coronin proteins lack a transmembrane domain, many of them co-localize with 
membranes possibly through their interaction with cholesterol and the cytoskeleton (John 
Gatfield et al. 2005; J. Gatfield and Pieters 2000).  
 
Figure 1. Structure of coronins. Classical structure of coronin proteins is shared by coronin 1 to coronin 
6, CorA from D. discoideum and Crn of S. cerevisiae. Coronin 7, POD1 and p70 consist of tandem repeats 
of WD fragment and lack the coiled coil region. WD Repeats – tryptophan/aspartate repeats; UD – unique 
domain; CC – coiled coil domain [adapted from (Jean Pieters, Müller, and Jayachandran 2013)].  
Coronin A, the first identified member of the coronin protein family in D. discoideum 
(Eckert, Hammesfahr, and Kollmar 2011; Jean Pieters, Müller, and Jayachandran 2013), 
was shown to co-precipitate with actin-myosin complexes (de Hostos et al. 1991). 
Deletion of this protein in D. discoideum manifests defects in motility, phagocytosis and 
chemotaxis of a slime mold (de Hostos et al. 1993; Gerisch et al. 1995). In addition, 
recently coronin A has been identified to be involved in cAMP signaling, sensing and 
development (Vinet et al. 2014). In mammals coronin 1, 2, 4 and 7 have been associated 
with F-actin (John Gatfield et al. 2005; W. Huang et al. 2011; Cai, Makhov, and Bear 
2007). Moreover, the interaction between coronin and actin also occurs in invertebrates 
and yeasts (John Gatfield et al. 2005; W. Huang et al. 2011; de Hostos et al. 1993; Galkin 
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et al. 2008). Together, it would suggest that coronins have evolved from a family of actin 
binding proteins in lower eukaryotes to regulators of physiological processes in mammals. 
Recent studies have shown an involvement of coronins in the development of several 
diseases including T cells immunodeficiency, development of invasive cancer and the 
resistance to autoimmunity (Haraldsson et al. 2008, 3; Shiow et al. 2009; Moshous et al. 
2013). 
 
2.1.1 Discovery, general features and function of Coronin 1 
Mammalian coronin 1 is the best-studied coronin, both in terms of structure and function. 
This protein is highly expressed in cells of hematopoietic origin, such as leukocytes 
(Ferrari et al. 1999; Jean Pieters 2008a) as well as in certain neural cell types 
(Jayachandran et al. 2014). Coronin 1 was initially discovered in macrophages where it 
prevents the intracellular degradation of Mycobacterium tuberculosis (Ferrari et al. 1999) 
which was linked to the ability of coronin 1 to activate the Ca2+/calcineurin pathway 
(Jayachandran et al. 2007). M. tuberculosis is the causing pathogen of tuberculosis 
disease, and is able to evade the host’s immune response through manipulating the 
phagosomes in which it resides. Macrophages, normally, represent the first barrier of the 
innate immune system by killing pathogens upon entry into the host (Jean Pieters 2008b). 
After internalization by macrophages, M. tuberculosis prevents maturation of phagosomes 
and its fusion with the lysosome (Armstrong and Hart 1975; D. G. Russell 2001). In doing 
so, M. tuberculosis induces favorable environment for its survival (Hasan et al. 1997). 
Interestingly, this ability is only found in live bacilli (Jean Pieters 2008b). To understand 
how mycobacteria prevent lysosomal delivery mechanistic level phagosomes containing 
live bacteria were isolated and a 51kDa protein was identified as being involved. The 
protein was termed Tryptophan-Aspartate containing coat protein (TACO) (Hasan et al. 
1997; Ferrari et al. 1999). After discovery of several homologues proteins, which were all 
related to the coronin family, also present in D. discoideum and S. cerevisiae, TACO is 
now referred to as a coronin 1. Several studies have implicated that coronin 1 is essential 
for intracellular survival of not only mycobacteria but also Mycobacterium leprea and 
Helicobacter pyroli in macrophages (Ferrari et al. 1999; Seto, Tsujimura, and Koide 
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2012; Montoya and Modlin 2010; Zheng and Jones 2003). The mechanism that enables 
coronin 1 to modulate mycobacterial survival is connected with calcium signaling 
following their entry into macrophages. Mycobacterial uptake is associated with transient 
increase of intracellular calcium levels, which activates the calcium-dependent 
phosphatase calcineurin (Jayachandran et al. 2007). It was shown that a depletion of 
intracellular calcium ions (by chelating agents) phenocopies coronin 1 deficiency leading 
to clearing of mycobacteria. Simultaneously, an increase of intracellular calcium ions in 
coronin 1-deficient macrophages results in survival of mycobacteria (Jayachandran et al. 
2007). Therefore, mycobacterial survival within macrophages is tightly linked to the 
coronin 1-dependent activation of the calcineurin pathway. 
	
Figure 2. Model of mycobacterial entry into macrophage and coronin 1 function. Upon mycobacterial 
entry into macrophage coronin 1 is recruited to the phagosomes containing M. tuberculosis. That leads to 
the activation of the calcium-dependent phosphatase calcineurin. Calcineurin blocks phagosome-lysosome 
fusion therefore allowing M. tuberculosis to survive. ER – endoplasmic reticulum [adapted from (Jean 
Pieters, Müller, and Jayachandran 2013)]. 
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2.1.2 Coronin 1 and T lymphocytes 
To understand the role of coronin 1 in vivo, a mouse line in which coronin 1 was deleted 
by homologous recombination was established. The analysis of these mice revealed that 
coronin 1 is essential for T cell homeostasis (Föger et al. 2006; Shiow et al. 2008; 
Haraldsson et al. 2008; Mueller et al. 2008) as it is involved in the generation of the 
second messenger inositol-1,4,5-triphosphate (IP3) after TCR activation (Jayachandran et 
al. 2007; Föger et al. 2006; Mueller et al. 2008). Thus, in the absence of coronin 1, 
intracellular Ca2+ release is impaired leading to defective activation of Ca2+-dependent 
phosphatase calcineurin (Winslow et al. 2006; Oh-hora and Rao 2008). As a result, the 
Ca2+-dependent phosphatase calcineurin fails to dephosphorylate the transcription factor 
NFAT and as a result there is defective expression of pro-survival genes. Thus coronin 1 
plays a crucial role in naïve T cells survival. That would explain the deletion of naïve T 
cells from the periphery in mice lacking coronin 1, which is the most striking phenotype 
of this mouse line. As an alternative explanation, defective F-actin dynamics in the 
absence of coronin 1 has been suggested to result in T cell death (Föger et al. 2006). 
However, more recent work has failed to find a correlation between increased phalloidin 
staining and naïve T cell survival, which indicates that changes in the levels of F-actin 
might not necessarily correlate with survival defects in T cells (Jean Pieters, Müller, and 
Jayachandran 2013; Shiow et al. 2008; Mueller, Liu, and Pieters 2011; Haraldsson et al. 
2008). Furthermore, coronin 1 mutation in human is also associated with severe 
peripheral T cell depletion (Moshous et al. 2013; Shiow et al. 2009; Shiow et al. 2008; 
Stray-Pedersen et al. 2014; Yee et al. 2016). Coronin 1-deficient mice have mainly 
depleted naïve T cells while the effector and memory T cells are less affected both in 
numbers and functionality (Föger et al. 2006; Mueller et al. 2008). That is why, the main 
fraction of residual T cells in these mice are central memory T cells characterized by high 
expression of CD44 and low expression of CD62L (Mueller et al. 2008; Mueller, Liu, and 
Pieters 2011; Mugnier et al. 2008). Findings that coronin 1 modulates downstream of the 
TCR signal transduction cascade is consistent with studies showing that T cell 
homeostasis and survival are tightly linked to the capacity of these cells to receive a tonic 
TCR stimulus. Additionally, coronin 1-deficient naïve T cells express more caspase 3 and 
have higher levels of cleaved caspase 3 product, and lower levels of the anti-apoptotic 
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molecule B cell lymphoma 2 (Bcl-2) (Mueller, Liu, and Pieters 2011). Thereby, coronin 1 
deficiency imitates the absence of TCR or MHC molecules in the periphery suggesting an 
essential role for this protein in tonic TCR stimulation (Surh and Sprent 2008; Polic et al. 
2001; Labrecque et al. 2001). What is more, thymic selection and cellularity is normal in 
the absence of coronin 1 (Mueller et al. 2008). Also, coronin 1-deficient mice show 
normal antigen processing and presentation by dendritic cells (Westritschnig et al. 2013), 
and the neutrophil population is fully functional (Moshous et al. 2013; Siegmund et al. 
2013; Combaluzier and Pieters 2009). Other immune cell types, such as B cells, 
macrophages, mast cells, and NK cells, that also express coronin 1, appear not to be 
affected by the deletion of coronin 1 (Combaluzier et al. 2009; Westritschnig et al. 2013). 
Interestingly, when coronin 1-deficient mice were infected with Lymphocytic 
Choriomeningitis Virus (LCMV), the CD8+ T cell response was relatively normal 
compared to wild type controls, and led to the clearance of the virus (Tchang et al. 2013). 
Simultaneously, after infection with Vesicular Stomatitis Virus (VSV) where the CD4+ T 
cells play crucial role, their response was impaired and mice were not protected from the 
virus (Tchang et al. 2013). These findings indicate that coronin 1 deficiency has a 
different impact on CD4+ and CD8+ T cell. Furthermore, these mice age normally and 
are not more susceptible to tumor development or infections despite their depletion in T 
cells (unpublished observations). Despite a relatively normal immune response against 
bacterial and viral antigens, mice deficient in coronin 1 are not susceptible to 
experimental autoimmune encephalomyelitis (EAE) (Siegmund et al. 2011) and protected 
against systemic lupus erythematosus (Haraldsson et al. 2008). Recent studies, using T 
cells-specific coronin 1 knockout mouse model, confirmed an intrinsic role of coronin 1 
in T cell function, as the phenotype observed in this study resembled whole-body coronin 
1 knockout mice (Siegmund et al. 2016). Although coronin 1 is expressed in all immune 
cells, its deficiency leads to specific kind of severe combined immunodeficiency (SCID), 
which is characterized by naïve T cells depletion and the ability to resist to specific 
infection while at the same time resistance to autoimmune diseases. 
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Figure 3. The impaired survival of coronin 1-deficient T cells in the periphery. The deletion of coronin 1 
in mice causes defective calcium mobilization downstream of T cell receptor (TCR) upon stimulation with 
peptide-MHC complexes. This impaired calcium signaling blocks activation of calcineurin, which in the end 
results in disturbed expression of pro-survival genes. CRAC – calcium release activated channel; ER – 
endoplasmic reticulum; IP3 – inositol-1,4,5-triphosphate; IP3R – IP3 receptor; NFAT – nuclear factor of 
activated T cells; PLCγ1 – phospholipase Cγ1; STIM1 – stromal interaction molecule 1 [adapted from (Jean 
Pieters, Müller, and Jayachandran 2013)]. 
 
2.1.3 Coronin 1 mutations effect in humans 
Similarly to murine immune system, coronin 1 plays an important role in humans. So far, 
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while B cells and NK cells were present (Shiow et al. 2009; Shiow et al. 2008; Moshous 
et al. 2013; Stray-Pedersen et al. 2014; Yee et al. 2016). Patients having mutation or 
deletion in coronin 1 gene, which resulted in total abrogation of the protein, were 
diagnosed with recurrent respiratory infections at early age (within first two years of age). 
Additionally, they suffered from Epstein-Barr Virus (EBV)-induced B-cell lymphomas 
and impairment in the development of cognitive function (such as social deficits, 
increased aggression and learning abilities) (Shiow et al. 2008; Shiow et al. 2009; 
Moshous et al. 2013; Jayachandran et al. 2014). Another two siblings, diagnosed with T-
B+NK+ cells SCID, described by Stray-Pedersen et al., showed late disease onset at the 
age of 7 years old. They possessed compound heterozygous variants and mutation in 
coronin 1 gene. Both suffered from multiple viral infections and the older patient died of 
EBV-induced lymphoma. Interestingly, despite of recurrent epidermal-dermal lesions 
(from tuberculosis leprea, epidermodysplasia verruciformis and molluscum) both patients 
did not suffer from pain (Stray-Pedersen et al. 2014). Strikingly, all of the male patients 
diagnosed with coronin 1 deficiency survived longer than female patients (Shiow et al. 
2008; Shiow et al. 2009; Moshous et al. 2013). There are two more young adult patients 
described with coronin 1 mutation, which resulted in deletion of coiled-coil (CC) domain 
that impairs oligomerization of coronin 1. These patients were diagnosed with CD4+ T 
cell lymphopenia resulting in recurrent viral infection as well as disseminated varicella 
and pneumonia, however, they continue to survive into young adulthood without SCID 
phenotype and lymphoproliferative disease (Yee et al. 2016).  
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2.2  Principles of immune activation 
Our body is constantly exposed to environmental pathogenic attacks, such as viruses and 
bacteria. Fortunately, we developed an immune system that serves as a safeguard 
shielding us from most of the dangers. The immune system provides innate and adaptive 
immune responses.  
Innate immunity consists of molecular and cellular mechanisms that are ready for 
immediate defense against infectious agents (viruses, bacteria, fungi or parasites). Innate 
response is considered as the less specific defense, however, it provides the first line of 
protection for the host. The main physical barriers of the innate immune system are the 
epithelial layers of the skin and the mucosal and glandular tissue surfaces, which block 
pathogen entry to the body. Additionally, soluble substances possessing antimicrobial 
activity and acidic pH are produced at these surfaces. The next barrier that is faced by 
pathogens is the cellular response of the innate immune system. This response is rapid, 
beginning within minutes after invasion. Cellular responses are triggered by cell surface 
and intracellular receptors that recognize conserved molecular patterns of pathogens 
(Akira, Uematsu, and Takeuchi 2006).  
Despite the many barriers of innate immune system, some pathogens are able to survive 
innate defenses and invade the organism. In this situation the adaptive immune responses 
are ready to take part in the defense. The adaptive immune system counters infection with 
a specific response to the attacking pathogen. This specific response is mounted within 
five to six days after infection. It is characterized by its high specificity to the recognized 
antigen and provides immunological memory. The recognition of billions of single 
structures is possible thanks to the capacity of the adaptive immunity to generate a 
remarkable diversity in recognized molecules. What is more important, the adaptive 
immune system has the capacity to discriminate self from non-self (Kindt, Osborne, and 
Goldsby 2006b; Billingham, Brent, and Medawar 2010; Burnet, F., M. and Fenner 1941; 
Burnet 1976). Adaptive immunity responses are conducted by B and T lymphocytes. 
Major task of B cells is to produce specific antibodies, whereas T cells play a role in 
recognizing, neutralizing and eliminating the invaders. T lymphocytes can be divided into 
two main populations: CD4+ and CD8+ T cells. CD4+ T lymphocytes provide help to B 
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cells by CD40L:CD40 interaction and production of cytokines. Furthermore, CD4+ T 
cells facilitate CD8+ T cell expansion and activation of macrophages through cytokine 
production, such as IL-2, IFNγ and TNF. CD8+ T lymphocytes, termed cytotoxic T cells, 
kill infected cells, via cell-cell interaction and by secretion of cytokines for example, IFNγ 
(S. Huang et al. 1993; Suzuki et al. 1988). Peptides derived from infectious agents and 
intracellular antigens are recognized by T cell receptors (TCR) only when bound to major 
histocompatibility complexes (MHC). There are two types of MHC molecules: MHC 
class I, expressed on almost all nucleated cells, and MHC class II molecules expressed 
only on professional antigen presenting cells (APC) (Kindt, Osborne, and Goldsby 
2006a). According to the convention, only cells presenting peptide via MHC class II 
molecules are called professional APC, cells presenting peptide on class I molecules are 
referred to as target cells. Three types of cells belong to APC: dendritic cells (DC), 
macrophages and B lymphocytes (Banchereau et al. 2000; Guermonprez et al. 2002). 
Antigen presenting cells are able to induce T cell responses following infection or organ 
transplantation. Dendritic cells constitutively express high levels of MHC class I and II 
molecules as well as co-stimulatory proteins of B7 family. Consequently, they are more 
potent in antigen presentation than macrophages and B cells, which have to be activated 
prior to antigen presentation. Additionally, DC can migrate to the site of inflammation in 
the periphery (Pulendran, Palucka, and Banchereau 2001). There are studies showing that 
also non-hematopoietic cells (like endothelial cells) can act as APC. Endothelial cells 
(EC) can be induced to express MHC class II upon inflammation and present antigens to 
T cells for short period of time (Marelli-Berg et al. 2001). Endothelial cells act as APC in 
the context of an allograft transplantation where they display antigens to T cells. 
Presentation by endothelial cells can be carried out through the direct presentation where 
they expose allo-MHC-peptide complexes, or via indirect pathway, which involves cross-
presentation of antigens (Marelli-Berg et al. 2001; Epperson and Pober 1994; Bagai et al. 
2005; Rose 1998).   
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Figure 4. Innate and adaptive immune responses. Physical and chemical barriers, that prevent infection, 
are key elements of innate immunity. Pathogen entry results in multiple cellular responses with cell surface 
and intracellular receptors recognizing molecular patterns on pathogens. After recognition of the pathogen, 
some cells are activated to phagocytose and degrade the intruder, other cells produce variety of 
antimicrobial substances that kill the pathogen. Secretion of cytokines and chemokines recruits leukocytes 
to the side of infection leading to the inflammation and stimulating adaptive immune responses. 
Additionally, natural killer (NK) cells of the innate immune system recognize and kill cells infected with 
viruses. Dendritic cells present pathogen to lymphocytes activating adaptive immune system [adapted from 
(Kindt, Osborne, and Goldsby 2006a)].  
 
2.2.1 T cell development and activation 
T cells are the cellular mediators of the adaptive immune system. They develop in the 
thymus in a strictly regulated process which task is to produce maximal degree of 
diversity and to remove self-reactive T cells. Immature T lymphocyte precursors when 
traveling from the bone marrow to the thymus express no mature T cell features and no 
antigen receptor. T cell development in the thymus can be divided into two groups of 
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events: early thymocyte development and selection processes. Early thymocyte 
development starts with uncommitted double negative (DN) CD4-CD8- cells and ends 
with T-cell receptor expressing double positive (DP) CD4+CD8+ cells. During this stage 
hematopoietic precursors are committed to the T cell lineage, TCR rearrangements are 
initiated and the selection and expansion of cells with successfully rearranged one of TCR 
genes conducted (Chiei et al. 1987; Hayday et al. 1985; Raulet et al. 1985). The second 
phase of selection events is mainly dependent on T-cell receptor interactions. This stage 
brings CD4+CD8+ cells to the mature CD4+ or CD8+ single positive (SP) T cells. During 
this second phase of development immature T cells need to undergo positive selection, 
that select for T cells which possess TCR responding to self-MHC. Afterwards, T cells 
are subjected to negative selection, in which cells with TCR reacting strongly to self-
peptide-MHC complexes are eliminated. In the end thymocytes are committed to effector 
cell lineages: CD4+ helper or CD8+ cytotoxic T cell populations. When leaving the 
thymus, mature T cells possess diverse specific receptors, which are tolerant to self and 
restricted to self-MHC (Carpenter and Bosselut 2010; Germain 2002; Singer 2010; Starr, 
Jameson, and Hogquist 2003; Teh et al. 1988).  
After development in the thymus, naïve T cells migrate to the periphery where their 
number is strictly regulated by T cells homeostasis. This process aims at keeping the 
naïve T cells in a non-proliferative state while maintaining diversity such that their 
numbers remain constant (Goldrath and Bevan 1999; Takada and Jameson 2009). Several 
mechanisms have been proposed to be responsible for the survival of naïve T cells. One is 
based on the T cell receptor (TCR) that is triggered by the self-peptide presented in a 
complex with major histocompatibility complex (MHC) class I and class II molecules 
(Kirberg, Berns, and Boehmer 1997); another is based on IL-7 signaling (Takada and 
Jameson 2009). Naïve T lymphocytes circulate in the blood and home with the help of 
CD62L and CCR7 to secondary lymphoid organs which include spleen and lymph nodes 
(Sallusto et al. 1999). Without previous activation, they are not able to enter peripheral 
non-lymphoid tissue. To become activated and develop into effector cells, T cells need to 
be triggered through antigen presentation (signal 1) and co-stimulatory signals (signal 2), 
both presented by antigen presenting cells (Salomon and Bluestone 2001) (Fig. 5). These 
interactions are based on cell-cell contact. Antigen presenting cells can present peptides to 
 	 	 	 	
	
Introduction 
	
	 	
35	
T cells only in the context of the MHC molecules. This phenomenon is called MHC-
restriction, where CD4+ T cells recognize antigenic peptide bound to MHC class II and 
CD8+ T cells recognize antigenic peptide bound to MHC class I molecules (Zinkernagel 
and Doherty 1974a; Zinkernagel and Doherty 1974b). Following interaction of the TCR 
with antigen presenting cells, T cells up-regulate the expression of CD28 and CD40L. 
One or more of these surface molecules is engaged with their specific ligands on APC, 
including CD40, CD80 and CD86. This interaction provides co-stimulation of T cells. 
After this process, activated T cells are recruited to the sites of inflammation. Adhesion 
molecule ligands expressed on activated T cells (L-selectin, LFA-1, VLA-4, Mac-1) 
enable contact with adhesion molecules of the activated endothelium (P-selectin, E-
selectin, VCAM-1, ICAM-1) resulting in entry of T cells to the periphery (Campbell et al. 
1998; R. M. Rao et al. 2007). 
 
2.2.2 T cell tolerance (central and peripheral tolerance) 
Each mature T cell expresses a unique antigen receptor that has been assembled in the 
thymus during T-cell development through random gene rearrangement (Tonegawa et al. 
1977; von Boehmer et al. 1988). Therefore, T cell development must be a highly 
controlled process where potentially self-reactive T cells are eliminated. This major self-
tolerance mechanism, which plays a key role, is referred to as central tolerance (Kappler, 
Roehm, and Marrack 1987; Hogquist, Baldwin, and Jameson 2005). Developing 
thymocytes proliferate and differentiate following determined pathways to become 
functionally distinct populations of T cells. During positive and negative selection they 
are submitted to the test of recognizing self-peptides and self-MHC molecules. These self-
antigens consist of peptides either ubiquitously expressed or those restricted to specific 
tissues, named tissue specific antigens (TSAs). Medullary thymic epithelial cells 
(mTECs) and bone marrow-derived dendritic cells, which capture the TSAs from mTECs 
and present them to the thymocytes, express TSAs (Kyewski and Derbinski 2004; 
Gallegos and Bevan 2004; Klein et al. 2009). However, it is possible that potentially self-
reactive T cells can be released to the periphery after they escape negative selection. 
Consequently, self-reactive T cells can become activated and induce autoimmunity. 
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Therefore, peripheral tolerance was developed in the periphery to control self-reactivity 
(Zehn and Bevan 2006). One mechanism of peripheral tolerance is an interaction of a T 
cell with an immature DC, which leads to T cell anergy rather than activation. Dendritic 
cells not activated by inflammation or infection lack expression of co-stimulatory 
molecules. Although immature DCs can deliver signal 1, they are not able to deliver 
signal 2 causing T cell tolerance (Fig. 5). As has been already described by Jenkins in 
1987, these two signals are essential for full T cell activation (Jenkins et al. 1987). 
Moreover, dendritic cells can express negative co-stimulatory signals, which inhibit TCR 
signaling. The molecules PD-1 and CTLA-4 expressed on the DCs are able to maintain 
peripheral tolerance of T cells. CTLA-4 is a member of the CD28 family and binds to 
CD80 and CD86 antagonizing T cell activating signals. Similarly, PD-1 inhibits TCR-
mediated T cell activation, and has been recently described to also regulate the 
differentiation of CD4+ CD25+ Foxp3+ regulatory T cells (Tregs) (Probst et al. 2005; 
Sakaguchi et al. 2006). Hence dendritic cells have been shown to induce tolerance by 
activation of Tregs (Sakaguchi 2004). Regulatory T cells play a crucial role in the 
prevention of autoimmunity (Sakaguchi et al. 2006), inhibition of anti-tumoral immunity 
(Beyer and Schultze 2006) and, additionally, maintenance of maternal tolerance to the 
fetus (Aluvihare, Kallikourdis, and Betz 2004). Natural regulatory T cells develop in the 
thymus where they are positively selected and enriched in auto specific cells (Bensinger et 
al. 2001). Dendritic cells specifically activate these regulatory cells through the 
presentation of autoantigens. Additionally, Tregs need IL-2 to proliferate. Regulatory T 
cells down-regulate inflammation via secretion of IL-10 and TGF-β, which have 
inhibitory effects on APCs, or by direct interaction with T cells (Asseman et al. 1999; 
Fahlén et al. 2005). Peripheral tolerance, through Tregs, is responsible for the induction of 
tolerance towards foreign antigens. Therefore, following transplantation, when the 
induction of specific allogeneic tolerance is a main aim to prevent transplant rejection, 
Tregs are of the great importance. The importance of regulatory T cells is also reflected in 
the scurfy mouse model, where mutation within the Foxp3 gene causes the lack of 
functional regulatory T cells.  Scurfy mice develop a lymphoproliferative disease and 
multiorgan inflammation caused by unrestrained activity of autoreactive CD4+ T cells. 
This X-linked mutation results in a death of homozygous males by 22 to 26 days of age 
(Brunkow et al. 2001; Clark et al. 1999; Godfrey et al. 1991).  
 	 	 	 	
	
Introduction 
	
	 	
37	
 
Figure 5. Immune activation and tolerance induction by dendritic cells. Three signals are required for the 
activation of naïve T cells: TCR signaling, co-stimulatory binding and cytokine secretion. Signal 1 is 
provided by TCR/peptide-MHC complex interaction together with CD4+/CD8+ co-receptors and adhesion 
molecules. Co-stimulatory molecules, including CD28 family of proteins, supply co-stimulation in signal 2. 
Signal 1 and signal 2 initiate signal transduction that results in activation of transcription factors and 
secretion of cytokines providing signal 3 [adapted from (Owen, Punt, and Stranford 2013)]. 
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2.3  Transplantations  
The elaborate mechanisms maintaining self-tolerance that are described above, are also 
responsible for rejection of any transplanted tissue or cells whenever the donor is not 
genetically identical to the recipient. Transplantation is an act of transferring cells, tissues 
or organs from one individual to another. We can distinguish several types of 
transplantation: autograft, the self-tissue transfer from one body site to another; isograft, 
where tissue is grafted between genetically identical individuals (inbred strains of mice or 
identical twins); allograft, tissue transfer between genetically different members of the 
same species (from one mouse strain to another); xenograft, is when the tissue is 
transferred between individuals from different species. Usually, autografts and isografts 
are accepted due to genetic identity of the donor and recipient. Allograft tissue, 
genetically different from the recipient, expresses unique antigens, thus is recognize as 
foreign by the immune system and therefore rejected. Xenograft, being the greatest 
challenge for the immune system, due to its genetic difference, displays vigorous graft 
rejection response (Alonso Arias, López-Vázquez, and López-Larrea 2012; Chinen and 
Buckley 2010). 
Transplantation of organs or cells saves or prolongs many lives each year. Bone marrow 
transplantation is an extremely effective treatment of malignant blood cell diseases and 
kidney transplantation is the most commonly performed therapy nowadays. The 
subsequent most commonly transplanted organ is liver, heart comes next, followed by 
lung and pancreas. In addition, corneal tissue graft is also frequent. However, despite 
advances in surgical technics and improved immunosuppressive drugs, successful long-
term survival of transplants is still restricted by late graft failure due to the immune 
responses (Alonso Arias, López-Vázquez, and López-Larrea 2012; Sayegh and Carpenter 
2004). The frequency of transplantations for a given organ depends primarily on: organ 
availability, alternative treatment, the level of procedure difficulty and successful survival 
rate of grafted tissue. Skin transplantation has been a subject of a great interest for 
surgeons for many years. Its vitality, easiness in dissecting a large portion of skin from a 
donor and its adaptation in a recipient made the skin transplantation a valuable tool for 
plastic surgeries. However, already in 1870 doctors described many limitations in using 
this technique (Steele 1870). As we know now, this limitation comes from recipient’s 
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immune system and alloreactivity. Therefore, most skin transplantations are conducted 
with autologous tissue. Rarely, after severe burns allogeneic skin grafts are used as a 
natural dressing, which in time is replaced with autologous skin. Allogeneic skin graft still 
gives high risk of rejection and infection nowadays (Scheuher 2016). 
 
2.3.1 Alloreactivity  
Transplantations are mainly performed between members of the same species thus 
referred to as allotransplants. The immune response to allotransplantation is called 
alloreactivity. The most intense graft rejection happens after transplantation between 
individuals with differences in ABO blood group. If the recipient carries antibodies to any 
of donor antigens, the grafted tissue will induce rapid antibody-mediated lysis of foreign 
donor cells. The next important match is the MHC compatibility between a donor and a 
recipient. But even when the MHC antigens are identical, the transplant can be rejected 
due to differences in the minor histocompatibility antigens (Sayegh and Carpenter 2004).  
When T cells mature in the thymus and undergo positive and negative selection, they are 
selected to recognize self-MHC bound with non-self peptides. There is no process 
preparing them to bind to foreign MHC molecules that are not expressed in the body. The 
direct recognition of alloreactive T cells with non-self MHC molecule presenting foreign 
peptide is not MHC-restricted. Allogeneic T cells recognize the foreign MHC complex in 
the process of the recognition of major histocompatibility antigens. Minor 
histocompatibility antigens, unlike MHC, are recognized only when presented in the 
context of self-MHC. Rejection caused by minor histocompatibility variability is less 
robust but can lead to graft rejection (Alonso Arias, López-Vázquez, and López-Larrea 
2012; Chinen and Buckley 2010). There are two models describing allogeneic T cell 
recognition of peptide-allogeneic-MHC complexes. One explains that T cell activation 
derives from the interaction between TCR and the allogeneic-MHC molecules (Bevan 
1984), whereas the other claims that the activation is due to the recognition of foreign 
peptide (Matzinger and Bevan 1977) (Fig. 6).  
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Figure 6. Conventional recognition and models of allorecognition of allogeneic-MHC complexes by T 
cells. T cell receptor recognizes peptide-self-MHC (conventional recognition, upper panel) as well as 
peptide-allogeneic-MHC (allorecognition, lower panel) complexes. While in conventional recognition TCR 
makes contact with a peptide and a self-MHC, during allorecognition some models suggest that the TCR 
makes contact with a peptide, other models claim that TCR makes contact with allogeneic-MHC molecule. 
However, in many situations, the interaction of allospecific T cell with peptide-allogeneic-MHC complex 
seems to be identical to conventional recognition. Red line indicates interaction between TCR and 
peptide/MHC [adapted from (Felix and Allen 2007)]. 
 
2.3.2 Major histocompatibility complexes 
MHC molecules are highly polymorphic, which means that more than one allele is present 
at the same locus. There are hundreds of variants of MHC molecules and although they 
show a huge degree of diversity all of them are relatively common in the population. 
Thanks to so many polymorphic amino acids localized in the binding groove, each MHC 
variant can present a different range of peptides. Polymorphism in the α-helical proteins 
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influences allorecognition, while polymorphism in the peptide-binding site affects the 
type of bound peptide and conformation of the whole complex (peptide-allogeneic MHC). 
It means that the type of peptide that a particular individual recognizes depends on their 
MHC proteins and varies from person to person (Alonso Arias, López-Vázquez, and 
López-Larrea 2012).  
The physiological function of MHC proteins is to present peptides to T lymphocytes. 
Thus, they are responsible for the organisms to be able to distinguish between self and 
foreign cells, consequently being responsible for the acceptance or rejection of transplant. 
There are two types of MHC complexes: MHC class I, which presents cytoplasmic 
peptides to CD8+ T cells, and MHC class II, binding proteins derived from extracellular 
molecules and presenting them to CD4+ T cells. MHC class I molecule consist of a 
cytoplasmic domain and a transmembrane region linked to an α-chain, which is composed 
of three domains α1, α2 and α3, and a small extracellular domain known as β2-
microglobulin (Simonsen 1985). The α3 domain has a relatively conserved structure that 
interacts with CD8 molecules of T cells. The α2 and α3 form a groove for binding peptides 
presented by the molecule. The MHC class I groove can only recognize peptides of 8-10 
amino acids (Pamer and Cresswell 1998). Only MHC molecule loaded with a peptide is 
expressed on the cell surface as the interaction between α-chain and β2-microglobulin is 
stabilized with the binding of the antigen to the groove MHC class I molecules are 
expressed on the surface of all nucleated cells and are considered as the identification card 
for T cell control (Alonso Arias, López-Vázquez, and López-Larrea 2012; Cunningham 
1977). The MHC class II molecules are constructed from two equal transmembrane 
molecules, α and β-chain. The α1 and β1 amino terminal segments interact with one 
another forming a binding groove, which is the most polymorphic site of the MHC class 
II molecule. The binding groove of MHC class II can bind peptides up to 30 amino acids. 
These peptides usually come from extracellular antigens that have entered the cell by 
endocytosis. The binding site for CD4 molecules is located in the β2 segment. 
Cytoplasmic tails follow transmembrane regions of both α and β-chains. Additionally, 
there is one more polypeptide which binds to recently synthesized MHC class II 
molecules, knows as the invariant chain. The invariant chain is involved in the formation 
and prevents binding of intracellular peptides to class II molecule. Also, invariant chain 
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facilitates transport of MHC class II proteins from ER to Golgi apparatus, which is 
followed by a fusion with late endosome containing extracellular degraded proteins, 
consequently is involved in loading proteins onto MHC class II (Cresswell 1994; 
Claesson et al. 1983; Tulp et al. 1994; Pieters 2001). MHC class II molecules are mainly 
expressed on a professional antigen presenting cells (APCs), which were described before 
in this Chapter (Alonso Arias, López-Vázquez, and López-Larrea 2012; Felix and Allen 
2007).  
The wide range of MHC variety is useful for the recognition and fighting pathogens, 
however, at the same time it is a great barrier to the transplantation. The fact that every 
individual carries different MHC molecules means that grafted tissues express foreign set 
of antigens that are recognized by the recipient and lead to rejection process. Naturally, 
when carrying out transplantation, the aim is to match MHC molecules between recipient 
and donor as similar as possible, consequently reducing the risk of rejection and 
increasing survival of the graft. 
 
2.3.3 Allograft rejection  
T lymphocytes play a major role in the process of rejection. These are the cells that 
recognize foreign tissue by distinguishing self from non-self MHC molecules in a process 
called allorecognition. Allorecognition is an immune response that the recipient develops 
against a transplant. The process consists of the same mechanism as the immune response 
for defense against pathogens. Without immunosuppressive drugs, alloreactivity leads to 
rejection of the graft. This is characterized by infiltration of host lymphocytes, mainly 
CD4+ and CD8+ T cells. There are two pathways in which the foreign antigens can be 
presented to the host T cells: directly – the antigen presenting cells originate from the 
donor graft; and indirectly – the antigen presenting cells come from the recipient (Fig. 7). 
The direct presentation involves both CD8+ and CD4+ T cells that recognize intact donor 
MHC class I and II molecules, respectively, on donor antigen presenting cells 
(Hernandez-Fuentes, Baker, and Lechler 1999; Larsen, Austyn, and Morris 1990). The 
allelic difference between graft and host MHC molecules is referred to as a major 
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histocompatibility antigen mismatch. Over time, more and more host antigen presenting 
cells enter the graft, pick up donor antigens and present it to host naïve T cells making the 
indirect presentation pathway more predominant (Felix and Allen 2007). Both, the direct 
and indirect pathway, lead to rejection of the graft through activation and proliferation of 
allospecific T cells and direct killing of donor cells (Benichou et al. 2011).  
The rate of allograft rejection differs according to the transferred tissue. Skin grafts are 
rejected faster than other tissues. Rejection occurs after a skin from inbred mouse is 
transplanted to another mouse from different strain. Firstly, the skin is revascularized 
within 3 to 7 days, and afterwards it is infiltrated with inflammatory cells. Then, after 7 to 
10 days the vascularization starts to decrease with sign of necrosis by day 10. Twelve to 
14 days after transplantation the skin is completely rejected (Benichou et al. 2011; 
Goldsby et al. 2002). 
The graft rejection process can be divided into two stages: sensitization and effector 
phase, and is caused by humoral and cell-mediated immune responses to alloantigens 
expressed on cells of the graft. The first stage of graft rejection – sensitization phase, 
begins shortly after transplantation and lasts until alloreactive lymphocytes of the 
recipient proliferate as a result of allorecognition. Upon tissue transplantation, 
polymorphonuclear cells, macrophages, dendritic cells, cytokines and acute-phase 
proteins of recipient infiltrate the graft. Donor dendritic cells carrying donor antigens 
migrate from the transplanted tissue to the secondary lymphoid organs of the recipient. By 
presenting donor antigen and allogeneic MHC molecules they elicit an adaptive immune 
response. The adaptive immune response is initiated by recipient T cells, which recognize 
foreign peptide-foreign MHC complexes. Following allorecognition, CD4+ and CD8+ T 
cells become activated and proliferate thereby secreting proinflammatory cytokines. Both 
major and minor histocompatibility antigens are recognized, however the response to 
minor histocompatibility antigens is weaker (Fig. 7B). Host CD4+ T helper (TH) cells 
become activated after receiving two signals (interaction of TCR-MHC complex and co-
stimulation) from APCs. Donor APCs, after traveling into recipient draining lymph nodes, 
as well as recipient APCs, which can migrate into transplant and endocytose foreign 
antigens, can provide the interaction with host T cells. Langerhans cells of the skin and 
endothelial cells lining blood vessels can present alloantigens in addition to dendritic cells 
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(Epperson and Pober 1994; Marelli-Berg et al. 2001; Bagai et al. 2005). Naïve T cells can 
only be activated within the secondary lymphoid organs and are not able to reject the graft 
in the absence of those organs (Lakkis et al. 2000). Only after differentiating into effector 
cells, T cells leave the secondary lymphoid organs and infiltrate the graft, where they 
mediate rejection by killing donor cells (Benichou et al. 2011). This event starts the 
second effector phase of graft rejection, which consists of immune destruction of the 
graft. The effector phase consist of cell-mediated reactions, antibody-mediated 
complement lysis and destruction by antibody-dependent cell-mediated cytotoxicity 
(ADCC). Cell mediated reactions involve an influx of immune cells, mainly T cells 
(mainly CD4+), APCs and macrophages, into the graft. Additionally, host CD8+ T cells 
can mediate CTL-mediated killing (cytotoxic T lymphocytes) (Chávez-Galán et al. 2009). 
Cytokines secreted by T helper cells play a central role in the mechanism of graft 
rejection. IL-2 and IFNγ (produced by TH1 cells) promote T cell proliferation and 
synthesis of IgG by B cells, leading to complement activation. Furthermore, cytokines 
produced by TH2 and TH17, have also been shown to be involved in graft rejection 
(Benichou et al. 2011). B cell activation cytokines, IL-4, -5 and -13, as well as IL-17 have 
all been related to allograft rejection. Antibody-mediated rejection, dependent on 
maintenance of alloreactive B cells by T lymphocytes, also contributes to the rejection of 
transplanted tissue (Benichou et al. 2011) (Fig. 7A).  
The role of CD4+ and CD8+ T cells in allograft rejection of skin grafts was outlined in 
studies using transplanted mice injected with monoclonal antibodies. The antibodies 
depleted one or two subpopulations of T cells and then the graft survival was accessed. 
Removal of CD8+ T cells alone had no effect on the graft survival. However, deletion of 
CD4+ T cells prolonged survival of the graft. Further, removing both of T cell 
populations, CD4+ and CD8+, resulted in long-term survival of the graft, thus confirming 
the collaboration between them (Fig. 8) (Auchincloss et al. 1993). Interestingly, inhibition 
of dendritic cells facilitate acceptance of the graft in mice (Cobbold et al. 1986) 
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Figure 7. Panel A. Different mechanisms of graft rejection process. The activation, proliferation and 
generation of various effector cells during graft rejection are stimulated by either direct or indirect 
recognition of alloantigens by T cells. B cells, stimulated by TH cells producing cytokines (IL-2, IL-4, IL-5, 
IL-6; marked with blue), secrete antibodies, which stimulate NK cells and macrophages to attack cells of 
the graft. Activated CD4+ and CD8+ T cells recognize MHC complexes on the surface of the graft causing 
membrane damage of grafted cells and cytotoxicity. Complement activation leads to lysis of foreign cells 
[adapted from (Goldsby et al. 2002)].  Panel B. Major and minor mismatch model. We refer to major 
mismatch when both MHC molecule and presented antigen are recognized as foreign (allogeneic). In this 
model donor and recipient come from different mouse strains. In minor mismatch only antigen is allogeneic 
and is presented by self-MHC thus only antigen is recognize as foreign by recipient T cell. 
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Figure 8. CD4+ and CD8+ T cell role in graft survival. Mice grafted with tail skin were treated with 
depleting monoclonal antibodies for CD4 and CD8, and observed daily for graft rejection. The depletion of 
CD8+ T cells did not delay rejection of skin grafts. Mice depleted of CD4+ T cells showed prolonged 
survival of transplants. Additionally, mice injected simultaneously with anti-CD4 and anti-CD8 antibodies 
kept the graft even longer than those injected only with anti-CD4 (Goldsby et al. 2002). 
 
2.3.3.1 Hyperacute rejection 
Hyperacute rejection is caused by preexisting host antibodies specific for antigens of the 
graft and results in rejection within the first 48 hours after transplantation. It is more 
common for highly vascularized graft, such as kidney and heart. During this process 
preexisting antibodies bind to endothelial cells of the graft activating the complement 
system, which leads to infiltration of neutrophils. This causes destruction of the 
endothelium, haemorrage, and thrombosis, which in the end results in necrosis of the 
grafted organ (Alonso Arias, López-Vázquez, and López-Larrea 2012). 
 
2.3.3.2 Acute rejection 
This type or rejection is a cell-mediated rejection, which can begin about 7 to 10 days 
after transplantation but may also occur within 3 months. It is manifested as an infiltration 
of macrophages and lymphocytes (both CD4+ and CD8+ T cells with activated or 
memory phenotype) at the site of tissue destruction (Alonso Arias, López-Vázquez, and 
López-Larrea 2012).  
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2.3.3.3 Chronic rejection 
The mechanisms of chronic rejection include both humoral and cell-mediated responses 
and can develop months or years after transplantation. Although, nowadays, survival of 
the graft within the first year after transplantation is increased due to the availability of 
immunosuppressive drugs, long-term survival is still a challenge. Immunosuppressive 
drugs usually do not prevent chronic rejection and therefore in many cases transplants 
show slow deterioration of function (Alonso Arias, López-Vázquez, and López-Larrea 
2012). 
 
2.3.4 Therapy of allograft rejection 
Allogeneic transplantations always require immunosuppression. There are several 
described methods to prevent allograft rejection. Most of these are nonspecific involving 
generalized suppression of responses to all antigens, not only those from the allograft. 
Nonspecific immunosuppressive drugs expose recipients to infection, which in fact, is the 
most common cause of transplant-related death. Recipients undergoing long-term 
immunosuppressive therapy are at risk of hypertension and metabolic bone disease. 
Selection of proper immunosuppressive drugs and eventually ceasing the therapy is the 
biggest challenge for doctors nowadays. One way, to obtain more specific suppression, is 
the use of immunosuppressive drugs that inhibit T cell signaling, for example Calcineurin 
inhibitors (Crabtree and Olson 2002; A. Rao, Luo, and Hogan 1997). Moreover 
development of drugs like cyclosporine A, FK506 (tacrolimus) and rapamycin, was a 
great breakthrough in a field of transplantation. These drugs are able to block activation 
and proliferation of resting T cells, and also prevent transcription of genes encoding T-
cell activation molecules (such as IL-2). The most specific immunosuppression is 
achieved with the use of monoclonal antibodies and soluble ligands that bind specific 
molecules on the T cell surface. This allows depletion of the recipient’s particular T cell 
population. Another way is the blockade of co-stimulatory signals between antigen 
presenting and T cells (for example CD28/CTLA:CD80/CD86 (Salomon and Bluestone 
2001; Lin et al. 1993) and CD40/CD40L (Guo et al. 2001)). Moreover, transfer of 
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regulatory T lymphocytes (CD4+CD25+Foxp3+ T cells) in mice has been described to 
prevent acute and chronic rejection (Joffre et al. 2004; Joffre et al. 2008).  
 
2.3.5 Tolerance induction in transplantation – the role of 
CD4+CD25+Foxp3+ T cells 
Regulatory T cells are a powerful mechanism to induce antigen-specific self-tolerance. A 
number of studies imply that these cells play a role in transplantation tolerance (Gorantla 
et al. 2010; Waldmann and Cobbold 2004; Joffre et al. 2004; Joffre et al. 2008). The 
survival of grafts in the absence of immunosuppressive drugs is accompanied by 
increased number of Tregs in the periphery and the grafted tissue. Tregs are believed to 
inhibit rejection by direct contact with alloreactive cells and secretion of TGF-β, IL-10 
and IL-35. The population of these cells is small which causes difficulties in their 
isolation and analysis, and limits Tregs use in inducing transplant tolerance. However, 
currently, different ways to induce specific T cell tolerance are described, including 
combination of CD4+CD25+Foxp3+ T cells and induction of chimerism. This prevents 
acute and chronic allograft rejection (Salisbury, Game, and Lechler 2014; Joffre et al. 
2004; Joffre et al. 2008; Thebault et al. 2007). Although regulatory T cells are a subject of 
intense studies, the mechanism of their suppression and regulation is not yet fully 
understood.   
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2.4  Survival and homeostasis of naïve T cells 
T cell development and homeostasis is an exhausting process for the body. Around 95% 
to 98% of thymocytes die by apoptosis due to defective TCR development (Starr, 
Jameson, and Hogquist 2003; Fesus 1991). Apoptosis also regulates immune cell 
homeostasis by restoring T cell numbers to their appropriate levels after their intense 
proliferation provoked by infection. T cell homeostasis is a process of maintaining mature 
naïve T cells in the periphery at constant level and requires signaling by TCR and 
appropriate cytokines. The maintenance of appropriate numbers of lymphocytes is an 
important mechanism to maintain an effective immune system (Takada and Jameson 
2009). Apoptosis, also called programmed cell death, is a process in which a cell induces 
its own death. Apoptotic cells dismantle their content without disturbing its membrane. 
Apoptotic cells are cleared by phagocytes without releasing any inflammatory materials, 
therefore without triggering a damaging inflammatory response. Apoptosis is 
characterized by a decrease in cell volume, modification of the cytoskeleton, condensation 
of chromatin and degradation of DNA into fragments (P. Waring, Kos, and Müllbacher 
1991). There are several ways in which lymphocytes can be triggered to undergo 
apoptosis, all resulting in the activation of caspases. In the periphery, most of TCR-
mediated apoptosis is induced by membrane-associated death receptors (including Fas, 
also known as CD95), which are called extrinsic pathways. Fas and Fas ligand (FasL) are 
co-expressed on the T cell surface upon persistent stimulation of TCR, causing Fas/FasL 
mediated cell death. This type of apoptosis induction is known as activation-induced cell 
death (AICD). AICD is a major homeostatic mechanism, which reduces the number of 
activated T cells, after antigen is cleared, and removes autoreactive T cell (McConkey, 
Orrenius, and Jondal 1990). Similarly, another member of the same receptor family, 
tumor necrosis factor (TNF) and its receptor (TNFR) can induce apoptosis via activation 
of caspase proteases. B-cell lymphoma 2 (Bcl-2) family of proteins consists of both anti-
apoptotic and pro-apoptotic proteins. Proteins of Bcl-2 family respond to the cell’s stress 
and regulate cytochrome c release by their incorporation into mitochondrial membranes. 
One of the members of this family, Bcl-2, contributes to long survival of lymphocytes. 
Therefore, Bcl-2 expression levels play an important role in regulating the life span of 
hematopoietic cells, for example, by eliminating unneeded activated lymphocytes. 
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Consequently, activated lymphocytes express lower levels of Bcl-2 and are more 
susceptible to apoptosis than naïve and memory cells, which express high levels of this 
protein. However, if the TCR activation continues, the expression of Bcl-2 is sustained 
thereby blocking the apoptotic pathway (Chávez-Galán et al. 2009; Bouillet et al. 2002).  
The next important player in maintaining homeostasis of T cells is programmed cell death 
protein 1 (PD-1), which is inducibly expressed on peripheral CD4+ and CD8+ T cells. Its 
expression is provoked by TCR signaling and remains at a high level upon persistent 
antigen stimulation. Non-functional and exhausted T cells, for example during chronic 
infection, express high levels of PD-1. This molecule transmits inhibitory signals when 
stimulated together with TCR. These inhibitory signals block T cell proliferation, 
cytokine production and cytolytic function, therefore impairs T cell survival. PD-1 
inhibits T cell function and survival directly via blocking activation signals (through 
CD28) or IL-2. However, the intensity of inhibition depends on the strength of the TCR 
signal. Lower levels of TCR signaling lead to a greater inhibition of T cells function. PD-
1 signaling protects against self-reactive T cells, thus prevents autoimmunity suggesting 
that PD-1 has a role in maintenance of tolerance. Furthermore, the PD-1 pathway 
promotes Treg development, maintenance, and function. Tregs induced by this pathway 
can assist in maintaining homeostasis, regulating the level of T cell activation. PD-1 
ligands (PD-L1 and PD-L2) are found on tolerogeneic dendritic cells where they can 
control induction of T cell activation or tolerance (Francisco, Sage, and Sharpe 2010). 
Recent thymic emigrants, which arrive in the periphery, so-called naïve T cells, are 
antigen inexperienced cells with the greatest potential to proliferate and differentiate. The 
maintenance of naïve T cells is necessary for lifelong immunocompetence. Survival of 
naïve CD8+ T cells requires signaling by IL-7 and engagement of TCR. This is a complex 
process, which demands precise intermittent stimulation with IL-7 and a proper strength 
of TCR induction to keep the cells alive. Continuous IL-7 signaling as well as insufficient 
TCR triggering induces CD8+ T cells to proliferate and produce IFNγ. Consequently, this 
leads to IFNγ-triggered cell death refer to as cytokine-induced cell death (CICD) (Kimura 
et al. 2013). The mechanisms involved in the survival of naïve CD4+ T cells in the 
periphery are less clear. However, most of the studies describe CD4+ T cell homeostatic 
proliferation to be dependent on interaction between TCR and low affinity self-peptide-
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MHC complexes. Engagement of TCR with self-MHC class II is required for long-term 
survival of CD4+ T cells, but the interaction should not be specific. The selective 
engagement of TCRs by peptide-MHC molecules promotes proliferation of CD4+ T cells, 
which is associated with activation. There are some studies describing this process to be 
additionally dependent on cytokines, such as IL-2 or IL-7 (Morris and Allen 2012; Clarke 
and Rudensky 2000; Martin et al. 2006; van der Geest et al. 2015) (Fig. 9). 
 
Figure 9. Homeostatic maintenance of naïve T cells. A. Scheme of proposed mechanisms involved in 
survival of CD8+ T cells. Low-affinity engagement of TCR by self-antigens and IL-7 signaling in the 
periphery are necessary for the homeostasis of CD8+ T cells. At the same time continuous strong IL-7 
signaling and inappropriate TCR triggering induces CD8+ T cells proliferation and activation. This in 
turns inhibits IL-7R expression and leads to increased production of IFNγ, which causes apoptosis by 
cytokine induces cell death (CICD) [based on (Kimura et al. 2013)]. B. Survival of naïve CD4+ T cells is a 
controversial topic. Most of the studies describe it to be dependent on low affinity self-peptide-MHC 
complexes interaction with TCRs [based on (Morris and Allen 2012)]. 
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3 Aim of the study 
 
Tissue transfer from a donor to a recipient triggers potent reaction by the recipient’s 
immune system. Mechanisms that are responsible for maintenance of self-tolerance 
participate in rejection of grafted tissue by a process called allorecognition. 
Allorecognition consists of the same mechanism as an immune response for defense 
against pathogens but it is mediated against differences in MHC class I and class II 
molecules between the host and the donor. T cells are the main players in allograft 
rejection (Alonso Arias, López-Vázquez, and López-Larrea 2012). Coronin 1-
deficient mice show a drastic reduction in the numbers of T cells in the periphery 
(Föger et al. 2006; Mueller et al. 2008). Interestingly, coronin 1 mutation in human is 
associated with severe peripheral T cell depletion (Moshous et al. 2013). Recently, 
coronin 1-deficient mice have been found to possess relatively normal T cell antigen-
induced responses upon infection while at the same time resisting the development of 
autoimmune diseases (Siegmund et al. 2011; Haraldsson et al. 2008; Tchang et al. 
2013). Preliminary observations of experiments in our laboratory showed prolonged 
survival of transplanted skin grafts in coronin 1-deficient recipients (not published). 
This observation suggests a critical role of coronin 1 in T cell-mediated allograft 
rejection. However, the physiological relevance for coronin 1 deficiency in allograft 
rejection is yet to be discovered. 
Based on the data described above, we hypothesized that coronin 1 plays an essential 
role in the activation of alloreactive CD4+ and CD8+ T cells during graft rejection. 
The goal of my thesis was to investigate the ability of coronin 1-deficient T cells to 
recognize foreign MHC complexes and to reject the allograft. We approached that by 
designing an appropriate experimental setup, in which we tested skin graft rejection in 
wild type and coronin 1-deficient mice. Furthermore, we analyzed the outcome of 
reduced frequency of coronin 1-deficient T cells on the graft rejection. We studied the 
ability of coronin 1-deficient T cells to become activated and proliferate. We also 
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explored the induction of tolerance after graft transplantation in coronin 1-deficient 
mice as a potential reason for the delay in graft rejection. 
 	
	
Results 
	
	 	
55	
	
4 Results  
 
4.1  Skin transplantation models: major and minor mismatch 
T lymphocytes play a major role in allorecognition and lead to rejection of 
transplanted tissue. Dendritic cells are the cells presenting foreign antigens to 
alloreactive T cells (Guermonprez et al. 2002). As mentioned above coronin 1-
deficient mice show decreased numbers of T cells (Moshous et al. 2013) and normal 
antigen processing and presentation by dendritic cells (Westritschnig et al. 2013). 
When coronin 1-deficient mice were infected with LCMV the CD8+ T cell response 
was relatively normal compared to wild type controls and led to the clearance of the 
virus (Tchang et al. 2013). On the other hand, after infection with VSV CD4+ T cells 
response was impaired and mice were not protected from the virus (Tchang et al. 
2013). Moreover, mice deficient in coronin 1 are not susceptible to EAE (Siegmund et 
al. 2011) and protected against systemic lupus erythematosus (Haraldsson et al. 
2008). These data demonstrate that despite the paucity in naïve T cells, coronin 1-
deficient mice are resistant to a variety of infections but not susceptible to 
autoimmune diseases. Since allorecognition is an immune response that the recipient 
develops against a transplant, the process consists of the same mechanism as the 
immune response for defense against pathogens (Benichou et al. 2011). Interestingly, 
preliminary results of experiments in our laboratory showed prolonged survival of 
transplants in coronin 1-deficient recipients. Although this could be the outcome of 
reduced frequency and/or impaired activation of T cells in the absence of coronin 1 
we would have expected similar defects in immune response against pathogens. To 
address the question regarding responses to allografts in coronin 1-deficient mice, two 
types of experiments were set up in our lab. These experiments included major and 
minor mismatch skin grafts. In the major mismatch model the donor and the recipient 
come from MHC-mismatched mouse strains and differ in both presented antigen and 
MHC molecules. When donor and recipient possess identical MHC molecules but 
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differ regarding the presented antigen, this is referred to as a minor mismatch 
(Fig.7B).  
4.1.1 Rejection of major mismatched grafts in coronin 1-deficient 
recipients  
Initially, to address the question how coronin 1-deficient mice behave in 
allorecognition, tissue transplantation was performed using mice from two different 
strains. Balb/c mice were used as donors and BL/6 wild type or coronin 1-deficient 
(on BL/6 background) mice were used as recipients. Donor skin was harvested from 
the tail of Balb/c mice and the transplantation procedure followed the protocol 
described before (Schmaler, Broggi, and Rossi 2014, and in this thesis Chapter 6.4). 
Following transplantation, all mice were scored for a duration of at least 100 days and 
tested for composition of immune cells at different time points. Transplantation of 
fully mismatched skin onto BL/6 mice resulted in rejection within 10-12 days, 
whereas grafts transplanted onto coronin 1-deficient mice survived until day 33 (Fig. 
10). The results indicated an impaired response to foreign tissue in mice lacking 
coronin 1.  
	
Figure 10. Rejection score (A) and skin graft survival (B) in BL/6 wild type and coronin 1-deficient 
recipients of Balb/c tail skin grafts. The surgery was done following the transplantation protocol 
described in Materials and Methods (Chapter 6.4). The survival of the graft was verified daily for at 
least 100 days. Each point represents mean of two mice for control groups (BL/6 onto BL/6 and Cor1-
/- onto Cor1-/-) and four mice for experimental groups (Balb/c onto BL/6 and Balb/c onto Cor1-/-1). 
The experiment was repeated four times, each time 2 to 6 mice were used per group and similar results 
were observed for each repeat. B6 – BL/6 wild type; Cor1-/- - coronin 1-deficient. Presented data were 
obtained by Rajesh Jayachandran. 
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Flow cytometry analysis of immune cell composition (B cells, NK cells and 
neutrophils) in transplanted mice did not show many significant differences between 
wild type and coronin 1-deficient mice (Fig. 11 and 12). T cell numbers in lymph 
nodes of coronin 1-deficient mice with skin transplants were decreased and 
maintained at levels comparable to naïve coronin 1-deficient mice (Fig. 11B and D). 
The retained counts of T cells (between naïve and transplanted coronin 1-deficient 
mice) could indicate defects in proliferation due to impaired antigen recognition or an 
impaired process of antigen recognition in coronin 1-deficient T cells. Although 
numbers of both CD4+ and CD8+ T cells in the lymph nodes of coronin 1-deficient 
transplanted mice were lower than in BL/6 recipients, they increased in coronin 1-
deficient and wild type mice (Fig. 12B and D). This could indicate an activation and 
proliferation of coronin 1-deficient T cells after transplantation but at a low level. 
Both CD4+ and CD8+ T cells numbers did not change in spleens of coronin 1-
deficient and wild type mice after transplantation. B cells numbers in naïve controls 
BL/6 wild type and mice lacking coronin 1 were similar. However, counts of B cells 
in lymph nodes of coronin 1-deficient recipients were lower than in wild type. 
Typically, after organ transplantation and stimulation by T cells, B cells undergo 
uncontrolled mobilization and activation which drives inflammation and results in 
graft loss (Coelho et al. 2013; Thibault-Espitia et al. 2012; Zarkhin, Chalasani, and 
Sarwal 2010). Lower counts of B cells in coronin 1-deficient lymph nodes could be 
explained by lower activation of B cells by decreased or impaired T cell numbers in 
recipients lacking coronin 1 (Fig. 11E and F) since B cells responses to protein 
antigens require help from T cells (Kwun et al. 2012). Moreover, although the overall 
numbers of B cells were reduced in coronin 1-deficient mice after transplantation, the 
rate of increase of these cells was comparable to wild type recipients. These results 
imply that the T cells were able to activate B cells but the activation was not as 
efficient as in the wild type recipients. That could be explained by decreased 
activation and numbers of T cells themselves.  
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Figure 11. Immune cells in lymph nodes of BL/6 wild type and coronin 1-deficient recipients of 
Balb/c skin grafts. The mice were transplanted following the transplantation protocol (Chapter 6.4) 
and analyzed at the day of rejection: day 12 for wild type and day 33 for Cor1-/- recipients. B cells and 
T cells were analyzed from lymph nodes (2x axillary, 2x brachial, 2x inguinal) with appropriate 
antibodies. Results were acquired using FACS. Each bar graph represents results for 3 (naïve and 
mock controls) or 6 individual mice (major mismatch). A and B shows CD4+ T cells in lymph nodes 
both in % (A) and numbers (B). C and D represents CD8+ T cells in % (C) as well as in numbers (D). 
Percentages of B cells in lymph nodes are shown in graph E, numbers in F. B6 – BL/6 wild type; Cor1-
/- - coronin 1-deficient.  
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Figure 12. Immune cells in spleen of BL/6 wild type and coronin 1-deficient mice transplanted with 
Balb/c tail skin (major mismatch) or mock controls. Skin transplantations were performed following 
the transplantation protocol (Chapter 6.4). The mice were analyzed at the day of rejection: day 12 for 
wild type and day 33 for Cor1-/- recipients. Cells from spleens were analyzed with antibodies specific 
for T and B cells. The results were acquired using FACS. Each bar graph represents results for 3 
(naïve and mock controls) or 6 individual mice (major mismatch).  A and B shows CD4+ T cells in 
spleen both in % (A) and numbers (B). C and D represents CD8+ T cells in % (C) as well as in 
numbers (D). Percentages of splenic B cells are shown in graph E, numbers in F. B6 – BL/6 wild type; 
Cor1-/- - coronin 1-deficient. 
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From previous studies we know that coronin 1-deficient mice can respond to viral and 
bacterial infection (Tchang et al. 2013) thus the above results suggest that coronin 1-
deficient mice have a specific problem with allorecognition by T cells or their 
efficient activation after transplantation.  
 
4.1.2 Survival of minor mismatched grafts in wild type and coronin 1-
deficient mice  
In order to further investigate impaired allorecognition of T cells in coronin 1-
deficient mice, we performed minor mismatch surgeries. To this end we used mouse 
strain 6.25% Balb/c in BL/6 generated in the lab (described in Materials and 
Methods). First, the strain was characterized for the expression of MHC complexes. 
We stained 6.25% Balb/c in BL/6, Balb/c and BL/6 mice for Balb/c specific MHC 
complexes: I-Ad (MHC class II), H2-Dd and H2-Kd (MHC class I) and BL/6 specific 
MHC complexes: I-Ab (MHC class II), H2-Db and H2-Kb (MHC class I) 
(Supplementary Fig. 1). The results showed that 6.25% Balb/c in BL/6 mice 
expressed all three BL/6 MHC proteins and none from Balb/c. This suggests that the 
response induced after transplantation was caused by differences in presented 
antigens but not by allorecognition of foreign MHC proteins. Additionally, 6.25% 
Balb/c in BL/6 mice were analyzed by the presence of single-nucleotide 
polymorphism (SNP) typical for either BL/6 or Balb/c mouse strain (data not shown). 
According to the SNP analysis the strain showed 96.9% of BL/6 recipient genome. 
As can be seen in Fig. 13A and B minor mismatched skin was rejected after 70 days 
in BL/6 mice. In coronin 1-deficient mice transplants were not rejected (data shown 
until day 100). Analysis of NK cells and neutrophils in transplanted mice did not 
show any significant differences between wild type and coronin 1-deficient mice. The 
T cell numbers in coronin 1-deficient mice with skin transplants were decreased and 
showed a slight (not significant) increase upon transplantation, which did not induce 
graft rejection (Fig. 13C – F). Similarly to major mismatch surgeries, B cells numbers 
in coronin 1-deficient recipients were lower than in the wild type.  
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Figure 13. A – B. Rejection score (A) and skin graft survival (B) in BL/6 wild type or coronin 1-
deficient recipients of 6.25% Balb/c in BL/6 tail skin grafts (minor mismatch). The surgery was done 
following the transplantation protocol (Chapter 6.4). The survival of grafts was verified daily for at 
least 150 days. Each point represents mean of three mice for control transplantations and five mice for 
minor mismatched surgeries. The experiment was repeated four times, each time 3 mice were used in 
controls and 5 mice were used in minor mismatched group. C – H. Composition of immune cells in 
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lymph nodes of transplanted or naïve mice 87 days after surgery. The mice were transplanted with 
minor mismatch skin grafts following the transplantation protocol (Chapter 6.4). Axillary, brachial 
and inguinal lymph nodes were harvested 87 days after surgery, processed and analyzed for immune 
cell composition by FACS staining with anti-CD3, CD4, CD8 and CD19 antibodies. C and D shows % 
and numbers of CD4+ T cells, respectively. CD8+ T cells percentage (E), CD8+ T cell numbers (F), B 
cells percentage (G) and B cell numbers (H) are represented on the bar graphs. Graphs represent 
mean ± standard deviation (SD) of 3 mice for naïve and mock controls, and mean ±SD of 5 mice of 
minor mismatch groups. B6 – BL/6 wild type; Cor1-/- - coronin 1-deficient. Data presented in Fig. 13A 
and B were obtained by Rajesh Jayachandran. 
 
In summary, coronin 1-deficient mice showed delayed rejection of major mismatch 
skin grafts compared with the wild type recipients. The coronin 1-deficient animals 
kept the graft approximately 3 times longer than BL/6 wild type. At the same time, 
coronin 1-deficient mice were not able to elicit rejection in minor mismatch setup. 
Additionally, cell analysis in the recipient mice showed relatively normal numbers of 
different immune cell types (neutrophils, NK cells and B cells) in blood, spleen and 
lymph nodes of coronin 1-deficient compared with BL/6 wild type recipients (Table 
2). Only the rates and numbers of T cells (CD4+ T cells as well as CD8+ T cells) 
were reduced in coronin 1-deficient mice when compared with wild type. Therefore 
the delayed rejection could be the consequence of the reduced numbers of T cells that 
need more time to reach the appropriate cell levels to be able to reject the graft.  
Therefore, we asked three major questions:  
I. Is the delayed rejection due to the lower number of T cells in the coronin 1- 
deficient mice? 
II. Are coronin 1-deficient T cells impaired in their function or allorecognition? 
III. Is the prolonged acceptance of the graft due to the induction of tolerance in 
coronin 1-deficient recipients? 
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4.2  CD4+ T cell-mediated allograft rejection (MHC class II 
mismatched transplantations)  
Interestingly, the delayed rejection in the major mismatched experiment resembled 
literature data in which CD4+ T cells were depleted with anti-CD4 antibody in skin 
transplantation model (Cobbold et al. 1986; Auchincloss et al. 1993) (Fig. 8). Based 
on this observation and previously described results, where the CD4+ T cells were 
impaired during infection (Tchang et al. 2013), we decided to perform CD4+ T cell-
dependent transplantation using bm12Rag2-/- mice as donors.  
	
Figure 14.	 Rejection score (A) and graft survival (B) in BL/6 wild type and coronin 1-deficient 
recipients of bm12Rag2-/- tail skin. BL/6 wt and coronin 1-deficient mice were transplanted according 
to the transplantation protocol and the graft survival was observed for at least 100 days. BL/6 wild 
type recipient group consist of 3 mice and Cor1-/- group of 6 mice. The experiment was repeated six 
times; each time at least 3 mice were used per group. Figure shows representative plot from one 
experiment. Coronin 1-deficient mice tolerate the bm12Rag2-/- skin grafts until day 100 while BL/6 
wild type recipients rejected grafts within 10 days. B6 – BL/6 wild type; Cor1-/- - coronin 1-deficient. 
In the CD4-dependent transplantation model we were using B6.C.H-2-bm12Rag2-/- 
(bm12Rag2-/-) mice as donors. Bm12 mice are BL/6 mice that have three-points 
mutation localized in the I-A subregion of the murine MHC class II (Lee, Hansen, and 
Cullen 1982). As a result, the CD4+ T cells of BL/6 mice will recognize MHC class II 
molecules of bm12 mice as foreign and thus induce a strong allogeneic activation of 
these cells (Schmaler, Broggi, and Rossi 2014). After transplantation of bm12Rag2-/- 
skin onto BL/6 wild type and coronin 1-deficient mice, wild type recipients rejected 
grafts within 10 days (Schmaler, Broggi, and Rossi 2014) while coronin 1-deficient 
mice showed no rejection (data shown until day 100, Fig. 14). The analysis of CD4+ 
T cells in transplanted mice did not show any significant differences in proliferation 
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or activation of these cells compared with major mismatch model (Fig. 15). 
Interestingly, we observed tolerance of bm12Rag2-/- skin graft in coronin 1-deficient 
mice, which could be caused by the defect in CD4+ T cells or induction of tolerance.  
	
Figure 15. CD4+ T cells in lymph nodes of BL/6 wild type and coronin 1-deficient mice with and 
without bm12Rag2-/- skin grafts. The mice were processed following the transplantation protocol 
(Chapter 6.4). BL/6 wt mice were sacrificed at day 13 after the surgery (graft rejection), Cor1-/- 
recipients were analyzed at day 50 after the surgery. Lymph nodes (2x axillary, 2x brachial, 2x 
inguinal) were harvested at the day of sacrifice and FACS stained with T cells specific antibodies 
(antiCD3 and anti-CD4). The group of naïve mice consisted of 3 mice; the transplanted group 
consisted of 4 mice. The experiment was performed several times, each time at least three mice were 
used per group. Figure shows representative plot from one experiment. A. % of CD4+ lymphocytes for 
naïve or transplanted BL/6 wt and Cor1-/- mice with bm12Rag2-/- tail skin. B. Number of CD4+ T 
cells for naïve or transplanted BL/6 wt and Cor1-/- mice with bm12Rag2-/- tail skin. B6 – BL/6 wild 
type; Cor1-/- - coronin 1-deficient; bm12 – bm12Rag2-/-; Tx – transplanted mice. 
We then went on to investigate the ability of CD8+ T cells of coronin 1-deficient mice 
to induce rejection. For MHC class I mismatched transplantations we used B6.C-H2-
K-bm1 (bm1) mice as a skin donors. The bm1 mice differ from the parental BL/6 
gene by seven nucleotides, which resolve in substitution of three amino acids in a 
subregion of class I H-2Kb (Schulze et al. 1983). Survival of bm1 skin graft on the 
BL/6 wild type or coronin 1-deficient mice is shown in Fig. 16. As can be seen bm1 
skin transplanted onto BL/6 wild type mice was rejected within 13 days. Coronin 1-
deficient recipients started to reject the graft after 36 days post transplantation. At day 
50 two out of four mice rejected the transplanted skin completely. At the end of the 
experiment (day 90) only one mouse kept the graft but showed signs of undergoing 
rejection (score 2). This result confirmed the previous findings that CD8+ T cells of 
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coronin 1-deficient mice are able to mount immune response (Tchang et al. 2013). 
The delayed rejection could be due to a lower number of these cells which need more 
time to proliferate and become activated sufficiently in order to reject a graft. 
Therefore, the result confirmed our hypothesis that the delayed rejection of major 
mismatch skin grafts was due to impairment in coronin 1-deficient CD4+ T cells. 
Thus, from now on, this thesis will focus mainly on CD4+ T cell responses using 
MHC class II mismatched transplantation model. 
	
Figure 16. Graft survival after CD8+ T cells-dependent (bm1) skin transplantations. The mice were 
transplanted following the transplantation protocol (Chapter 6.4), graft score was observed for at least 
90 days. Each transplanted group consisted of minimum three mice. Bm1 skin transplanted onto BL/6 
wild type mice was rejected within 13 days, coronin 1-deficient recipients started to reject the graft 
after 36 days post transplantation; at day 50 two out of four mice rejected the transplanted skin 
completely; at the end of the experiment only one mouse kept the graft (with score 2). B6 – BL/6 wild 
type; Cor1-/- - coronin 1-deficient. 
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4.3  Analysis of differences in T cell numbers between wild type and 
coronin 1-deficient mice and their influence on graft rejection 
To investigate whether decreased numbers of coronin 1-deficient T cells are the cause 
of delayed rejection, bm12Rag2-/- skin was transplanted onto Rag2-/- mice. The 
absence of T cells in Rag2-/- mice allows skin graft tolerance. The acceptance of the 
graft can be overcome by adoptive transfer of 20 000 BL/6 wild type CD4+ T cells 
(Schmaler, Broggi, and Rossi 2014). Therefore, three weeks after surgeries, we 
adoptively transferred CD4+ T cells purified from either BL/6 wild type or coronin 1-
deficient spleens. Transplanted mice injected with 20 000 of BL/6 wild type CD4+ T 
cells rejected the grafts within 12 days (Fig. 17). Coronin 1-deficient CD4+ T cells 
recipients received 20 000, 50 000, 100 000 and 1 000 000 cells by adoptive transfer 
and none of the group rejected the graft (Fig. 17). The data suggests that increasing 
coronin 1-deficient CD4+ T cells numbers does not lead to rejection in this model. 
Consequently decreased numbers of T cells in coronin 1-deficient mice alone were 
not responsible for delayed rejection. Additionally, to confirm the above statement we 
performed analysis of survival of wild type and coronin 1-deficient CD4+ T cells in 
Rag2-/- mice. We noticed defects in survival of coronin 1-deficient cells when 
compared with wild type. This issue is discussed later in Section 4.4.5 (Concentration 
dependence in survival of coronin 1-deficient T cells in vivo) of this Chapter.   
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Figure 17. Survival of bm12Rag2-/- skin grafts in Rag2-/- recipients after transfer of BL/6 wild type 
and coronin 1-deficient CD4+ T lymphocytes. The mice were transplanted following the 
transplantation protocol (Chapter 6.4); CD4+ T cells were adoptively transferred into tail vein 30 
days after surgery. Rejection was scored for 100 days. Group I shows survival of bm12Rag2-/- skin 
grafts in Rag2-/- mice after transfer of 20 000 negatively sorted BL/6 wild type CD4+ T cells. All mice 
in group I rejected skin within 12 days after cell transfer. Group II to V showed survival of bm12Rag2-
/- grafts in Rag2-/- recipients after transfer of: 20 000 (group II), 50 000 (group III), 100 000 (group 
IV) and 1 000 000 (group V) coronin 1-deficient CD4+ T cells. Mice from group II to V kept graft until 
day 100 after cell transfer (end point of the experiment). Each group consisted of 5 mice. B6 – BL/6 
wild type; Cor1-/- - coronin 1-deficient. 
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4.4  Study of T cell function in coronin 1-deficient compared to wild 
type mice 
 
4.4.1 Mixed lymphocyte reaction experiment in the study of proliferation 
of T cells 
In order to analyze proliferation and activation of T cells after allorecognition we 
performed mixed lymphocyte reaction experiments (MLR). This in vitro system 
allowed us to use the same number of wild type and coronin 1-deficient T cells 
thereby to compensate for the decreased numbers of these cells in the periphery of 
coronin 1-deficient mice. Mixed lymphocyte reaction experiment mimics rejection in 
vitro, where MHC mismatched cells are used as stimulators and responders. This 
experiment is an assay between two allogeneic populations, which was originally 
used to analyze leukocytes, mixed from two unrelated individuals in culture, to 
identify their compatibility as a donor and a recipient. Reaction of cultured 
lymphocytes was measured by blast formation, DNA synthesis and their proliferation 
quantified using incorporation of radioactive nucleosides (3H-thymidine or 5-bromo-
2’-deoxyuridine, BrdU) (Bach and Hirschhorn 1964; Bain, B, Vas, M., and 
Lowenstein, L. 1963).  
In our MLR experiments Balb/c splenocytes, depleted of erythrocytes and CD3+ 
cells, and then treated with mitomycin c to prevent proliferation, were used as 
stimulators. Total wild type or coronin 1-deficient T cells isolated from spleens were 
added to the Balb/c cultures and incubated for 52 hours. Afterwards thymidine was 
added and the cultures were further incubated for 20 hours. The thymidine 
incorporation into DNA reflects proliferation of cells. As can be seen in Fig. 18A, 
there was a significant difference in proliferation of total T cells from wild type and 
coronin 1-deficient mice. The coronin 1-deficient T cell proliferation rate was 
decreased, however it showed a similar trend as in for wild type with cells the highest 
proliferation at 400 000 stimulators. When the CD4+ (Fig. 18B) and CD8+ (Fig. 18C) 
T cells were purified and plated separately there was also a variety in the proliferation 
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rate between wild type and coronin 1-deficient cells – the coronin 1-deficient cells 
had reduced cell growth for both types of T cells. Additionally, the proliferation of 
CD4+ T cells was much lower that CD8+ T cells, which is consistent with the 
literature (Foulds et al. 2002). We concluded that the proliferation of coronin 1-
deficient cells is impaired compared with the wild type. However, with this type of 
experiment we could not measure survival of T cells and thus we could not be sure if 
the decreased rate of proliferation in coronin 1-deficient T cells is due to lower 
activation or lower survival rate of these cells compared to wild type. Therefore we 
decided to introduce immune staining instead of thymidine incorporation to 
investigate the status of the T cells within the MLR assay further.  
	
Figure 18. Mixed lymphocyte reaction (MLR) experiments with major mismatch antigens (Balb/c) 
for total (A), CD4+ (B) and CD8+ (C) T cells from BL/6 wild type or coronin 1-deficient mice. The 
cells were purified from mice spleen following the MLR protocol described in Materials and Methods 
(Chapter 6.20), plated onto 96-well plate and cultured for 72h. Balb/c splenocytes treated with 
mitomycin C were used as stimulators. Thymidine incorporation was measured as an indicator of 
proliferation of stimulated cells. Each point is a mean of three replicates; each experiment was 
repeated three times. All the points showing Cor1-/- proliferation were statistically different from wt. 
B6 – BL/6 wild type; Cor1-/- - coronin 1-deficient. 
 
4.4.2 Proliferation and survival of wild type and coronin 1-deficient T 
cells upon allorecognition  
The use of flow cytometry analysis provided important information about activation, 
survival and proliferation rate of T cells. The Balb/c splenocytes depleted of 
erythrocytes and CD3+ T cells were treated with mitomycin c and used as stimulators. 
Responder BL/6 wild type and coronin 1-deficient T cells were purified from mouse 
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spleens, labeled with Cell Trace Violet (CTV) and plated together with Balb/c 
stimulators. Antibody staining allowed to distinguish the CD4+ and CD8+ 
populations of T cells. The MLR experiments were performed with different numbers 
of stimulators and incubation times. Fig. 19 shows results of experiment performed 
with 100 000 total T cells as responders and analyzed for CD4+ T cells. Interestingly 
coronin 1-deficient CD4+ T cells seemed to start to proliferate earlier than wild type 
cells as can be seen, for example, in Fig. 21A and F. However, after 72h wild type 
CD4+ T cells started intense proliferation and general numbers of proliferated wild 
type cells were higher than for coronin 1-deficient T cells. Interestingly for the 
highest number of stimulators, coronin 1-deficient CD4+ T cells proliferated better 
than the wild type cells. We also detected similar differences in proliferation for 
CD8+ T cells (Supplementary Fig. 2). Coronin 1-deficient CD8+ T cells started to 
proliferate sooner (between 48 – 72h), however, generally wild type CD8+ T cells 
proliferated better than coronin 1-deficient cells for all the conditions. These data 
suggest that coronin 1-deficient T cells are able to initiate proliferation earlier than 
wild type cells upon activation. The proliferation of coronin 1-deficient T cells was 
noticeable after 48h in culture while wild type cells need at least 48 hours to initiate 
activation in MLR experiment (Elves 1969). Interestingly, when we compared rates of 
proliferation (percentage of proliferated cells within live cell population) between 
wild type and coronin 1-deficient T cells, they were similar for both CD4+ and CD8+ 
T cells. This suggests that the same percentage of surviving coronin 1-deficient T 
cells as in the wild type sample proliferated hence the proliferation itself is not 
decreased in coronin 1-deficient cells. These results further support our hypothesis 
that coronin 1-deficient T cell have impaired survival compared to wild type cells. 
The mechanism underlying a similar or even enhanced proliferation of coronin 1-
deficient T cells upon an increase in stimulators (Fig. 19F) is unclear and subject to 
further investigations (Section 4.4.4 Analysis of concentration dependence in survival 
of coronin 1-deficient T cells in vitro). 
Moreover, to test the specific activation of CD4+ T cells in a MHC class II 
mismatched model, we performed MLR experiments using bm12 splenocytes as 
stimulators. The activation of coronin 1-deficient CD4+ T cells was decreased 
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compared to wild type cells and similar to the background activation level. 
Additionally, coronin 1-deficient CD8+ T cells did not proliferate. These results 
suggest that in this experiment coronin 1-deficient CD4+ T cells could not be 
activated alone or their activation was suppressed, possibly indicating the impairment 
in coronin 1-deficient CD4+ T cells function to activate CD8+ T cells. 
	
Figure 19. CD4+ T cells proliferation analysis in a mixed lymphocyte reaction (MLR) for total T 
cells from BL/6 wild type and coronin 1-deficient mice as responders and different concentrations of 
Balb/c splenocytes as stimulators. Total T cells were purified as described in Materials and Methods 
Chapter 6.20. Stimulators Balb/c splenocytes were depleted of CD3 positive cells and erythrocytes 
(with anti-CD3 and anti-TER119 antibody, respectively). The cells were treated with mitomycin c to 
eliminate background proliferation of the stimulators. Then both cells were plated together in numbers 
indicated on each graph, in 96-well plates and cultured for 48, 72, 96 or 120h. The cells were analyzed 
by FACS using the same sample volume, time and speed of acquisition. A – F. Analysis of CD4+ T 
cells proliferation in a culture of 100 000 T cells with different numbers of Balb/c stimulators. An 
asterisk always shows the significance in the difference between BL/6 wt and Cor1-/- sample. Each 
time point shows a mean of 3 replicates. B6 – BL/6 wild type; Cor1-/- - coronin 1-deficient. 
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4.4.3 Survival of wild type and coronin 1-deficient T cells 
Furthermore, we decided to analyze survival of coronin 1-deficient T cells in in vitro 
assays. We established a series of negatively purified CD4+ and CD8+ T cells 
cultures with or without stimulation in 96-well plates. Fig. 20 shows a short-term 
experiment (5 – 300 min) in which the cells were cultured either in an absence of 
stimuli or stimulated with dendritic cells, CD3/CD28 antibodies or PMA/I (phorbol 
12-myristate 13-acetate/ionomycin). As we can see coronin 1-deficient T cells, both 
CD4+ and CD8+ T cells, had decreased survival with the biggest difference when 
stimulated with PMA/I and the smallest in the co-culture with dendritic cells. These 
results suggest that the coronin 1-deficient cells died more in response to a strong 
stimulation (Fig. 20C, G) and/or needed a survival signal from other cells (Fig. 20D, 
H). The difference in T cell survival between coronin 1-deficient and wild type cells 
could be explained by our previous observation that coronin 1-deficient T cells 
respond to the stimuli faster than wild type cells (Section 4.4.2. Proliferation and 
survival of wild type and coronin 1-deficient T cells upon allorecognition).  
	
Figure 20. Survival of CD4+ (A-D) and CD8+ (E-H) T cells in vitro without (A and E) or with 
stimulation with anti-CD3 and anti-CD28 (B and F), PMA and ionomycin (C and G), or dendritic 
cells (D and H). The CD4+ and CD8+ T cells were negatively sorted following the protocol described 
in Chapter 6.7, plated onto 96-well plate and cultured for 5, 15, 30, 60, 120 and 300 min at 37oC. Then 
the cells were stained following the FACS staining protocol (Chapter 6.6) and analyzed by FACS. 
Each point shows a mean of three replicates. Both experiments were repeated at least three times. 
Graphs show difference in survival between cell purified from BL/6 wt and coronin 1-deficient mice. 
B6 – BL/6 wild type; Cor1-/- - coronin 1-deficient. 
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4.4.4 Analysis of concentration dependence in survival of coronin 1-
deficient T cells in vitro 
It drew our attention that defect of coronin 1-deficient T cells to proliferate is 
overcome by increasing the numbers of stimulators. The highest concentration of 
stimulators (800 000) in major mismatched MLR experiment induced proliferation of 
coronin 1-deficient CD4+ T cells at similar level to the wild type (Fig. 19).  
Therefore, we decided to double the number of plated T cells. Interestingly, 200 000 
of coronin 1-deficient CD4+ T cells proliferated at a similar level as wild type cells 
(Fig. 21). Still, some differences could be seen (for 100 000, 200 000 and 400 000 
stimulators) but much lower than for 100 000 responder CD4+ T cells. This indicates 
that the coronin 1-deficient T cells were sensitive to the cell density and behaved 
better when plated in higher numbers. Higher numbers of responders (Supplementary 
Fig. 3) improved coronin 1-deficient CD8+ T cells proliferation, yet did not rescue it 
to the wild type levels.   
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Figure 21. CD4+ T cells proliferation analysis in a mixed lymphocyte reaction (MLR) for total T 
cells from BL/6 wild type and coronin 1-deficient mice as responders and different concentrations of 
Balb/c splenocytes as stimulators. Total T cells were purified as described in Materials and Methods 
Chapter 6.20. Stimulators Balb/c splenocytes were depleted of CD3 positive cells and erythrocytes 
(with anti-CD3 and anti-TER119 antibody, respectively). The cells were treated with mitomycin c to 
eliminate background proliferation of the stimulators. Then both cells were plated together in numbers 
indicated on each graph, in 96-well plates and cultured for 48, 72, 96 or 120h. The cells were analyzed 
by FACS using the same sample volume, time and speed of acquisition. A – F. Analysis of CD4+ T 
cells proliferation in a culture of 200 000 T cells with different numbers of Balb/c stimulators. An 
asterisk always shows the significance in the difference between BL/6 wt and Cor1-/- sample. Each 
time point shows a mean of 3 replicates. B6 – BL/6 wild type; Cor1-/- - coronin 1-deficient. 
 
4.4.5 Concentration dependence of the survival of coronin 1-deficient T 
cells in vivo 
In order to further characterize coronin 1-deficient T cell survival, we decided to 
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above coronin 1-deficient T cells survival and proliferation seemed to be dependent 
on the density of plated cells therefore, we adoptively transferred 20 000, 100 000 and 
1 000 000 of wild type or coronin 1-deficient CD4+ T cells into Rag2-/- mice (Fig. 
22). At day 30 after the cell transfer, mice were sacrificed and analyzed for numbers 
of surviving CD4+ T cells.  
When 20 000 of coronin 1-deficient cells were injected we could not recover many 
cells from Rag2-/- mice while 20 000 of wild type cells survived and additionally 
proliferated in the immunodeficient environment (Fig. 22A and B). However we 
could find coronin 1-deficient CD4+ T cells after transfer of 100 000 cells but the 
numbers were significantly lower than for the wild type (22 993 vs 254 987 cells, Fig 
22C and D). Transfer of 1 000 000 of cells gave relatively better survival of coronin 
1-deficient CD4+ T cells when compared with the wild type (Fig. 22E and F). These 
three experiments were done separately and it is surprising that the general number of 
surviving cells was the lowest for 1 000 000 wild type CD4+ T cells injected, where 
the difference between wild type and coronin 1-deficient cells was also the lowest. On 
the contrary, survival of wild type CD4+ T cells was similar for the adoptive transfer 
of 20 000 and 100 000. Observation that number of surviving T cells, upon adoptive 
transfer into lymphopenic environment, is independent of the number of injected T 
cell population was described before in a study on homeostatic proliferation and a 
pool size of T cells in lymphopenic environment in vivo (Rocha, Dautigny, and 
Pereira 1989). The T cells, both CD4+ and CD8+, after transfer to the lymphopenic 
host always expand to a certain number. The accumulation of their number is not 
dependent on the number of injected cells or their potential to proliferate; however, 
higher number of injected cells enables to reach the plateau faster. Moreover, they do 
not require exogenous antigen stimulation to proliferate. There must be a homeostatic 
mechanism controlling the number of T cells in the periphery that maintain the T cell 
pool size (Rocha, Dautigny, and Pereira 1989). However, survival of coronin 1-
deficient CD4+ T cells differed between those experiments significantly. Taken 
together, these results indicate that coronin 1-deficient CD4+ T cells had impaired 
proliferation and/or survival upon transfer into Rag2-/- mice, but which is dependent 
on their density.  
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To analyze the activation and proliferation level of coronin 1-deficient and wild type 
cells, we stained for the expression of three markers: Ki-67, CD62L and CD44 (Fig. 
23G-I). Ki-67 is a marker related to the proliferation (Scholzen and Gerdes 2000) and 
it was significantly higher on coronin 1-deficient cells when compered with wild type 
CD4+ T cells indicating that they were undergoing more intense proliferation than the 
wild type. CD62L and CD44 are markers of the activation of cells. Additionally, high 
expression of CD62L and CD44 indicates homeostatic proliferation of cells, which 
keeps the cell number at the constant level (Sprent and Surh 2011; Goldrath, 
Bogatzki, and Bevan 2000). The expression of CD62L and CD44 markers was high 
on the wild type cells. At the same time CD62L was low on the coronin 1-deficient 
CD4+ T cells, which signified their activation. The data suggested that the 
proliferation of coronin 1-deficient CD4+ T cells could not be impaired, however the 
cells were more activated and were undergoing more intense proliferation than wild 
type cells. However, increased activation of coronin 1-deficient T cells in general can 
be explained by the difference in subpopulation compared to wild type T cells. As 
reported before, coronin 1-deficient mice are depleted mainly of naïve T cells while 
memory/effector T cells are still present (Föger et al. 2006; Mueller et al. 2008).  
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Figure 22. Survival of CD4+ T cells from BL/6 wild type and coronin 1-deficient mice after adoptive 
transfer into tail vein of Rag2-/- mice. A and B. Transfer of 20 000 CD4+ T cells. C and D. Transfer 
of 100 000 CD4+ T cells. E and F. Transfer of 106 CD4+ T cells. G and H. Surface expression of 
CD62L and CD44 after adoptive transfer of 100 000 CD4+ T cells. I. Expression of Ki67 after transfer 
of 100 000 CD4+ T cells. CD4+ T cells were negatively purified from spleens of BL/6 wt or Cor1-/- 
mice and adoptively transferred into Rag2-/- mice. The mice were sacrifice 30 days after cell injection. 
Immune cells from lymph nodes (2x axillary, 2x brachial, 2x inguinal) were harvested, stained using 
anti-CD3 and anti-CD4 antibodies and analyzed with FACS. Each bar graph is a mean of 3 to 5 mice. 
B6 – BL/6 wild type; Cor1-/- - coronin 1-deficient. 
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Consistent with the result obtained in MLR assays, we noticed that survival of 
coronin 1-deficient CD4+ T cells was dependent on the density of these cells. Higher 
numbers of transferred cells resulted in better survival of coronin 1-deficient CD4+ T 
cells compared with the wild type. Furthermore, high expression level of Ki-67 in 
coronin 1-deficient CD4+ T cells and similar proliferation rate between wild type and 
coronin 1-deficient cells in MLR suggested that the proliferation of coronin 1-
deficient CD4+ T cells was not impaired. However the survival of cells seemed to be 
decreased in coronin 1-deficient T cells when compared with wild type. High 
expression of CD44 and low expression of CD62L of coronin 1-deficient CD4+ T 
cells indicate that these cells were activated and did not maintain homeostatic 
proliferation after transfer into Rag2-/- mice, in contrary to wild type cells. 
 
4.4.6 Characterization of cell proliferation in co-culture of coronin 1-
deficient with wild type T cells 
In order to investigate whether differences in cytokine production or surface protein 
expression between wild type and coronin 1-deficient T cells have an influence on the 
proliferation rate of these cells we co-cultured wild type and coronin 1-deficient T 
cells with different stimuli (major mismatched stimulators, dendritic cells, anti-CD3 
and anti-CD28 or PMA/I, Fig. 23). Fig. 23A illustrates the proliferation of total T 
cells (either wild type or coronin 1-deficient) in separate cultures (lines) and in a co-
culture of these cells together (using half of the cell number, bars). The cells were 
plated with Balb/c splenocytes depleted of CD3+ cells and erythrocytes as 
stimulators. The proliferation rate was measured as an incorporation of 3H-thymidine 
into the DNA. As described previously in this thesis, coronin 1-deficient T cells had 
decreased proliferation rate comparable with wild type cells. However, the 
proliferation of wild type and coronin 1-deficient T cells increased together with 
elevated numbers of stimulators. Although, co-culture of these cells showed better 
proliferation than coronin 1-deficient T cells alone, it did not a show similar rise in 
proliferation. These results suggest suppression of proliferation in co-culture of 
coronin 1-deficient and wild type T cells. To define a possible source of suppression 
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we co-cultured negatively sorted CD8+ T cells isolated from wild type and coronin 1-
deficient mice (Fig. 23B). Since in co-culture we used half of the coronin 1-deficient 
and wild type cell numbers the total proliferation rate for co-culture is decreased. 
However, growth of separate types of cells for coronin 1-deficient (orange line) and 
wild type (grey line) cells, in co-culture were similar to the proliferation in separate 
cultures. Therefore, we conclude that coronin 1-deficient CD8+ T cells did not 
interfere the proliferation of wild type cells. These results suggest that the suppression 
of T cells growth came from CD4+ T cells. 
	
Figure 23. Co-culture of BL/6 wild type and coronin 1-deficient T cells after stimulation with either 
MHC mismatched splenocytes (A) or autologous dendritic cells, anti-CD3 and anti-CD28, and 
PMA/I (B). A. Co-culture of total T cells (gray bar) and separate culture for BL/6 wt (black line) and 
Cor1-/- (red line) in the present of Balb/c splenocytes as a stimulators. The cells were obtained and 
plated as described before (MLR experiments). The proliferation was measured by incorporation of 
thymidine. B. Co-culture of CD8+ T cells (grey bar) and separate culture of BL/6 wt (black line) and 
Cor1-/- (red line) cells. Grey line represents proliferation of CD8+ T cells from BL/6 wt in the co-
culture, orange line – proliferation of Cor1-/- in the co-culture. The cells were processed and plated 
following the protocol from proliferation and cytokine production assay (Chapter 6.18). For the 
separate culture 300 000 cells/well were used (from either BL/wt or Cor1-/- mice). For the co-culture 
150 000 cells were used from both BL/6 wt and Cor1-/- mice. The cells were analyzed using FACS. 
Each time point shows a mean of three individual mice used per sample. wt – BL/6 wild type; Cor1-/- - 
coronin 1-deficient. 
 
4.4.7 Cytokine production by coronin 1-deficient and wild type T cells 
Cytokines, important players in modulating immune responses, are secreted by 
different types of cells, immune as well as non-immune cells, and are able to 
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stimulate or inhibit other cell responses. Since the development of mature 
immunocompetent lymphoid cells from precursors, their antigen-driven responses and 
suppression are highly dependent on cytokines, to characterize the functionality of 
coronin 1-deficient T cells in response to different stimuli we analyzed secretion of 
three cytokines by these cells compared with the wild type. We chose to stain for 
interleukin-2 (IL-2), interferon-γ (IFNγ) and tumor necrosis factor-α (TNFα). IL-2 is a 
pleiotropic cytokine that drives T cell growth and development, induces 
differentiation of regulatory T cells and mediates activation-induced cell death. 
Therefore the appropriate level of IL-2 is important for proper T cell homeostasis and 
survival (Malek and Castro 2010; Liao, Lin, and Leonard 2011). IFNγ is another 
pleiotropic cytokine that modulates an adaptive immune response, for example, by 
promoting differentiation of cytotoxic T cells and enhancing antigen-presentation 
abilities causing increase in expression of MHC complexes (Cannon 2000). Recently, 
IFNγ has been reported to be involved, together with IL-7R, in CD8+ T cells 
maintenance (Kimura et al. 2013). IFNγ, together with TNFα, is considered a 
proinfammatory cytokine. IFNγ enhances activity of TNFα, which stimulates 
leukocyte proliferation, cytotoxicity and secretion of other cytokines (Dinarello 
2000). These three cytokines are involved in T maintenance, therefore their abnormal 
secretion can influence the T cell function and survival.  
To investigate secretion levels of IL-2, IFNγ and TNFα of coronin 1-deficient T cells 
compared with the wild type, we performed a series of in vitro experiments. 
Negatively purified CD4+ and CD8+ T cells were cultured either in the absence of 
stimuli or stimulated for up to 300 min with dendritic cells, CD3/CD28 antibodies or 
PMA/I (Supplementary Fig. 4, 5 and Table 2). Interestingly, as reported before 
(Dinarello 2000), the level of IFNγ produced by coronin 1-deficient CD8+ T cells was 
higher than for wild type; this could mean increased activation of these cells (Kimura 
et al. 2013). Enhanced levels of INFγ upon stimulation by IL-7 signaling leads to 
activation-induced cell death, which may explain impaired survival of coronin 1-
deficient CD8+ T cells (Kimura et al. 2013). Also, after 300 min of stimulation with 
PMA/I, IFNγ was increased in coronin 1-deficient CD4+ T cells when compared with 
wild type. Hence indicating that coronin 1-deficient CD4+ T cells, upon activation, 
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would preferably differentiated into TH1 helper cell. However, there were no 
significant changes in the expression of IL-2, which is also associated with TH1 
maturation (Mosmann et al. 1986). Interestingly, CD4+ T cells are reported to 
enhance their proliferation and survival rate when exposed to IFNγ (Reed, Branigan, 
and Bamezai 2008), which is the opposite of what we observed in the MLR 
experiments. As mentioned above, IL-2 secretion was not changed in coronin 1-
deficient CD4+ T cells in the culture with or without stimulation. The same 
observation was true for coronin 1-deficient CD8+ T cells. TNFα secretion was 
decreased in coronin 1-deficient CD4+ T cells after 120 min of activation with 
PMA/I, which indicates activation of these cells (Hill et al. 2000). To further 
characterize activation and exhaustion of T cells we analyzed expression of several 
cell surface markers. The results are discussed below.  
T cell 
type 
Stimuli Cytokine stained LAMP-1 IFNγ TNFα IL-2 
CD4+ 
 
No (medium) 
No significant 
differences 
No significant 
differences No significant 
differences 
No significant 
differences 
DC Significant increase 
CD3/CD28 No significant 
differences PMA/I Increase after 300 min in Cor1-/- cells 
Decrease after 120h 
in Cor1-/- cells 
CD8+ 
No (medium) No difference between 
BL/6 wt and Cor1-/- 
No significant 
differences 
No significant 
differences 
No significant 
differences 
DC 
CD3/CD28 Significant increase in 
Cor1-/- cells 
compared with wt PMA/I 
Table 2. Summary comparison of cytokine (IFN-gamma, TNF-alpha, IL-2) and LAMP-1 
production in BL/6 wild type and Cor1-/- mice after stimulation with dendritic cells (DC), 
CD3/CD28 or PMA/I over time. Dendritic cells were obtained from bone marrow of BL/6 wt mice 
after one week of culture in the presence of GM-CSF (as described in Materials and Methods). Then 
the cells were plated in 96-well plate at the concentration of 30 000 cells/well one day before T cells 
culture started. CD4+ or CD8+ T cells were negatively purified following the protocol (Chapter 6.7), 
plated in 96-well plate at the concentration of 200 000 cells/well, in the absence or presence of the 
stimuli. The cells were analyzed using FACS. The table shows the summary of results attached in the 
supplement (Supplementary Fig. 4 and 5).  
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In addition to cytokine staining, we analyzed surface expression of lysosomal 
associated membrane protein 1 (Lamp-1). Lamp-1 (CD107a) is a transmembrane 
protein residing within lysosomes that upon stimulation can be expressed at the cell 
surface. For example, cell surface expression of Lamp-1 occurs due to the lysosomal 
fusion with the cell membrane, and it is found on cytotoxic T cells or metastatic 
cancer cells where it acts as a ligand for selectins (Kima, Burleigh, and Andrews 
2000; Laferte and Dennis 1989). We found a significant increase in surface 
expression of Lamp-1 in coronin 1-deficient CD4+ T cells only when stimulated with 
dendritic cells (Supplementary Fig. 4 and 5, Table 2). The expression was enhanced 
between 30 and 120 min with noticeable decrease at 300 min, possibly as a result of 
cell-to-cell interaction in this cultured condition. 
 
4.4.8 Expression of specific markers by coronin 1-deficient T cells 
Furthermore, we analyzed specific markers in coronin 1-deficient and wild type T 
cells (Table 3 and Supplementary Fig. 6, 7 and 8).  
Ki-67 a proliferation marker 
As mentioned before in this thesis, we characterized growth of cells by staining for 
expression of proliferation marker Ki-67. Since this protein can be detected in active 
phases of cell cycle (G1, S, G2 and mitosis) and is absence in resting cells (phase G0), 
it is strictly associated with proliferation and can be used to determine growth of cells 
(Scholzen and Gerdes 2000). Expression of this marker was enhanced in spleen and 
lymph nodes in both CD4+ and CD8+ T cells of coronin 1-deficient mice when 
compared with the wild type. This indicates that the coronin 1-deficient T cells 
underwent more intense proliferation than the wild type in the absence of external 
stimuli. Which implies that the coronin 1-deficient T cells are activated even in naïve 
mice, which could cause their exhaustion. Interestingly, Ki-67 expression was 
decreased in coronin 1-deficient thymocytes compared with wild type cells. Reduced 
expression of Ki-67 and increased apoptosis in the thymus is associated with thymic 
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involution (Kanavaros et al. 2001). However, the thymus in coronin 1-deficient mice 
is normal compared with the wild type (Mueller et al. 2008). 
  PD-1 and Bcl-2 expression in coronin 1-deficient and wild type T cells 
Bcl-2 is an anti-apoptotic marker regulating normal life span of the cell. High 
expression of this protein occurs in long-lived cells, thus activated lymphocytes, when 
not continuously stimulated, express lower levels of Bcl-2. Memory lymphocytes 
have more of this marker on the surface (Chávez-Galán et al. 2009; Bouillet et al. 
2002). Bcl-2 expression was significantly increased in coronin 1-deficient CD8+ T 
cells of spleen and lymph nodes. CD4+ T cells Bcl-2 levels were not affected by the 
deletion of coronin 1, as shown previously (Mueller, Liu, and Pieters 2011). Being 
consistent with this result, PD-1 levels were enhanced in spleen and lymph nodes in 
both CD4+ and CD8+ T cells of coronin 1-deficient mice compared with the wild 
type. PD-1, an immune exhaustion marker, and its high expression is induced by 
persistent TCR signaling. During chronic infection, continuously activated exhausted 
T cells overexpress PD-1 at the cell surface. This inhibits T cell function and survival, 
and has been reported to promote Treg development (Francisco, Sage, and Sharpe 
2010). Bcl-2 and PD-1 are highly expressed on the surface of continuously stimulated 
and activated T cell, we noticed increased expression of both markers on coronin 1-
deficient CD8+ T cells when compared with wild type. PD-1 level was also increased 
on coronin 1-deficient CD4+ T cells. 
 Expression of CD5 molecule 
CD5 molecule associates with T and B cell receptor complexes modulating their 
signals and plays an essential role in T cell development. This molecule is a positive 
as well as a negative regulator of antigen receptor signaling. Therefore, alteration of 
CD5 expression levels in T cells affects TCR responses, for example, its high 
expression effects in the development of antigen-specific unresponsiveness in T cells 
(Soldevila, Raman, and Lozano 2011). Moreover, CD5 has a pro-survival role, is 
associated with strong activation of T cells (Osman, Ley, and Crumpton 1992) and 
high level of this protein is found on Tregs (Ordoñez-Rueda et al. 2009). CD5 
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expression levels were increased in spleen and lymph nodes in both CD4+ and CD8+ 
T cells of coronin 1-deficient mice compared with wild type T cells. 
 Surface levels of IL-7 receptor  
IL-7 signaling plays a crucial role in T cell homeostasis. Increased continuous IL-7 
level and insufficient TCR signaling result in induced CD8+ T cells proliferation and 
activation. This in turn triggers enhanced secretion of INFγ and suppresses IL-7 
receptor expression on cell surface leading to cell death (Kimura et al. 2013). 
Moreover, IL-7 signaling participates in survival of CD4+ T cells, however, the 
mechanisms of that are still under an intensive studies (Fig. 8) (Hataye et al. 2006). 
Expression of IL-7 receptor was decreased in CD4+ and CD8+ T cells of coronin 1-
deficient spleen and lymph nodes when compared with the wild type. These results, in 
agreement with previously described staining, shows increase in activation of coronin 
1-deficient T cells. Furthermore, decrease in IL-7R surface expression together with 
enhanced levels of INFγ (described in Section 4.4.7 Cytokine production by coronin 
1-deficient and wild type T cells) suggests a cytokine-induced cell death (CICD) as a 
possible apoptotic pathway of CD8+ T cells of coronin 1-deficient mice.  
Expression of FasL 
Fas ligand (FasL) is expressed on activated T cells and it induces cell death via 
apoptosis. This cell death induced by engagement of Fas/FasL pathway plays an 
important role in modulation of immune homeostasis through stimulation of 
activation-induced cell death (AICD) which limits expansion of T cells after 
elimination of pathogen and inactivate autoreactive peripheral T cells (Paul Waring 
and Müllbacher 1999; Schneider et al. 1997; Ashwell, Longo, and Bridges 1987). We 
found increased expression of FasL on coronin 1-deficient CD4+ T cells in spleen, 
lymph nodes and thymus compared to wild type cells. Surface level of FasL was also 
increased on coronin 1-deficient CD8+ T cells when compared to wild type cells but 
the increase was not significant. 
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Marker T cell type Organ spleen LNs thymus 
Ki67 
 
CD4+ Significant increase in Cor1-/- 
Significant increase in 
Cor1-/- Decrease in Cor1-/- 
CD8+ Significant increase in Cor1-/- 
Significant increase in 
Cor1-/- 
Significant decrease in 
Cor1-/- 
PD-1 
CD4+ Significant increase in Cor1-/- 
Significant increase in 
Cor1-/- No significant difference 
CD8+ Significant increase in Cor1-/- No significant difference No significant difference 
IL-7R 
CD4+ Significant decrease in Cor1-/- 
Significant decrease in 
Cor1-/- 
Significant decrease in 
Cor1-/- 
CD8+ Decrease in Cor1-/- Decrease in Cor1-/- Significant decrease in Cor1-/- 
CD5 
CD4+ Significant increase in Cor1-/ - No significant difference No significant difference 
CD8+ Significant increase in Cor1-/- 
Significant increase in 
Cor1-/- No significant difference 
Bcl-2 
CD4+ No significant difference No significant difference No significant difference 
CD8+ Significant increase in Cor1-/- 
Significant increase in 
Cor1-/- No significant difference 
FasL 
CD4+ Significant increase in Cor1-/- 
Significant increase in 
Cor1-/- 
Significant increase in 
Cor1-/- 
CD8+ No significant changes No significant changes No significant changes 
Table 3. Summary of cell markers expression. The cells from spleen, lymph nodes and thymus were 
harvested and processed following the protocol (Chapter 6.5). Then they were FACS stained for Ki67, 
PD-1, IL-7R, CD5 and Bcl2 as described in the protocol for surface and intracellular FACS staining in 
the Materials and Methods Section 6.6. The results are attached in the supplement (Supplementary 
Fig.6, 7 and 8). Cor1-/- - coronin 1-deficient mice. 
 
Taken together, coronin 1-deficient T cells expressed increased levels of PD-1, Bcl-2, 
FasL and CD5 when compared with wild type cells. Enhanced surface expression of 
these markers is correlated with intense stimulation, high activation and exhaustion of 
T cells. Additionally, expression of IL-7R on coronin 1-deficient T cells was 
decreased compared to wild type cells, which indicates continuous stimulation of T 
cell or insufficient TCR signaling and is correlated with increased secretion of IFNγ 
(data described above). Interestingly, activated T cells usually undergo intense 
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proliferation and coronin 1-deficient T cells showed increased levels of Ki-67 
compared to wild type cells.  
At the same time, expression of most of those markers was not changed in the thymus 
of coronin 1-deficient mice compared with the wild type (no significant differences in 
PD-1, CD5 and Bcl-2 levels). IL-7R showed significant decrease in the thymus of 
coronin 1-deficient mice compared with the wild type, which could indicate defects in 
the thymocytes development and impaired balance between naïve and 
activated/memory T cells in the periphery (Nasi et al. 2006; Shitara et al. 2013). 
Therefore, we decided to perform an in-depth analysis of T cell numbers in wild type 
and coronin 1-deficient mice.   
 
4.4.9 Numbers of T cell subsets in coronin 1-deficient mice 
The peripheral T cell population is maintained at a stable number thanks to two 
mechanisms: peripheral T cell homeostasis and thymic output of newly generated T 
cells. Mature T cells leaving the thymus are referred to as recent thymic emigrants 
(RTE). They are a distinct population as they are not as functionally mature as 
peripheral naïve T cells (in terms of proliferation and cytokine production) 
(Boursalian et al. 2004). Using two different markers (CD24 and Qa-2 (Paiva et al. 
2013; Boursalian et al. 2004)) we were able to obtain similar results, which showed 
that, although coronin 1-deficient mice have reduced numbers of recent thymic 
emigrants compared with the wild type, we could find them in the periphery of adult 
mice (Fig. 24E, F, M and N). All of the other T cell type numbers were decreased in 
the periphery (Fig. 24, as reported before (Föger et al. 2006; Mueller et al. 2008)). 
Generally decreased numbers of peripheral T cells explained elevated percentage of 
RTE in coronin 1-deficient mice. In order to eliminate T cell arrest in the thymus of 
coronin 1-deficient mice we analyzed thymus for the percentage and number of cells 
(Fig. 25). Rates and numbers of double positive (CD4+CD8+), double negative, 
CD4+ and CD8+ thymocytes were comparable between wild type and coronin 1-
deficient mice. These results suggest that the production and egress of T cells in the 
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thymus of coronin 1-deficient mice are functional. However, it drew our attention that 
coronin 1-depleted mice showed elevated rate of CD25+ cells within the CD4+ T cell 
population (Fig. 24G and O). This observation is further discussed in the next Section 
of this Chapter. 
	
Figure 24. Different T cells subsets in BL/6 wild type compared with coronin 1-deficient mice. A and 
B show T cells percentage and numbers in lymph nodes, respectively. C and D – naïve, memory CD4+ 
and CD8+ T cell rates and numbers in lymph nodes. E and F, recent thymic emigrants (RTE) 
quantities in lymph nodes. G and H represent activated CD4+ and CD8+ T cells (CD25+) in lymph 
nodes. I and J show T cells percentage and numbers in spleen, respectively. K and L – naïve, memory 
CD4+ and CD8+ T cell rates and numbers in spleens. M and N, recent thymic emigrants (RTE) 
quantities in spleens. O and P represent activated CD4+ and CD8+ T cells (CD25+) in spleens. The 
organs were harvested and processed following the protocol (Chapter 6.5). The cells were stained 
using surface and intracellular staining protocol from Materials and Methods. Afterwards, the cells 
were analyzed with the FACS. The figure shows representative results from one experiment where five 
mice were used per group. B6 wt – BL/6 wild type; Cor1-/- - coronin 1-deficient. 
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Figure 25. Percentage (A) and numbers (B) of different T cells subsets in the thymus of BL/6 wt and 
Cor1-/- mice. Thymi were harvested and processed following the protocol described in Chapter 6.5. 
The cells were stained for surface antigens. The figures shows representative results from one 
experiment where five mice were used per group. B6 wt– BL/6 wild type; Cor1-/- - coronin 1-deficient. 
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4.5  Analysis of tolerance induction after skin transplantation in coronin 
1-deficient recipients  
 
4.5.1 Regulatory T cells in coronin 1-deficient mice 
To address the question whether prolonged graft survival in coronin 1-deficient 
recipients is due to tolerance induction, first we characterized frequencies and 
numbers of regulatory T cells (CD4+CD25+Foxp3+ T cells, called Tregs) in naïve 
and transplanted mice. Tregs provide an additional mechanism, beside anergy and 
apoptosis, to maintain tolerance. They are found not only in the secondary lymphoid 
organs, but also in sites of infection where they can down-regulate immune process 
(Sakaguchi 2004). Thus, after transplantations Tregs are present in recipient lymphoid 
tissue and at the graft site. In resting conditions Tregs represent about 5 – 10% of total 
CD4+ T cells in the periphery (X. C. Li and Turka 2010). The analysis showed 
increased frequencies of regulatory T cells in lymph nodes and spleens of knockout 
animals compared with wild type mice (Fig. 26A). However, the number of Tregs 
remained decreased in coronin 1-deficient mice when compared with the wild type. 
This suggests that Tregs were also affected by coronin 1-deficiency but at a lower 
level than other T cells, thereby influencing the balance between regulatory and 
conventional CD4+ T cells. Additionally, analysis of transplanted animals showed 
enhanced rates of regulatory T cells in coronin 1-deficient recipients when compared 
with the wild type (Fig. 26B).  
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Figure 26. Frequencies and numbers of regulatory T cells (Tregs) in naïve (A) and mice 
transplanted with bm12Rag2-/- skin (B). A. Percentage and number of Tregs in spleens and lymph 
nodes of naïve BL/6 wild type and Cor1-/- mice. Organs were harvested and processed followed the 
protocol described in Chapter 6.5. Then the cells were stained with CD3, CD4, CD25 and Foxp3 
antibodies as described in intracellular FACS staining protocol. The experiment shows a 
representative graph from one out of three separate experiment were 5 mice per group were used for 
staining. B. Percentage and number of Tregs in lymph nodes of BL/6 wild type and Cor1-/- after 
transplantation with bm12Rag2-/- skin graphs compared with naïve mice. The mice were transplanted 
according to the  transplantation protocol described in Chapter 6.4. The wild type mice were sacrificed 
at the day of the rejection (day 12 after transplantation), coronin 1-deficient mice were sacrificed at 
day 100 after the surgery. Lymph nodes were processed and stained as described before. The graph 
shows results pooled from two separate experiments where at least 3 mice were used per experimental 
group. B6 wt – BL/6 wild type; Cor1-/- - coronin 1-deficient. 
 
4.5.2 Tolerance maintenance after skin graft transplantation 
To further determine if increased frequencies of Tregs and induction of tolerance are 
the main reason for the prolonged graft survival in coronin 1-deficient recipients, we 
challenged them with transfer of wild type CD4+ T cells. To this end we performed 
spleen LNs
0
5
10
15
20
%
 o
f F
ox
p3
+C
D
25
+ 
C
D
4+
 T
 c
el
ls
0,0003
0,0007
spleen LNs
0.0
5.0 105
1.0 106
1.5 106
2.0 106
nu
m
be
r o
f F
ox
p3
+C
D2
5+
 C
D4
+ 
T 
ce
lls
B6.wt
Cor1-/-
0,003
0,001
na
ive
bm
12
 Tx
na
ive
bm
12
 Tx
0
10
20
30
40
%
 o
f F
ox
p3
+C
D
25
+ 
C
D
4+
 T
 c
el
ls
wt Cor1-/-
na
ive
bm
12
 Tx na
ive
bm
12
 Tx
0.0
5.0 104
1.0 105
1.5 105
2.0 105
2.5 105
nu
mb
er
 o
f F
ox
p3
+C
D2
5+
 C
D4
+ 
T 
ce
lls
wt Cor1-/-
A
B
 	
	
Results 
	
	 	
91	
bm12Rag2-/- skin transplantation onto coronin 1-deficient mice. Additionally, we 
transplanted Rag2-/- mice with bm12Rag2-/- skin graft to use as a control. Then, 48 
days after surgeries we injected wild type CD4+ T cells into coronin 1-deficient and 
Rag2-/- recipients. Rag2-/- mice, when transplanted with skin grafts, did not show any 
rejection. After adoptive transfer of 20 000 wild type CD4+ T cells, Rag2-/- recipients 
rejected within 29 days (Fig. 27). Similarly, coronin 1-deficient recipients did not 
reject bm12Rag2-/- skin grafts. However, after injection of wild type CD4+ T cells, 
we observed several rejections within coronin 1-deficient mice. However, all 
rejections were delayed when compared with Rag2-/- controls. Interestingly, we 
injected different numbers of wild type CD4+ T cells into coronin 1-deficient 
recipients (20 000, 100 000, 106 and 5x106) and the rate of rejection varied between 
different groups. In the group where 20 000 wild type CD4+ T cells were adoptively 
transferred, two out of four mice rejected skin transplants. Similar rejection was 
observed after injection of 5x106 cells (2 out of 4 rejected). Mice injected with 100 
000 cells showed rejection in two out of five mice. Interestingly, none of graft 
recipients receiving 106 of wild type CD4+ T cells rejected (five mice in the group). 
When we repeated this experiment we obtained even longer delay in rejection (after 
transfer with 20 000, 100 000 and 106 of wild type CD4+ T cells) when compared 
with Rag2-/- controls (50 vs. 14 days, data not shown). Notwithstanding, the delayed 
rejection in mice injected with wild type CD4+ T cells suggests suppression of these 
cells through interference in their function or their death. The variability in graft 
tolerance within the same group could be caused by different survival of transferred 
wild type CD4+ T cells and the adequate rate of Tregs:cCD4 that is required to 
maintain tolerance. This rate varies according to the level of allospecificity of 
recipient regulatory T cells (Graca et al. 2002).  
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Figure 27. Adoptive transfer of BL/6 wt CD4+ T cells into Cor1-/- mice transplanted with 
bm12Rag2-/- skin. The coronin 1-deficient (Cor1-/-), Rag2-/- and BL/6 wild type (B6 wt) mice were 
transplanted with bm12Rag2-/- skin according to the protocol. The BL/6 wt recipients rejected grafts 
after two weeks; Rag2-/- and Cor1-/- mice kept the grafts and were intravenously injected with BL/6 wt 
CD4+ T cells 48 days after transplantation. Rag2-/- recipients were used as a control for the transfer 
and vitality of injected cells. Graph shows transfer of 20 000, 100 000, 1 00 000 and 5 000 000 wt 
CD4+ T cells. Graphs represent survival of skin grafts after adoptive transfer of cells up to 100 days 
after transplantation. Each group represents at least 4 mice. 
 
4.5.3 Induction of graft rejection in coronin 1-deficient recipients  
The transgenic ABM mice have antigen-specific CD4+ T cells towards the I-Abm12, 
which can be tracked using the expression of the Vα2.1/Vβ8.1 TcR chains 
(Bäckström et al. 1998). Therefore, we decided to use bm12-specific (ABM) T cells 
to induce specific rejection in coronin 1-deficient mice after transplantation with 
bm12Rag2-/- skin. In order to do so, we performed bm12Rag2-/- skin transplantations 
onto Rag2-/- or coronin 1-deficient mice. Afterwards, at day 28 after surgeries the 
mice were injected with different numbers of ABM cells (20 000, 100 000 and 106, 
Fig. 28). Rag2-/- recipients rejected skin grafts within 12 days after adoptive transfer 
(both groups receiving 20 000 and 100 000 wild type CD4+ T cells). In the 
experimental groups we observed tolerance in most of the coronin 1-deficient 
recipients while several animals showed rejection. Consistent with previous 
experiments (Section 4.5.2. Tolerance maintenance after skin graft transplantation) 
the rejection rate did not depend on the number of transferred cells. One out of four 
mice rejected in both groups receiving 100 000 and 106 of ABM cells, while two out 
of four mice rejected after injection of 20 000 ABM cells. It seemed that there was a 
slight difference between tolerance and rejection in coronin 1-deficient mice, however 
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the reasons are unknown. One possibility is that these differences in graft tolerance of 
coronin 1-deficient mice depend on the number of recipient’s suppressive cells, which 
can vary from mouse to mouse due to their impaired survival in the absence of 
coronin 1. Indeed, there are studies describing that the balance between effectors and 
regulatory T lymphocytes controls the outcome of allografts (Benghiat et al. 2005; 
Graca et al. 2004; Tang and Lee 2012; Graca et al. 2002). 
	
Figure 28. Adoptive transfer of ABM cells into Cor1-/- mice transplanted with bm12Rag2-/- skin. 
The Cor1-/-, Rag2-/- and BL/6 wild type mice were transplanted with bm12Rag2-/- skin as described in 
Materials and Methods. The BL/6 wt recipients rejected grafts within two weeks; Rag2-/- and Cor1-/- 
mice kept the grafts and were intravenously injected with 20 000, 100 000 and 1 00 000 of ABM cells 
28 days after transplantation. Rag2-/- recipients were used as a control for the transfer and vitality of 
injected cells. Each group consisted of at least 3 mice. Cor1-/- - coronin 1-deficient; bm12 – 
bm12Rag2-/- mice. 
 
4.5.4 Induction of rejection in immunodeficient recipients 
To minimize the influence of other immune cells (such as B cells, NK cells, 
neutrophils and dendritic cells) and the effect of reduced CD4+ T cell numbers in 
coronin 1-deficient mice we decided to use Rag2-/- mice as graft recipients. Due to 
the fact that Rag2-/- mice are lacking T cells (Shinkai et al. 1992) we could 
manipulate numbers of injected T cells from coronin 1-deficient and wild type mice. 
Additionally, we tried to induce rejection by adoptive transfer of ABM cells. Firstly, 
the Rag2-/- mice were transplanted with bm12Rag2-/- skin grafts, 30 days after they 
were adoptively transferred with 20 000 coronin 1-deficient CD4+ T cells. 
Afterwards, at day 30 after CD4+ T cell transfer, the mice were additionally injected 
with 100 000 ABM cells. The results show that only one out of five mice rejected the 
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skin transplant when challenged with ABM cells (Fig. 29). The single rejection could 
be explained by poor survival of coronin 1-deficient CD4+ T cells after injection of 
such a low number (20 000) of cells in this mouse, since the other four mice kept the 
graft and therefore the results suggest that coronin 1-deficient CD4+ T cells can 
maintain tolerance of bm12Rag2-/- skin.  
	
Figure 29. Transfer of BL/6 wild type and coronin 1-deficient CD4+ T cells into Rag2-/- mice 
transplanted with bm12Rag2-/- skin and additional challenge with ABM cells. Rags2-/- mice were 
transplanted with bm12Rag2-/- following the transplantation protocol (Chapter 6.4). 30 days later 
recipients were injected with either BL/6 wt or Cor1-/- CD4+ T cells. Recipients of the wild type CD4+ 
T cells rejected skin grafts 12 days after injection. Rag2-/- recipients receiving Cor1-/- CD4+ T cells 
were additionally adoptively transferred with 100 000 ABM cells 30 days after the first injection. Only 
one out of five mice rejected the skin graft in this group. Each experimental group consisted of 5 mice. 
B6 wt – BL/6 wild type; Cor1-/- - coronin 1-deficient. 
 
4.5.5 Analysis of graft rejection in CD25-depleted skin transplantation 
model 
When the transplanted tissue is accepted Tregs numbers are increased in the periphery 
and in the graft (Salisbury, Game, and Lechler 2014; Joffre et al. 2008). Removal of 
CD25+ cells subset, which contains Tregs, results in prevention of spontaneous 
transplant tolerance in mice (W. Li et al. 2006). Depleting rat anti-mouse CD25 mAb 
(PC61) is widely used to characterize Tregs in vivo (Setiady, Coccia, and Park 2010; 
Siegmund et al. 2011). PC61 antibody removes 70% of CD4+CD25+Foxp3+ T cells 
from the peripheral blood after single dose. The mechanism of depletion by PC61 is 
based on phagocytosis of antibody-bound cells. While the antigen-binding fragment 
of the PC61 antibody binds to the CD25+ cells the Fc fragment is recognized by 
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FcγRIII receptor expressed on phagocytes, such as macrophages.  The binding of Fc 
fragment to its receptor mediates antibody-dependent phagocytosis thereby depleting 
CD25+ cells (Setiady, Coccia, and Park 2010). To further determine if Tregs are the 
main reason for the prolonged graft survival in coronin 1-deficient recipients, we 
performed bm12Rag2-/- skin transplantation onto coronin 1-deficient mice with either 
depleted or not CD25+ cells. Depleting anti-mouse CD25 mAb was given to the 
recipients 5 and 3 days pretransplantation and additionally 3 days after surgeries at a 
dose 0.5 mg per mouse. The level of Tregs was controlled in the blood by staining the 
day before surgery, and additionally 7 days after surgery (Supplementary Fig. 9). 
Moreover, coronin 1-deficient mice kept low numbers of Tregs until day 28. Treg 
numbers in coronin 1-deficient recipients recovered by day 65 after surgery. As 
expected, wild type recipients rejected skin grafts after 12-14 days (controls and 
CD25-depleted mice, Fig. 30). Normally, skin grafts in CD25+ T cells depleted mice 
are rejected earlier compared to non-depleted mice (Mai et al. 2014). Interestingly, in 
coronin 1-deficient mice depleted of CD25+ cells the graft survived longer than in 
controls. While eventually mice were able to reject skin grafts the rejection occurred 
at the time Tregs were replenished (started rejecting at day 58, rejected by day 78 
after surgery). The delay in rejection could be explained by decreased number of 
conventional CD4+ (cCD4+) T cells that needed more time to proliferate and lead to 
the rejection, or the suppressive function of coronin 1-deficient cCD4+ T cells.  
	
Figure 30. Rejection score (A) and graft survival (B) after transplantation of bm12 Rag2-/- skin 
grafts onto BL/6 wild type and Cor1-/- mice depleted or not of CD25+ cells. The mice were injected 
with 0.5mg of PC61 antibody. The injection was performed 5 and 3 days before and 3 days after 
transplantation to remove CD25+ cells. The transplantation was done following the transplantation 
protocol (Chapter 6.4) and the mice were observed up to 100 days after surgery. At least 3 mice were 
used in each experimental group. BL6 – BL/6 wild type; Cor1-/- - coronin 1-deficient. 
20 40 60 80 100
0
1
2
3
days after surgery
re
je
ct
io
n 
sc
or
e
20 40 60 80 100
0
50
100
days after surgery
gr
af
t s
ur
vi
va
l [
%
] bm12->BL6
bm12-> Cor1-/-
bm12 -> BL6 + 
CD25 depletion
bm12 -> Cor1-/- 
+ CD25 depletion
A B
 	
	
Results 
	
	 	
96	
To dissect this hypothesis and find the source of increased Treg frequency in coronin 
1-deficient mice, we performed two sets of experiments: first, to test the function and 
proliferation of Tregs; second, to investigate the suppressive ability of coronin 1-
deficient cCD4+ T cells.  
 
4.5.6 In vitro induction of regulatory T cells from wild type and coronin 
1-deficient cCD4+ T cells 
Regulatory T cells, produced by the thymus, are referred to as naturally occurring 
Tregs. They are functionally unique T cell population, proliferate poorly in the 
response to antigens, unless the IL-2 is present, and have a potential to suppress the 
activation of other T cells in an antigen non-specific manner. There exists another 
population of regulatory T cells, called induced Tregs, which develops in the 
periphery from naïve T cells upon TCR stimulation with signaling from appropriate 
cytokines (TGF-β and IL-2) (Chen et al. 2003; X. C. Li and Turka 2010). Regulatory 
T cells are generated in vitro from CD4+CD25- T cells through co-stimulation with 
TCR in a presence of TGF-β and IL-2 (Fantini et al. 2007; Chen et al. 2003). To test 
induction of wild type and coronin 1-deficient Tregs in vitro, we stimulated 
conventional (CD4+CD25-) wild type or coronin 1-deficient CD4+ T cells with anti-
CD3 and anti-CD28 in the presence of IL-2 and TGF-β (Fantini et al. 2007). Firstly, 
the CD4+CD25- cells were isolated from spleens of wild type and coronin 1-deficient 
mice by FACS sort. The cells were cultured for 2, 3, 4 and 5 days in the presence of 
stimulation or not. Then the surviving cells were analyzed for the percentage of 
CD4+CD25+Foxp3+ in coronin 1-deficient and wild type samples. The percentage of 
surviving Tregs in coronin 1-deficient samples after 3 days in culture was higher than 
in the wild type. However the numbers of coronin 1-deficient Tregs were significantly 
decreased (Fig. 31). At day 5 of culture almost all coronin 1-deficient Tregs were 
dead, in addition, the total number of cells in culture was low when compared to the 
wild type sample. Wild type Treg percentage and numbers were the highest at day 5 
in culture which is consistent with the literature (Fantini et al. 2007). These results 
suggest that coronin 1-deficient Tregs survived better than conventional CD4+ T cells 
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(until day 3), however not as good as the wild type cells. The conversion of coronin 1-
deficient cCD4+ into Tregs occurred earlier than in the wild type, and the cells 
survived for a shorter period of time.  
	
Figure 31. In vitro generation of Tregs from CD25- CD4+ T cells. The experiment followed the 
procedure described before elsewhere (Fantini et al. 2007) and in Materials and Methods of this 
thesis. CD4+ T cells from wild type and coronin 1-deficient mice were negatively purified and depleted 
of CD25+ cells using proper antibodies and magnetic beads. The cell purity was tested before plating 
(A). The cells were cultured in presence of IL-2 and TGFβ and analyzed with the FACS at day 1, 2, 3, 4 
and 5 (B). The figure shows representative results from one out of three repetitions. Cor1-/- - coronin 
1-deficient. 
 
4.5.7 In vivo regulatory T cells numbers after skin transplantation 
Separately, Treg frequencies were analyzed after skin transplantation in vivo. To this 
end we transplanted coronin 1-deficient and wild type mice with bm12Rag2-/- skin. 
Following transplantation, mice were analyzed for frequencies and numbers of 
immune cells at different time points (Fig. 32). Fig. 32A shows the rejection score for 
wild type and coronin 1-deficient transplanted mice and, as previously shown in this 
thesis, we observed fast rejection in BL/6 wild type mice and no rejection in coronin 
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1-deficient recipients. Flow cytometry analysis of immune cell composition showed 
that enhanced rate of Treg cells was present in coronin 1-deficient recipients 
compared with wild type mice. Numbers of Tregs in coronin 1-deficient were lower 
than in wild type, however they increased in a similar manner. Elevation of regulatory 
T cells percentages in coronin 1-deficient mice can be partially explained by low 
changes in numbers of other CD4+ and CD8+ T cells. Additionally, proliferation of B 
cells in lymph nodes of coronin 1-deficient recipients was similar to that in the wild 
type mock transplantations (BL/6àBL/6, Fig. 32I). This is consistent with the 
observation that the activation of B cells in coronin 1-deficient mice was not 
sufficient to cause rejection alone. Interestingly, the level of Tregs was similar after 
transplantation of bm12Rag2-/- onto coronin 1-deficient mice and mock surgeries 
(Cor1-/-àCor1-/-, Fig. 32B and C), which indicates that these cells were not 
generated specifically in response to alloantigen.  
In order to further study the increase of Tregs in coronin 1-deficient and wild type 
mice after transplantation, we performed a time course experiment with shorter time 
point for analysis. This time we examined only mock surgeries, as we found their 
Tregs rates similar to MHC class II mismatched transplantations. The results showed 
that Tregs percentage increase was higher in coronin 1-deficient than in the wild type 
(slope of 1.186 and 0.584 for coronin 1-deficient and wild type cells, respectively, 
Fig. 33A), the numbers however are not changing a lot (Fig. 33E). The increase in the 
Tregs numbers was greater for wild type recipients than coronin 1-deficient (slope of 
26255 and 4104 for coronin 1-deficient and wild type cells, respectively). The rise of 
CD4+ and CD8+ cells was decreased in the coronin 1-deficient recipients (in both 
numbers as well as percentage, Fig. 33B, C, F and G). Interestingly, B cells growth 
(%) was similar between wild type and coronin 1-deficient mice, indicating that these 
cells are not impaired in coronin 1-deficient recipients upon mock transplantation 
(Fig. 33D and H).  
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Figure 32. Regulatory T cells generation after skin transplantation in bm12Rag2-/- recipients. 
Rejection score (A) and variability of cells (B – O) in spleen and lymph nodes of BL/6 and Cor1-/- mice 
after transplantation with bm12Rag2-/- skin and mock surgeries. BL/6 wild type and coronin 1-
deficient mice were transplanted with bm12 Rag2-/- skin following the transplantation protocol 
(Chapter 6.4). Each group consisted of 10 mice for mock surgery and 15 mice for the mismatch 
transplantations. 7, 14 and 23 days later groups of 3 to 4 (mock surgery) and 5 (bm12Rag2-/-) mice 
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were sacrifice and the quantities of Tregs (CD4+Foxp3+CD25+ T cells), CD4+ and CD8+ T cells, 
and B cells were characterized with antibody staining and flow cytometry analysis. B and C show 
percentage and number of Tregs in the lymph nodes, respectively. D, E and F cell rate of CD4+, 
CD8+ and B cells in lymph node. G, H and I number of CD4+, CD8+ and B cells in lymph nodes. J, K 
and L show percentage of CD4+, CD8+ and B cells in spleen. M, N and O - number of CD4+, CD8+ 
and B cells in spleen. Asterix always signify statistical difference between coronin 1-deficient and wild 
type transplant recipients. BL6 – BL/6 wild type; Cor1-/- - coronin 1-deficient; bm12 – bm12Rag2-/- 
mice. 
Taken together the greater increase of Tregs percentages in coronin 1-deficient mice 
can be explained by changes in other cell types – in wild type recipients we can see an 
increase in both CD4+ and CD8+ T cells while these cell numbers are decreased in 
coronin 1-deficient mice. This further confirmed our previous finding, with in vitro 
Tregs induction, that coronin 1-deficient regulatory T cells were not induced at a 
higher level than the wild type in the periphery. Although, Treg numbers were lower 
in coronin 1-deficient recipients, their enhanced levels in comparison with 
conventional T cells could be responsible for the suppression of T cells in coronin 1-
deficient recipients after allotransplantions.  
	
Figure 33. Mock skin transplantations (BL/6 wild type onto BL/6 wild type and Cor1-/- onto Cor1-/-) 
and cell quantities 3, 5 and 7 days after surgeries. A – D shows percentage of regulatory T cells 
(CD4+Foxp3+CD25+), CD4+, CD8+ and B (CD19+) cells, respectively. E – H. Numbers of Tregs, 
CD4+, CD8+ and B cells after skin transplantation. Each graph shows linear regression lines for 
coronin 1-deficient and wild type cells. Mice were transplanted following the transplantation protocol 
(Chapter 6.4). 3 mice were sacrificed at each time point from both BL/6 wild type and coronin 1-
deficient recipient group. Lymph nodes were harvested and the cells were analyzed using appropriate 
antibody, both following the protocols from Materials and Methods (Chapter 6.5 and 6.6). BL6 – BL/6 
wild type; Cor1-/- - coronin 1-deficient. 
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4.5.8 Analysis of the suppression capacity of coronin 1-deficient and 
wild type regulatory T cells in vitro 
The coronin 1-deficient Treg cells suppressive abilities have been studied before and 
described not to differ from the wild type regulatory T cells (Siegmund et al. 2011). 
However, we decided to confirm this result to exclude their more efficient function as 
a reason of prolonged graft survival. To investigate that we performed in vitro 
suppression assay with wild type T cells as responders and either wild type or coronin 
1-deficient Tregs as repressors. The cells were plated together in a different ratio, as 
described in Supplementary Fig. 10, and stimulated with Balb/c splenocytes (depleted 
of CD3+ cells) for 72h. The proliferation rate was measured by 3H-thymidine 
incorporation. The assay showed no difference in suppressive abilities between 
coronin 1-deficient and wild type Treg (Supplementary Fig. 10A). Therefore we 
concluded that coronin 1-deficient Tregs were not better in their suppression of wild 
type CD4+ CD25- T cell proliferation excluding this as a reason for prolonged graft 
tolerance in coronin 1-deficient recipients.  
 
4.5.9 Proliferation of CD4+ T cells in the absence of CD4+CD25+ T 
cells 
We then could confirm that in vitro, coronin 1-deficient CD25+ T cells were not 
responsible for the decreased proliferation of coronin 1-deficient T cells. To this end 
we used MLR experiments in which we cultured T cells either CD25-depleted or not 
(responder cells) with splenocytes from Balb/c mice (stimulators). The data shown in 
Supplementary Fig. 10B and C indicates that there was no significant difference in 
proliferation between total T cells and T cells depleted of CD25+ cells. These results 
further supported our hypothesis that coronin 1-deficient Tregs are not the reason for 
reduced proliferation of coronin 1-deficient T cells in vitro.  
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4.5.10 Analysis of suppressive abilities of conventional coronin 1-
deficient CD4+ T cells  
To analyze whether the suppressive activity could be conferred by coronin 1-deficient 
conventional CD4+ T cells, we decided to use cCD4+ T cells (CD4+CD25- T cells) 
as repressors in several assays in vitro as well as in vivo. 
In vitro co-culture of coronin 1-deficient and wild type cCD4+ T cells 
First, we carried out a co-culture of coronin 1-deficient with wild type cCD4+ T cells 
in vitro (Workman et al. 2011). Wild type Ly5.1 CD4+ and coronin 1-deficient Ly5.2 
CD4+ T cells were negatively sorted with magnetic beads. Then, the cells were 
stained with anti-CD4 and anti-CD25 antibodies and FACS sorted for CD4+CD25- T 
cells. Afterwards, both isolated populations were plated either together or separately 
in 96-well plates. The cultures were stimulated or not with anti-CD3 and anti-CD28 
antibodies. After 72 hours of culture the cells were analyzed for proliferation. When 
cultured without stimulation, coronin 1-deficient cCD4+ T cells were not able to 
suppress proliferation of wild type cCD4+ T cells. On the contrary, there was an 
enhancement in numbers of recovered wild type cCD4+ T cells when co-cultured 
with coronin 1-deficient cells upon stimulation with anti-CD3 and anti-CD28 
antibody (Fig. 34A and B). Furthermore, we noticed improved survival of coronin 1-
deficient cCD4+ when co-cultured with wild type cells without stimulation. Therefore 
we were not able to confirm the suppressive abilities of coronin 1-deficient cCD4+ T 
cells in vitro.  
 In vivo competition assay 
To further characterize the potential suppressive abilities of coronin 1-deficient 
cCD4+ T cells we performed in vivo suppression assay where instead of regulatory T 
cells we used coronin 1-deficient cCD4+ T cells as repressors. In this experiment two 
types of cells, responders (in our case wild type Ly5.1 CD4+CD25- T cells) and 
repressors (coronin 1-deficient Ly5.2 CD4+CD25- T cells) were adoptively 
transferred together into immunodeficient Rag2-/- mice. Reduction of cell 
proliferation defined the suppressed population (Song et al. 2012). Both cell 
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populations were purified from murine spleens and enriched for CD4+ T cells with 
negative magnetic beads separation as described in Material and Methods (Chapter 
6.7). Subsequently, the cells were stained with anti-CD4 and anti-CD25 antibodies 
and sorted for CD4+CD25- cells. We co-transferred 1 000 000 CD4+CD25- T cells 
purified from the wild type and 1 000 000 CD4+CD25- T from coronin 1-deficient 
mice into Rag2-/- recipients. The mice were sacrificed two weeks after injection and 
flow cytometry analysis of spleen and lymph nodes cell composition were performed. 
In contrast to the results obtained in vitro a significant decrease in recovered number 
of wild type cells was observed after co-transfer with coronin 1-deficient cCD4+ T 
cells, when compared with transfer of wild type cells alone (Fig. 34C). This reduced 
proliferation of wild type cells in the present of coronin 1-deficient CD4+CD25- T 
cells suggests a suppressive ability of coronin 1-deficient cells.  
Graft survival in a transfer model with cCD4+ T cells 
Regulatory T cells adoptively transferred into immunodeficient mouse with an 
allograft are able to prevent rejection mediated by conventional CD4+ T cells 
(Nagahama, Nishimura, and Sakaguchi 2007). Therefore, to test the hypothesis 
whether coronin 1-deficient CD4+CD25- T cells are able to suppress rejection of an 
allograft, we decided to perform in vivo suppression assays in transplanted Rag2-/- 
mice using coronin 1-deficient CD4+CD25- T cells instead of Tregs. To this end, 
Rag2-/- mice were transplanted with bm12Rag2-/- skin grafts. Subsequently, 30 days 
after transplantations, the mice were injected with CD4+CD25- T cells isolated from 
wild type and coronin 1-deficient mice (Fig. 34D). Mice receiving 20 000 of wild 
type CD4+CD25- T cells rejected grafts within 20 days. The group adoptively 
transferred with 20 000 of wild type and 20 000 of coronin 1-deficient CD4+CD25- T 
cells started to show signs of rejection earlier than wild type controls and at the end of 
experiment 2 out of 3 mice rejected skin completely. Interestingly, mice co-
transferred with 20 000 of wild type and 100 000 of coronin 1-deficient CD4+CD25- 
T cells started to reject rapidly (day 12), and all mice rejected within 19 days after 
surgeries. What is more, group transferred with coronin 1-deficient 100 000 
CD4+CD25- T cells also showed signs of rejection. At the end of the experiment one 
mouse rejected the graft completely, one was about to reject and one started the 
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process of rejection (showing some redness on grafted tissue). This shows that 
CD4+CD25- T cells from coronin 1-deficient mice were not able to suppress wild 
type cell but, in contrary, accelerated the rejection of bm12 grafts. Thus, from these 
experiments, we could not conclude that suppressive abilities of conventional CD4+ T 
cells contribute to the delayed rejection in coronin 1-deficient recipients. 
 
Together these data show that while in vitro coronin 1-deficient cCD4+ T cells were 
not able to suppress wild type cell proliferation, in vivo the numbers of wild type 
cCD4+ T cells after co-transfer with coronin 1-deficient cells were decreased, 
suggesting suppressive activity. However, in a skin transplantation setting, coronin 1-
deficient conventional CD4+ T cells did not alter the rejection course. Additionally, 
coronin 1-deficient CD4+ T cells depleted of regulatory T cells were able to induce 
rejection of bm12 grafts in Rag2-/- recipients.  
 
 
 
 	
	
Results 
	
	 	
105	
	
Figure 34. In vitro (A and B) and in vivo (C and D) competition assay of conventional CD4+ T cells 
(CD4+CD25-) from BL/6 wt and Cor1-/- mice. A. and B. Co-culture of cCD4+ T cells from BL/6 wt 
(Ly5.1) and Cor1-/- (Ly5.2) mice in the absence (B) or presence (A) of CD3/CD28 antibody 
stimulation. The cells were sorted following the negative selection of CD4+ T cells and FACS sort for 
CD25- cells. They were plated in 96-well plate and incubated for 72h. Afterwards, the cells were 
stained and acquired with the FACS. The experiment was repeated 3 times. Figure shows 
representative results. C. In vivo competition assay where 1 000 000 of BL/6 wild (Ly5.1) type and 
Cor1-/- (Ly5.2) cells were injected together into tail vein of Rag2-/- mice. The cells were obtained from 
spleen after negative CD4+ T cells sort with the kit and additional FACS sort of CD4+CD25- cells. 
The BL/6 wt cells were either adoptively transferred alone or together with Cor1-/- cells. Mice (5 per 
group) were sacrifice two weeks later and the cells were quantified by FACS staining. The plot shows 
number of cells obtained from spleen and 6 lymph nodes of Rag2-/- mice (axillary, brachial and 
inguinal). The experiment was repeated 3 times. The plot shows representative result from one 
experiment. D. Suppression of BL/6 wt cCD4+ T cells (CD4+CD25-) by Cor1-/- cCD4+ T cells. Rag2-
/- mice were transplanted with bm12Rag2-/- skin grafts following the transplantation protocol 
(Chapter 6.4). 28 days after surgery the mice were injected with 20 000 of BL/6 wt (Ly5.1), 100 000 
Cor1-/- (Ly5.2) cCD4 T cells and co-transferred with 20 000 BL/6 wt and 20 000 Cor1-/- cCD4+ T 
cells or 20 000 BL/6 wt and 100 000 Cor1-/- cCD4+ T cells. The mice were observed for graft survival 
and sacrificed 21 days after cell transfer. Numbers of cCD4+ T cells were quantified by FACS staining 
of spleen and lymph nodes (axillary, brachial and inguinal) cells. Three mice were used per group. B6 
wt– BL/6 wild type; Cor1-/- - coronin 1-deficient. 
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5 Discussion  
 
After recognition of an allogeneic skin graft by a recipient’s immune system an 
organism induces several mechanisms by which the graft can be destroyed. The 
allograft can be rejected via nonspecifically activated inflammatory cells infiltrating 
the tissue, which leads to the vascular occlusion or by cytolityc soluble factors 
secreted by those activated inflammatory cells. The more specific mechanism 
responsible for graft destruction consist of antigen-specific responses conducted by 
antibodies and T cells. Antigen-specific T cells appear to be the major effector cells 
mediating skin graft rejection. T helper (TH) cells activated by antigen recognition 
secrete cytokines that, when combined with antigen presentation, induce cytotoxic T 
(TC) cells to proliferate and differentiate into effector cells that are able to reject 
grafted tissue. T cells are most efficient in rapid graft rejection when they combine 
both the helper and cytotoxic function (Rosenberg and Singer 1992; Boisgérault et al. 
2009). Considering the severely reduced numbers of peripheral T cells in coronin 1-
deficient mice, we would expect them to be highly susceptible to various infections 
but impaired in graft rejection (Föger et al. 2006; Mueller et al. 2008; Haraldsson et 
al. 2008; Shiow et al. 2008). Interestingly, while coronin 1-deficient mice are able of 
mounting an response against infection (Tchang et al. 2013) these mice fail to 
normally reject allografts. 
It is known that both CD4+ and CD8+ T cells contribute to allograft rejection. The 
detailed interaction of T cells subpopulations during rejection has been investigated in 
several studies (Cobbold et al. 1986; Rosenberg et al. 1987; Auchincloss et al. 1993; 
Rosenberg and Singer 1992; Auchincloss et al. 1993; Boisgérault et al. 2009). All of 
these studies showed that CD4+ T cells are required in the rapid rejection of major 
mismatched skin grafts. Addtionally, CD4+ T cells are capable of elicitading acute 
rejection of a major mismatched transplants in the absence of CD8+ T cells 
(Boisgérault et al. 2009). Interestingly, when a minor mismatched skin is transplanted 
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onto recipients depleted of CD4+ T cells grafts are tolerated even longer (Auchincloss 
et al. 1993; Youssef et al. 2004, 4). As described in this thesis, when major 
mismatched skin was transplanted onto coronin 1-deficient mice, the graft rejection 
was delayed when compared with wild type recipients. Minor mismatched 
transplantations showed tolerance in coronin 1-recipients. Therefore we hypothesized 
that coronin 1-deficient CD4+ T cells are impaired in their function upon allograft 
stimulation.  
To find out whether coronin 1-deficient CD4+ T cells are the main impaired 
population of T cells we performed surgeries with MHC class II (bm12) or MHC 
class I (bm1) allogeneic skin. Indeed, our results showed that coronin 1-deficient 
CD8+ T cells were able to induce rejection of bm1 grafts, however, with a delay. The 
delay could be due to the decreased numbers of coronin 1-deficient CD8+ T cells. 
Coronin 1-deficient mice, on the contrary, did not reject bm12 skin grafts. These 
results suggest that not only the CD4+ T cells were impaired in rejection but also 
there had to be a mechanism that induced tolerance in coronin 1-deficient recipients. 
Following these findings, in subsequent experiments, we focused on CD4+ T cell 
dependent rejection. 
In our subsequent studies we considered three hypothesis that could possible explain 
the delayed rejection in coronin 1-deficient mice: it could be the result of decreased 
numbers of T cells in coronin 1-deficient recipients, there was the possibility that T 
cells posses an impaired capacity to recognize alloantigens, or coronin 1-deficient 
mice could be very efficient in induction and maintenance of tolerance.   
 
5.1  Is the delayed rejection due to the lower number of T cells in the 
coronin 1- deficient mice? 
We concluded that delayed rejection of major mismatched grafts could not be the 
outcome of decreased numbers of coronin 1-deficient T cells only. This was shown by 
the fact that adoptive transfer of highest numbers of coronin 1-deficient CD4+ T cells 
used in the Rag2-/- recipients did not lead to rejection. Even despite the impaired 
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survival of coronin 1-deficient CD4+ T cells after injection into Rag2-/- mice as we 
transferred high number of these cells (1 000 000 of Cor1-/- vs 20 000 of wt cells). 
Thus, the reduced T cell numbers per se do not explain the absence of graft rejection 
in coronin 1-deficient mice. 
 
5.2  Are coronin 1-deficient T cells impaired in their functionality? 
Although the retained lower counts of CD4+ T cells after major mismatched skin 
transplantation could indicate a defect in proliferation or alloantigen recognition, 
further in vitro experiments suggest that coronin 1-deficient T cells were able to 
recognize antigen through their TCR’s and respond, could become activated and 
could proliferate. Furthermore, cytokines and cell marker analysis suggest that 
coronin 1-deficient T cells were under the stress of high activation and intense 
proliferation that could cause exhaustion, which may contribute to their in vivo 
depletion. The same markers were not changed in the thymus of coronin 1-deficient 
mice and the mice could produce recent thymic emigrants. Since TCR-mediated 
signaling is crucial for thymocyte development this suggest that the inability to reject 
allografts by coronin 1-deficient T cells is not due to an impaired capacity to respond 
towards TCR ligands. 
 Activation of coronin 1-deficient T cells 
From previous studies we know that coronin 1-deficient mice can respond to various 
viral and bacterial infections thus our preliminary results suggest that coronin 1-
deficient mice might have a problem specifically with allorecognition by T cells or 
their efficient activation after transplantation (Tchang et al. 2013). Alloantigens can 
be recognized by T cells either as an intact MHC molecule presented by donor APC 
(direct presentation), or after processing of those that produces allopeptides presented 
by recipients MHC complexes expressed by recipient APC (indirect presentation) 
(Guermonprez et al. 2002). We tested both of this recognition using major and minor 
mismatched skin donors. Interestingly, as described before, coronin 1-deficient mice 
were able to reject major mismatched (although with significant delay) but fully 
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tolerated minor mismatched grafts. Moreover, in vitro, when stimulated with major 
mismatched splenocytes, coronin 1-deficient T cells became activated and 
proliferated. Therefore the allorecognition by coronin 1-deficient T cells could not be 
impaired and could not be the reason of delayed rejection in coronin 1-deficient mice.  
 Survival and proliferation of coronin 1-deficient T cells 
Although in vivo, the survival of coronin 1-deficient T cells is decreased compared 
with the wild type, interestingly, both the proliferation rate and cell survival of 
coronin 1-deficient CD4+ T cells in mixed lymphocyte reaction (MLR) experiments 
turned out to be dependent on the starting number of cultured cells. When we plated 
100 000 of T cells, the number of proliferated CD4+ T cells was significantly lower in 
the coronin 1-deficient sample as compared to the wild type sample. However, plating 
200 000 of T cells resulted in similar proliferation of CD4+ T cells in the wild type 
and coronin 1-deficient sample. Since the cell density is very important for the in vitro 
activation and expansion of T cells (Ma et al. 2010; Pilling et al. 2000), these results 
indicate that coronin 1-deficient T cells are even more sensitive to cell density than 
wild type T cells. In vitro activated T cells secrete abundant cytokines and growth 
factors, which improves their proliferation and survival (Ma et al. 2010). One possible 
explanation therefore is that coronin 1-deficient T cells are impaired in secretion of 
such a factor and therefore require a higher density for their proper survival. 
Consistent with these in vitro observations, the survival of coronin 1-deficient CD4+ 
T cells in vivo, after adoptive transfer into Rag2-/- mice, was also found to be 
dependent on the numbers of injected cells. Transfer of small numbers of mature T 
cells into immunodeficient mice, such as Rag2-/-, results in rapid T cell proliferation 
in the periphery (Clarke and Rudensky 2000). While is known that increasing 
numbers of wild type T cells injected into lymphopenic mice does not increase the 
number of surviving cells, it improved survival for the coronin 1-deficient T cells. 
Normally, adoptively transferred T cells have their capacity to proliferate and expand 
to a certain population size. The number of injected cells determines the time needed 
for the T cells to reach their growth plateau (Rocha, Dautigny, and Pereira 1989). In 
our study, population of coronin 1-deficient CD4+ T cells that were adoptively 
transferred into Rag2-/- mice could never reach the size of wild type sample, however 
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the number of these cells that we could recover depended on the number of injected 
cells. Together these results suggest that both in vitro and in vivo coronin-1 deficient 
T cells survive better upon being seeded at higher density.  
 Cell markers expression and cytokines secretion 
A characterization of specific markers and cytokines expressed by wild type and 
coronin 1-deficient T cells suggested that coronin 1-deficient T cells showed a 
stimulated (IFNγhi and IL-7Rlo) and strongly activated (CD5hi) phenotype undergoing 
intense proliferation (Ki67hi) and being exhausted (PD-1hi). Interestingly the co-
culture of coronin 1-deficient and wild type T cells reduced the growth of wild type 
cells. As the CD8+ T cells from wild type and coronin 1-deficient mice co-cultured 
together did not influence each other’s proliferation this suggests a suppressive 
function of coronin 1-deficient CD4+ T cells. 
Analysis of coronin 1-deficient and wild type T cells showed that coronin 1-deficient 
T cells, both CD4+ and CD8+ T cells, produced increased levels of IFNγ, when 
compared to wild type cells. Enhanced levels of IFNγ together with intense or 
defective TCR signaling might lead to the activation of coronin 1-deficient T cells and 
cause the downregulation of the IL-7R receptor (which we observed in our studies) as 
well as increase proliferation of those cells (indicated by upregulation of Ki-67). All 
of these factors, mainly endogenous IFNγ, promote activation-induced cell death 
(AICD) (Thebault et al. 2007; Sobek et al. 2002). Interestingly, AICD is linked with 
antigenic engagement of TCR, which, in our studies, was correlated with enhanced 
expression of CD5 in coronin 1-deficient compared with wild type cells. However, 
higher expression of CD5 in coronin 1-deficient T cells can be related with their stage 
of maturation (coronin 1-deficent T cells are CD44hi and CD62Llo), as CD5hi 
expression is typical in mature T cells (Foulds et al. 2002).  
High activation of coronin 1-deficient T cells can lead to their exhaustion, which is 
related to enhanced expression of PD-1 by coronin 1-deficient T cells when compared 
to wild type cells (Francisco, Sage, and Sharpe 2010). Increased expression of PD-1 
can facilitate apoptosis of T cells and induction of tolerance. PD-1 ligands are 
expressed on APCs and peripheral tissues. Binding of PD-1 to its ligands eliminates 
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self-reactive T cells via promoting AICD thereby protecting organism against 
autoimmunity and self-destruction (Francisco, Sage, and Sharpe 2010).  
What is more, AICD leads to the cell death through Fas/FasL pathway. FasL was 
another marker which increased expression was found on the coronin 1-deficient T 
cells. Expression of FasL has been reported to be dependent on nuclear factor of 
activated T cells (NFAT) which function is disrupted in coronin 1-deficient mice 
(Winslow et al. 2006; Oh-hora and Rao 2008; J. H. Russell 1995; Zhang, Xu, and Liu 
2004).  
Taken together, coronin 1-deficient T cells express high levels of cell death markers 
(Ki-67, PD-1, CD5 and FasL) while downregulating IL-7R (which is also a sign of 
AICD (Kimura et al. 2013; Mai et al. 2014)), which could suggest that they undergo 
activation-induced cell death resulting in decreased numbers in coronin 1-deficient 
mice. These results are supported by the findings that coronin 1-deficient T cells 
express more caspase 3, which is involved in apoptosis (Mueller, Liu, and Pieters 
2011; Tewari et al. 1995; Nicholson et al. 1995). On the other hand, coronin 1-
deficient T cells could have impaired TCR self-signals causing their malfunction, 
which results in a stage where they are about to die and express multiple markers 
involved in cell death and survival.  
Interestingly, several markers involved in the apoptosis of activated T cells promote 
survival of regulatory T cells. Expression of PD-1 and its ligation with PD-L1 or PD-
L2 promotes survival of Tregs (Francisco, Sage, and Sharpe 2010). PD-1 ligands are 
expressed on tolerogenic dendritic cells, controlling the decision between T cell 
activation or tolerance by induction of regulatory T cells and control of their 
development, maintenance and function (Francisco, Sage, and Sharpe 2010). 
Moreover blockade of IL-7R and enhanced IFNγ secretion has been described to be 
important for the survival of Tregs (Thebault et al. 2007; Mai et al. 2014). Therefore, 
this could explain increased frequencies of regulatory T cells in coronin 1-deficient 
mice compared with wild type. After skin transplantation coronin 1-deficient T cells 
travel to the transplantation tissue, which expressed PD-1 ligands. Highly expressed 
PD-1 on coronin 1-deficient T cells could bind to its ligand causing apoptosis of 
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conventional T cells and promoting survival and proliferation of coronin 1 regulatory 
T cells thereby inducing graft tolerance.  
 
5.3  Is the prolonged acceptance of the graft due to induction of 
tolerance in coronin 1-deficient recipients? 
In-depth analysis of T cells subtypes in the periphery and thymus of coronin 1-
deficient mice showed decreased numbers of T cells in the periphery, with RTE 
present also at lower numbers, enhanced rates of CD4+CD25+ T cells and normal 
composition of thymus. Normal development of T cells in the thymus and reduced 
numbers of RTE suggest their immediate death after egress or during maturation into 
naïve then activated/memory T cells. Both of these T cell subsets might have 
impaired survival themselves.  
Further analysis of regulatory T cells in coronin 1-deficient mice showed no 
difference in suppressive abilities compared with wild type cells. Moreover, we 
demonstrated that the cells did not generate or proliferate better in coronin 1-deficient 
mice. Nevertheless, their superior survival over conventional CD4+ T cells in vitro 
could explain their higher frequencies in coronin 1-deficient mice and could be linked 
to the enhanced expression of PD-1. This, in turn, promotes apoptosis in antigen-
specific T cells while increasing the survival of Tregs (Francisco, Sage, and Sharpe 
2010). Therefore, the absence or delay in rejection in coronin 1-deficient recipients 
caused by induction of tolerance may be due to elevated rate of Tregs, the suppressive 
abilities of conventional CD4+ (cCD4+) T cells or combination of these. Indeed, there 
are studies describing that the balance between effectors and regulatory T 
lymphocytes controls the outcome of allografts (Benghiat et al. 2005; Graca et al. 
2004; Tang and Lee 2012). Interestingly, when we tried to interfere the ratio between 
Tregs and cCD4+ T cells in coronin 1-deficient mice by adoptive transfer of either 
wild type CD4+ T cells or ABM cells, we did not observe rapid rejection in recipient 
mice. Although, some of the injected mice rejected skin grafts, the rejection was 
delayed when compared with controls and additionally, we observed acceptance of 
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the graft in most cases. Therefore we suspected that cCD4+ T cells in coronin 1-
deficient mice might have suppressive abilities and support tolerance maintenance 
after transplantation. Moreover, preliminary results suggest increased levels of cAMP 
in coronin 1-deficient CD4+ T cells (unpublished). This secondary messenger, cAMP, 
is also increased in regulatory T cells and is described to play a role in suppression by 
these cells (Bopp et al. 2007).   
Furthermore, CD25-depleted coronin 1-deficient recipients rejected skin grafts with 
the delay compared with the control, which could indicate suppression within coronin 
1-deficient cCD4+ T cell subset as well. Although, there are studies showing that 
depletion of CD25+ cells result in rapid rejection (W. Li et al. 2006; Mai et al. 2014), 
there are others describing that under certain conditions the influence of CD25-
depletion on suppression of graft rejection may be limited (Graca et al. 2002, 4; 
Benghiat et al. 2005). The same paper discusses the suppressive abilities of 
CD4+CD25- cells in graft rejection suggesting that higher numbers of cCD4+ T cells 
are able to suppress the rejection of skin grafts as well as CD4+CD25+ cells 
(Benghiat et al. 2005). 
To find out whether coronin 1-deficient cCD4+ T cells are able to suppress the 
rejection we performed several in vitro and in vivo assays. While in vivo after 
adoptive transfer into Rag2-/- mice, coronin 1-deficient cCD4+ T cells caused the 
decreased survival of wild type cells, the in vitro co-culture did not show any 
influence of coronin 1-deficient cCD4+ T cells on the proliferation of wild type cells. 
Additionally, when we co-transferred coronin 1-deficient and wild type cCD4+ T 
cells into Rag2-/- mice, previously transplanted with bm12 skin grafts, we observed 
rapid rejection of grafts. At the same time, control mice, transferred only with coronin 
1-deficient cCD4+ T cells, also rejected bm12 grafts. This suggests that not only 
coronin 1-deficient cCD4+ T cells are not able to suppress the rejection by wild type 
cells, but also they are able to induce rejection by themselves in the absence of 
regulatory T cells. However, the results obtained in these studies were contradictory 
and difficult to interpret. 
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5.4  Conclusions 
The exact role of coronin 1 protein in promoting T cells homeostasis as well as the 
role of the coronin 1-dependent T cells in allorecognition and graft rejection remains 
largely unknown. This project provides novel insight into the role of coronin 1 in the 
induction of prolonged graft survival. Despite advances in immunosuppressive 
therapies, current clinical skin transplantation is still limited to autotransplantation. 
Thus, there is a need for new methods to induce immune tolerance to allografts. The 
knowledge of the role of coronin 1 in the regulation of tolerance might deliver new 
therapeutic approaches in the prevention of allograft rejection in humans. As stated 
earlier, one way to prevent allograft rejection is the use of immunosuppressants. 
However, currently used immunosuppressive drugs, such as cyclosporine A and 
FK506, target a pathway (Ca2+/calcineurin) that operates in every cell type, and hence 
these drugs are associated with severe toxicity and risks towards opportunistic 
infections (Crabtree and Olson 2002; A. Rao, Luo, and Hogan 1997). Thanks to the 
restricted expression of coronin 1, deletion or suppression of this protein might not 
lead to toxicity. 
In this thesis we demonstrated that, coronin 1-deficient mice showed delayed 
rejection of major mismatched skin grafts compared with wild type recipients. There 
are several explanations for the observed prolonged graft tolerance. First, it could be 
that the decreased numbers of T cells in coronin 1-deficient mice are not able to 
induce rejection of skin graft. However, since adoptive transfer of large numbers of 
coronin 1-deficient T cells, failed to induce rejection, this is less likely to be the main 
reason for observed tolerance. Second, there is the possibility that T cells posses an 
impaired capacity to recognize alloantigens and therefore fail to induce rejection. The 
proliferation, activation and survival of coronin 1-deficient T cells were investigated 
in this thesis and were shown to depend on the density of coronin 1-deficient T cells. 
However, these also appeared to be implausible to be the main reason for the delayed 
graft rejection since we observed tolerance in minor mismatched and an MHC class 
II-dependent model. Moreover the delayed graft rejection and tolerance in some 
models could be explained by impaired homing of dendritic cells into secondary 
lymphoid organs. That would prevent antigen presentation to T cells and their 
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efficient activation (Rosenberg and Singer 1992). Since the interaction of dendritic 
cells with T cells has been studied before we excluded this hypothesis in our studies 
(Westritschnig et al. 2013). Lastly, we hypothesized that the main reason of the 
prolonged graft survival in coronin 1-deficient mice was the tolerance induction. As 
we found increased frequencies of regulatory T cells in coronin 1-deficient mice this 
could contribute to suppression of graft rejection. Additionally, this was shown by the 
fact that adoptively transferred coronin 1-deficient CD4+ T cells depleted of CD25+ 
cells were able to induce graft rejection. Furthermore, preliminary results showed that 
coronin 1-deficient mice, when depleted of CD25+ cells, rejected skin graft, although 
with significant delay due to the impact of decreased T cells in general 
 
Taken together, our results demonstrated that the delay of graft rejection in coronin 1-
deficient mice may be a result of several factors combined together: the tolerance 
induction by increased Tregs numbers, the reduced numbers of T cells in general as 
well as a consequence of impaired T cells survival and proliferation.  
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6 Materials and Methods 
 
6.1  Buffers and media 
- Ammonium-Chloride-Potassium (ACK) buffer: 155mM NH4Cl, 10mM 
KHCO2, 1mM EDTA, pH 7.4 - Complete media for dendritic cells: RPMI 1640 (Sigma-Aldrich, Ref. No 
R8758) media containing 10% FCS (PAA clone, The Cell Culture Company, 
Ref. No A15-101) heat inactivated, 2mM L-glutamine, 50µM 2-
mercaptoethanol (Sigma-Aldrich, Ref. No M7522) and 10ng/ml GM-CSF 
(Recombinant Mouse GM-CSF CF, Biolegend, Ref. No 576306) - Complete media for T cells: RPMI 1640 (Sigma-Aldrich, Ref. No R8758) 
supplemented with 10% FSC (PAA clone, The Cell Culture Company, Ref. 
No A15-101), 500µg/ml Pen-Strep (Gibco, Ref. No 15140-122), 1% NEAA 
(Non-essential Amino Acid Solution, Sigma-Aldrich, Ref. No M7145), 10µM 
β-mercaptoethanol (Sigma-Aldrich, Ref. No M7522), 1µM Na-Py (Sodium 
Pyruvate, Sigma-Aldrich, Ref. No S8636) - Culture media for hybridoma cells: SF-IMDM, 2% FCS low IgG, Pen-Strep - FACS buffer: PBS, 2%FCS, 5mM EDTA - FACS Lysing Solution (BD Biosciences, Ref. No 349202) - Foxp3 Permeabiliation/Permeabilization buffer (FOXP3 Fix/Perm Buffer, 
BioLegend, Ref. No 421401) - Foxp3 Permeabiliation buffer (FOXP3 Perm Buffer, BioLegend, Ref. No 
421402) - PBS: 10mM NaCl, 50mM HNa2PO4 12H20, pH 8 - RPMI 1640 without phenol red (Life Technologies, Ref. No 11835-063) 
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6.2  Antibody list 
Name Antigen Specificity Clo
ne 
Isotype Compa
ny 
Ref. No Dilution/ 
concentration 
CD3 LEAF CD3ε 
chain 
 
mouse 145-
2C1
1 
Armenian 
Hamster 
IgG, κ 
BioLeg
end 
100314 10µg/ml 
CD3-biotin 100304 50µg/ml 
CD3-PE 100308 1:200 
CD3-PE/Cy7 100320 1:100 
CD3-Pacific Blue 100334 1:50 
CD3-Alexa Fluor 700 100216 1:100 
CD4-Brillinat Violet 
510 
CD4 
(L3T4) 
mouse RM
4-5 
Rat IgG2a, 
κ 
BioLeg
end 
100559 1:50 
CD4-Pacific Blue 100531 1:50 
CD4-PE/Cy7 100528 1:100 
CD4-PE 100512 1:100 
CD4-PerCP 100538 1:100 
CD4-APC 100516 1:100 
CD8-APC CD8a 
(Ly-2) 
mouse 53-
6.7 
Rat IgG2a, 
κ 
BioLeg
end 
100712 1:100 
CD8-Pacific Blue 100725 1:50 
CD8-Brilliant Violet 
510 
100751 1:50 
CD8-Alexa Fluor 700 100730 1:100 
CD8-PE 100708 1:100 
CD11c-Alexa Fluor 647 CD11c mouse N41
8 
Armenian 
Hamster 
IgG1, λ2 
BioLeg
end 
117312 1:100 
CD19-APC CD19 mouse 6D5 Rat IgG2a, 
κ 
BioLeg
end 
115512 1:100 
CD19-PE/Cy7 CD19 mouse 6D5 Rat IgG2a, 
κ 
BioLeg
end 
115520 1:100 
CD24-Brilliant Violet 
421 
CD24 mouse M1/
69 
Rat IgG2b, 
κ 
BioLeg
end 
101826 1:100 
CD25-biotin CD25 
(IL-2Rα 
chain 
p55) 
mouse PC6
1 
Rat IgG1, λ BioLeg
end 
102004 50µg/ml 
CD25-PE/Cy7 102016 1:100 
CD28 LEAF LEAF 
purified 
anti-
CD28 
mouse 37.5
1 
IgG BioLeg
end 
102112 2µg/ml 
CD44-APC CD44 
(Pgp-1, 
Ly-24) 
mouse/ human IM7 Rat IgG2b, 
κ 
BioLeg
end 
103012 1:100 
CD44-Brilliand Violet 
421 
103039 1:50 
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CD44-PE/Cy 103030 1:100 
CD45.1-Brilliand Violet 
421 
CD45.1 
(Ly5.1) 
mouse A20 Mouse 
IgG2a, κ 
BioLeg
end 
110732 1:100 
CD45.1-Alexa Fluor 
700 
110724 1:200 
CD45.2-Brilliand Violet 
510 
CD45.2 
(Ly5.2) 
mouse 104 Mouse, 
IgG2a, κ 
BioLeg
end 
109837 1:100 
CD62L-PerCP CD62L 
(L-
selectin) 
mouse ME
L14 
Rat IgG2a, 
κ 
BioLeg
end 
104430 1:200 
CD62L-PerCp/Cy5.5 104432 1:200 
CD69-PE/Cy7 CD69 
(Very 
Early 
Activatio
n 
Antigen) 
mouse H1.
2F3 
Armenian 
Hamster 
IgG1, λ3 
BioLeg
end 
104512 1:100 
CD107a-Brilliand 
Violet 421 
LAMP-1 mouse 1D4
B 
Rat, IgG2a, 
κ 
BioLeg
end 
121617 1:50 
CD127-PE IL-7Ra mouse A7
R34 
Rat, IgG2a, 
κ 
BioLeg
end 
135010 1:100 
CD178-PE FasL mouse MF
L3 
Armenian 
Hamster, 
IgG 
BioLeg
end 
106606 1:100 
CD279-PE/Cy7 PD-1 mouse RM
P1-
30 
Rat, IgG2b, 
κ 
BioLeg
end 
109110 1:100 
Gr1-PerCP/Cy5.5 Ly-6G 
and Ly-
6C 
mouse RB6
-
6C6 
Rat IgG2b, 
κ 
BioLeg
end 
108428 1:100 
H-2Db-APC B6 MHC 
class I 
mouse KH
95 
Mouse, 
IgG2b, κ 
BioLeg
end 
111513 1:25 
H-2Dd-PE Balb/c 
MHC I 
mouse 34-
2-12 
Mouse, 
IgG2a, κ 
BioLeg
end 
110608 1:50 
H-2Kb-PerCp/Cy5.5 B6 MHC 
class I 
mouse AF6
-
88.5 
Rat, IgG2a, 
κ 
BioLeg
end 
116515 1:25 
H-2Kd-Pacific Blue Balb/c 
MHC I 
mouse SF1
-1.1 
Mouse, 
IgG2a, κ 
BioLeg
end 
116615 1:25 
I-Ab-PE/Cy7 B6 MHC 
class II 
mouse AF6
120.
1 
Mouse, 
IgG2a, κ 
BioLeg
end 
116420 1:50 
I-Ad-FITC Balb/c 
MHC II 
mouse 39-
10-8 
Mouse, 
IgG3, κ 
BioLeg
end 
115005 1:50 
IL-2-Alexa Fluor 647 IL-2 mouse JES
6-
5H4 
Rat, IgG2b, 
κ 
BioLeg
end 
503814 1:100 
IFN-γ-PE IFN-γ mouse XM
G1.
2 
Rat, IgG1, 
κ 
BioLeg
end 
505808 1:100 
NK1.1-Alexa Fluor 647 NK1.1 mouse  PK1
36 
Mouse 
IgG2a, κ 
BioLeg
end 
108720 1:100 
TNF-α-PerCP/Cy5.5 TNF-α mouse MP
6-
XT2
2 
Rat, IgG1, 
κ 
BioLeg
end 
506322 1:100 
TER-119-Alexa Fluor 
488 
TER-119/ 
erythrocy
tes 
Mouse TE
R-
119 
Rat, IgG2b, 
κ 
BioLeg
end 
116215 1:100 
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TER119-biotin TER-119/ 
erythrocy
tes 
mouse TE
R-
119 
Rat, IgG2b, 
κ 
BioLeg
end 
116204 50µg/ml 
Qa-2-Alexa Fluor 647 H2-Qa2 mouse 695
H1-
9-9 
Mouse, 
IgG2a, κ 
BioLeg
end 
121708 1:100 
TCR Vα2-APC Vα2 T 
cell 
receptor 
mouse B20
.1 
Rat IgG2a, 
λ 
BioLeg
end 
127810 1:100 
TCR Vα2-PE Vα2 T 
cell 
receptor 
mouse B20
.1 
Rat IgG2a, 
λ 
BioLeg
end 
127808 1:100 
TCR Vβ5.1/2-APC Vβ5.1/2 
T cell 
receptor 
mouse MR
9-4 
Mouse, 
IgG1, κ 
BioLeg
end 
139506 1:100 
TCR Vβ8.1/2 TCR 
Vβ8.1/2 
T cell 
receptor 
mouse KJ1
6-
133.
18 
Rat IgG2a, 
κ 
BioLeg
end 
118408 1:100 
Live/dead APC/Cy7 reaction 
with free 
cellular 
amines 
- - - Life 
technol
ogies 
L10119 1µl of 20µl 
dilution/stain 
Table 4.  Antibody list. 
6.3  Mouse lines 
C57BL/6 mice and the previously generated transgenic coronin-1 mice (Jayachandran 
et al. 2007) were bred in-house and were kept under specific pathogen free (SPF) 
conditions. Bm12Rag2-/- (I-Abm12), ABMRAG2-/- (TCR transgenic for I-Abm12) and 
Rag2-/- mice were a gift from Dr. Simona Rossi Girard and were farther bred in-
house under SPF conditions (Lee, Hansen, and Cullen 1982).  
Ly5.1 mice were obtained from SwIMMR (Swiss Immunological Mutant Mouse 
Repository) and farther bred in-house. Bm1 (H-2bm1) were a gift from Prof. Antonius 
Rolink (Schulze et al. 1983). Balb/c mice were bought from Janvier Labs. 6.5% 
Balb/c in the C57BL/6 (Cor1 wt or Cor1-/-) were bred in-house by crossing Balb/c 
mice with C57BL/6 by a two times backcrossing of a F1 (BL/6xBalb/C) mouse to the 
BL/6 background. The mice were tested for SNP (Taconic tests) and according to 
1449 SNP analysis data sample had 96.90% of C57BL/6 genome and 3% of Balb/c 
SNPs. All animals’ experiments were conducted according to the regulations of the 
Cantonal Veterinary Office (Basel, Switzerland). 6-12 old mice were used for 
experiments, if not indicated otherwise. 
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Experimental set up skin transplantation 
Major mismatch model: Balb/C skin is transplanted onto BL/6 wild type or coronin 1-
deficient (Cor1-/-) recipients.  
Minor mismatch model: Skin from a BL/6 mouse, which has been generated by two-
time backcrossing of a F1 (BL/6xBalb/C) mouse to the BL/6 background (6.25% 
Balb/c in BL/6), is transplanted onto BL/6 wild type and Cor1-/- recipients.  
B6.C.H-2-bm12 model: this mice express a mutated MHC-II molecule (I-Ab) which 
has been shown to induce graft rejection by bm12-specific CD4+ T cells if 
transplanted onto wild type BL/6 mice (McKenzie et al. 1979). 
Rag2-/- model: Rag2-/- mice are lacking the recombinase-2 gene needed for the 
generation of B and T cells (Shinkai et al. 1992); transplanted with B6.C.H-2-
bm12Rag2-/- (bm12Rag2-/-) skin, the mice tolerate skin, however after transfer of 
BL/6 wild type CD4+ T cells they induce graft rejection and become major mismatch 
model (Schmaler, Broggi, and Rossi 2014). 
6.4  Transplantation procedure and graft scoring 
Skin transplantation procedure followed the protocol by Dr. Simona Rossi Girard 
described in paper: Transplantation of tail skin to study allogeneic CD4+ T cell 
responses in mice (Schmaler M, Broggi MA, Rossi SW.) In general: the donor mouse 
was sacrificed using CO2. The tail was cleaned with tissue soaped with Betadine 
(Mundipharma, swissmedic No 34282021) and the skin was ripped off using scalpel 
and tweezers. The skin was placed in the Petri dish and cleaned with sterile cold PBS. 
The tail skin was cut into 1cm pieces. Corners of each piece were cut off to make the 
skin graft more round. Skin graft prepared this way was ready for transplantation. 
Recipient mouse was injected with Temgesic (50µg/kg of mouse diluted in sterile 
PBS, ESSEZ Chemie AG, Swissmedic No 41931035) at least 30min before surgery. 
Then the mouse was anesthetized with Isoflurane (Attane, Swissmedic No 
56761002)). Sleeping mouse was placed on the surgery (with a heating pad) table 
with a continuous access to the Isoflurane containing anesthetic tube. The back of the 
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mouse was shaved, the hair was removed and the skin was cleaned with Betadine. A 
piece of skin was cut off with a round-ended scissors. The previously prepared donor 
skin graft was placed in the cut without overlapping the edges of the skin. The skin 
graft was glued using tissue adhesive Histo-Acryl (BBRAUN, Ref. No 1050052) 
glue. Then the graft was bandaged with Pflaster (Hansaplast Finger Strips, 
Swissmedic No 02321607) covered with Vaseline (Vifor SA, Swissmedic No 
01667290) and Leukotype (2cmx10m,). The mouse was marked with the ear punch. 
Each mouse was kept under red heating lamp until it woke up after surgery. For one 
week after surgery, transplanted mice were given water with Defalgan syrup (3mg/ml 
in H20, UPSA, Swissmedic No 01340235). The bandage was removed 7 days after 
surgery and the graft score was assess from that point every day for first month, then 
every second day and later twice a week.  
6.4.1 Rejection score 
The graft health and survival was scored with the mark scaling from 0 to 3, where 0 
means the rejection of skin graft (no remaining graft on recipient mouse) and 3 means 
healthy and accepted skin graft (with the black stripe for B6 donor) with growing hair. 
 
 
6.5 Organ harvesting and processing for analysis 
The mice were euthanized with CO2. Spleen, thymus and LNs were harvested in an 
ice cold PBS, smashed through a grid of stainless steel. Cell debris was removed by 
Figure 35. Scoring for the health and rejection of skin grafts after the 
transplantation. Examples of scores given to BL/6 wild type or coronin 1-
deficient mice transplanted with bm12Rag2-/- skin grafts. The mice were 
transplanted following the protocol then observed for the signs of rejection 
at least for 100 days. Score 3 – healthy skin graft with black stipe and 
growing hair. Score 2 – graft shrank significantly and shows red dot 
(wound). Score 1 – whole grafted skin is cover with wound (the rejection 
process ongoing). Score 0 – the graft is rejected and only the scrub is left 
that soon fells out leaving a scar. 
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quick spin (500rpm, 10s, 40C). The supernatant was transferred to new tubes. 
Afterward, cells were centrifuged for 10min, 350g at 40C. The supernatant was 
removed. Spleen cells (pallet) were treated with Ammonium-Chloride-Potassium 
(ACK) buffer (155mM NH4Cl, 10mM KHCO2, 1mM EDTA, pH 7.4), for 1min at 
room temperature, to remove red blood cells. Then, 10ml of PBS was added and cells 
were centrifuged for 10min, 350g at 40C. Cell pallets from spleen, thymus and LN 
were resuspended in PBS. Cells were counted using Neubauer chamber and dead cells 
were excluded using trypan blue. Cells prepared that way were taken for a FACS 
staining analysis. 
6.6  FACS staining of cells 
Cells were resuspended at the concentration of 20x10^6 cells/ml and 100µl/well was 
distributed into 96-well plate. The cells were washed by centrifugation for 5min, 350g 
at 40C. The cells were stained in 50µl/well FACS buffer (PBS, 2%FCS, 5mM EDTA) 
containing proper antibodies for 30min at 40C in the dark.  - For surface markers staining: the cells were washed with 150µl/well of FACS 
buffer and resuspended in 200ul of FACS buffer. The fluorescence was measured 
using BD LSR Fortessa or CantoII FACS Analyzer. - For intracellular staining: the cells were washed with 150µl/well of FACS buffer 
and incubated in 100µl/well Foxp3 Fixation/Permeabilization buffer (FOXP3 
Fix/Perm Buffer, BioLegend, Ref. No 421401) for 20min, room temperature in 
the dark. Afterwards, the cells were washed twice: with 150µl/well FACS buffer 
and 150µl/well Foxp3 Permeabiliation buffer (FOXP3 Perm Buffer, BioLegend, 
Ref. No 421402). The cells were incubated in Foxp Permeabilization buffer for 
15min, room temp. in the dark. Then, the cells were centrifuged (5min, 350g at 
40C), incubated in 50µl/well Foxp3 Permeabilzation buffer containing Foxp3-
APC or appropriate isotype control antibody for 30min at room temp. in the dark. 
After incubation cells were washed twice with the same buffer and resuspended 
in 200ul of FACS buffer. The fluorescence was measured with BD LSR Fortessa 
or CantoII FACS Analyzer. 
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6.7  Cell enrichment procedure (total T cells, CD4+, CD8+ T cells) 
Spleens from either B6 wt or Cor1-/- mice were harvested in PBS supplemented with 
2% FCS and 2mM EDTA, and then smashed through a grid of stainless steel. Cell 
debris was removed by quick spin (500rpm, 10s). The cell numbers were counted and 
cells were sorted for total T cells, CD4+ or CD8+ T cells using negative selection T 
cell, CD4+ or CD8+ T Cell Enrichment Kit, respectively (EasySep, StemCell 
technologies, Ref. No 19751, 19752, 19753). Cells were sorted following the protocol 
from proper selection kit. Cells were counted using Neubauer chamber and dead cells 
were excluded using trypan blue. 
6.8  Cell sorting by FACS sorter for CD25- and CD25+CD4+ T cells 
After CD4+ enrichment with StemCell kit the cells were additionally sorted using 
FACS sorter. Enriched CD4+ T cells were resuspended at the concentration of 
20x10^6 cells/ml in PBS supplemented with 2% FCS and 2mM EDTA and stained 
with saturating amount of antibodies (1/200 CD3-PE, 1/50 CD4-Brilliant Violet 510, 
1/100 CD25-PE-Cy7, LIVE/DEAD® Fixable Near-IR Dead Cell Stain). The cells 
were incubated for 30min at 40C in the dark. After incubation, stained cells were 
washed with PBS supplemented with 2% FCS and 2mM EDTA, centrifuged 5min at 
350g, resuspended at the concentration of 8x10^6 cells/ml and filtered through 30 µm 
Pre-Separation Filters (Miltenyi Biotec, Ref. No 130-041-407). Then the cells were 
sorted with Aria III BD FACS Sorter for CD4+CD25- cells. After sorting the cells 
were counted, washed and resuspended in plain RPMI 1640 without phenol red (Life 
Technologies, Ref. No 11835-063) for adoptive transfer of cells or in RPMI 1640 
(Sigma-Aldrich, Ref. No R8758) supplemented with 10% FSC (PAA clone, The Cell 
Culture Company, Ref. No A15-101), 500µg/ml Pen-Strep (Gibco, Ref. No 15140-
122), 1% NEAA (Non-essential Amino Acid Solution, Sigma-Aldrich, Ref. No 
M7145), 10µM β-mercaptoethanol (Sigma-Aldrich, Ref. No M7522), 1µM Na-Py 
(Sodium Pyruvate, Sigma-Aldrich, Ref. No S8636) for in vitro culture of cells. 
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6.9  Adoptive transfer of cells into mouse recipients 
For the adoptive transfer of cells, the cells were enriched with the StemCell kit (for 
CD4+ T cells transfer) and sorted with FACS sorter (for CD4+CD25- T cells transfer) 
as described before. The cells were resuspended in plain RPMI 1640 without phenol 
red (Life Technologies, Ref. No 11835-063) and transferred to Insulin Syringe with 
sterile interior (BD Micro Fine, Ref. No 324824). 200ul of cell suspension was 
injected into tail veil per mouse. 
6.10 Blood test  
Blood test was done to phenotype some lines of mice (OT-I, OT-II, 6.25% Balb/c in 
BL6 and ABM) and to confirm the depletion of CD25+ cells by the injection of 
antibody. For taking blood, the mouse was placed in the mouse restrainer, tail vein 
was punched with a Needle Violet 24G (BD Microlance 3, Ref. No 304100) and 
about 10 drops of blood was collected into FACS tube containing 3ml of FACS buffer 
(PBS, 2%FCS, 5mM EDTA). The samples were kept on ice all the time. The cells 
were spin down at 450g, 40C for 5min. The supernatant was aspirated using the 
sucking pomp. Afterwards, the pellet was resuspended in 50ul FACS buffer 
containing proper antibodies. The samples were vortexed shortly and incubated for 
20min at 40C in the dark. Then, the samples were washed by addition of 3ml of FACS 
buffer and centrifugation (450g, 40C for 5min). The supernatant was aspirated with 
the pomp and red blood cells were lysed with 1-2ml of BD FACS Lysing Solution 
(BD Biosciences, Ref. No 349202) and incubation at room temperature for about 60s. 
3ml of FACS buffer was added to the samples and they were centrifuged (450g, 40C 
for 5min). The supernatant was pour off and pellet was resuspened in 250µl of FACS 
buffer. The samples were acquired using FACS Canto II or LSR Fortessa BD 
Analyzer.  
6.11 CD25-depletion 
CD25+ cells were depleted from mice by intraperitoneal (i.p.) injection with 0.5mg of 
anti-CD25 (PC61) antibody per mouse and per injection at day 5, 3 before and day 3 
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after transplantation. The antibody was made in-house from hybridoma cells culture 
as described in point Antibody production and purification. Mice were bled to 
establish level of CD25+ cells at day 6, 1 before and day 7 after surgery. Additionally 
Cor1-/- recipients (that did not reject the grafts) were bled at day 15, 28 and 65 after 
transplantation. Blood was obtained as described in point Blood test. The samples 
were stained for surface markers: CD3, CD4, CD25, LIVE/DEAD® Fixable Near-IR 
Dead Cell Stain and intracellular transcription factor Foxp3 as described in point 
FACS staining of cells. 
6.12 CD25 (PC61) monoclonal antibody production from hybridoma 
cells  
The hybridoma cells were thawed out in 370C water bath. The cells were transferred 
into 15ml falcon tube containing 10ml of pre-wormed culture media (SF-IMDM, 2% 
FCS low IgG, Pen-Strep). Then, the cells were spun down at 300g, 3min, room 
temperature. The pellet was resuspended gently with 1ml of culture media and then 
transferred into T-75cm2 flask with 15ml of culture media. The cells were placed in 
humidified 37oC, 5% CO2 incubator. When the cells reached 70% confluence, they 
were split into 15cm gridded cell culture treated petri dishes with 50ml of culture 
media. Then the step was repeated: when the cells reached 70% confluence each petri 
dish was split into 10 new petri dishes. The total culture volume was 1l. The cells 
were allowed to grow for two weeks (until the media turned yellow). After that the 
cells were harvested into Oakridge styled tubes and centrifuged at 4000rpm for 
30min, 40C. The supernatant was transferred into sterile bottles and filtered.  
6.13 CD25 (PC61) antibody purification from culture supernatant 
The column used for purification: self-packed column (Bio-Rad poly-Prep 
Chromatography column, Ref. No 731-1550) containing 3.5ml of GammaBind Plus 
Sepharose (GE Healthcare Life Sciences, Ref. No 170886-01).  
The column was equilibrated with 15ml PBS. The culture supernatant was loaded by 
gravity flow. Then the column was washed with 50ml of PBS. The antibody was 
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eluted with 5ml of 100mM Glycine pH3.0 and collected as 500µl fractions in tubes 
containing 100µl 1M Tris-HCl, pH 8.0. After elution the column was washed with 
15ml of 100mM Glycine pH 2.3 and 40ml of PBS. From each step the eluent was 
kept and 20µl of each sample was evaluated by SDS-PAGE gel electrophoresis. The 
samples were mixed with SDS loading buffer and boiled for 7min. 10µl of sample 
was run in 10% Acrylamide gel. The gel was stained with Coomassie blue. The 
fractions containing the highest concentration of antibody were pooled and dialyzed 
against PBS for 1h, 3h and overnight in 1l of buffer at 40C. The protein solution was 
collected, sterile filtered and the concentration was measured by OD280. The 
antibody was stored at 40C. 
The specificity of produced antibody was analyzed by FACS staining using 
splenocytes from B6 wild type mouse as a sample, goat anti-rat-PE (1:200) as 
secondary antibody and commercial antibodies: anti-CD25-PE/Cy7 (1:100, clone 
PC61, Biolegend, Ref. No 102016) and anti-CD25-PE (1:100, clone 3C7, Biolegend, 
Ref. No 101904) as controls.  
6.14 Dendritic cells differentiation and culture 
Femurs and tibiae were harvested from 6-8 weeks old mice. The bones were washed 
once with 70% EtOH and twice with sterile PBS. Both ends of bones were cut and the 
bone marrow was flush out with 21-gauage needle (BD Microlance) and 20ml syringe 
(BBraun, Ref. No 4616200V) into 50ml falcon tube. The bone marrow was 
resuspended with the needle and centrifuged for 5min, 350g, room temperature. The 
red blood cells were lysed with ACK buffer (described before), incubated 1min at 
room temperature, neutralized with 10ml of PBS and centrifuged for 5min, 350g, 
room temp. Then the cells were washed twice with RPMI 1640 media (Sigma-
Aldrich, Ref. No R8758) and counted using Neubauer chamber (dead cells were 
excluded using trypan blue). The cells were spin down (5min, 350g, RT) and 
resuspended at the concentration of 1x106 cells/ml in RPMI media containing 10% 
FCS PAA clone (heat inactivated), 2mM L-glutamine, 50µM 2-mercaptoethanol and 
10ng/ml GM-CSF (Recombinant Mouse GM-CSF CF, Biolegend, Ref. No 576306) 
freshly added to the media. 8ml of cell suspension was plated per 10cm2 bacteria (non 
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cell culture treated) petri dish. The cells were cultured in humidified 37oC, 5% CO2 
incubator. 4ml of the media was replaced with a fresh one (freshly adding 10ng/ml og 
GM-CSF) at day 2, 4 and 6 of culture. At day 7 the cells were used farther for the co-
culture proliferation experiment.  
	
Figure 36. Test of dendritic cell culture obtained from bone marrow of BL/6 wild type mice after 
one-week culture in the presence of GM-CSF (10ng/ml). The cells were use as stimulators in 
proliferation, survival and cytokine secretion experiments. A shows side and forward scatter of 
dendritic cells after one week of culture. B – expression of dendritic cell markers (CD11c and CD86), 
C – expression of MHC calls II. 
6.15 Plate coating and stimulation with antibodies 
For stimulation with CD3 and CD28 antibodies the plate was either coated or soluble 
antibodies were added to the media. The method of stimulation is indicated in every 
experiment. 96-well plate was coated with 10µg/ml of LEAF purified anti-mouse 
CD3 antibody (Biolegend, Ref. No 1003014) in 100µl/well of PBS at 370C for two 
hours. After incubation the plate was centrifuged (350g, 5min, 40C), the supernatant 
was removed and then it was washed once with 100µl of PBS. LEAF purified anti-
mouse CD28 antibody (Biolegend, Ref. No 102112) was added directly to the culture 
media at the concentration of 2µg/ml. Soluble antibodies were added directly to the 
culture media at the concentration of 1ug/ml for anti-CD3 and 2ug/ml for anti-CD28.  
6.16 Cell Trace Violet (CTV) labeling 
Purified total, CD4+ or CD8+ T cells were resuspended at the concentration of 107 
cells/ml in RPMI medium. CTV was resuspend in DMSO at the concentration of 
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5mM and 1µl of the CTV was added to every 1ml of cell suspension. The cells were 
incubated for 20min at 370C. After that cells were washed with culture T cells 
medium to quench any unbound die (incubated 5min with the medium at room 
temperature and centrifuged at 350g for 5min, 40C). The cells were resuspend in 
culture T cell medium and counted.  
6.17 Proliferation assay 
Generated dendritic cells were collected and centrifuged (350g, 10min, RT). The cells 
were counted using Neubauer chamber (dead cells were excluded using trypan blue). 
Dendritic cells were resuspended at the concentration of 3x105 cells/ml in RPMI 
complete media for dendritic cells. 100µl per well of cell suspension was plated in 96-
well plate. The cells were incubated over night in humidified 37oC, 5% CO2 
incubator. The next day, before addition of T cells, the plate was centrifuged at 350g, 
5min, 40C and the supernatant was removed. 
Spleens were harvested following the protocol described in section 6.5. Organ 
harvesting and processing for analysis. Total, CD4+ or CD8+ T cells were enriched 
using Cell Enrichment Kit, (EasySep, StemCell technologies) as described before 
(section 6.7. Cell enrichment procedure). The cells were labeled with CTV (Section 
6.16) and resuspended at the concentration of 2x106 cells/ml in complete RPMI media 
for T cells and 100µl of cell suspension was plated per well in 96-well plate. 
The T cells were co-cultured with dendritic cells (generation protocol described in 
Dendritic cells differentiation and culture), or stimulated with CD3 and CD28 
antibody (Plate coating and stimulation with antibodies) or PMA (phorbol 12-
myristate 13-acetate, 20ng/ml, Sigma, Ref. No P8139) and Ionomycin (500ng/ml, 
Calbiochem, Ref. No 407951) for 24-96h in humidified 37oC, 5% CO2 incubator. 
After incubation cells were centrifuged (350g, 5min, 40C) and processed following 
FACS staining protocol.  
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6.18 In vitro cytokine analysis 
For in vitro cytokine staining, the cells were processed as described in Proliferation 
assay (Chapter 6.17). Brefeldin A (10µg/ml, Calbiochem, Ref. No 203729) and anti-
LAMP1-Brilliand Violet 421 (1:50, CD107a, Biolegend, Ref. No 121617) antibody 
was added to the cell culture and the cells were incubated for: 5, 15, 30, 60 and 
120min at 370C. Afterwards, the cells were stained following intracellular FACS 
staining protocol (from Chapter 6.6) for CD3, CD4 or CD8, L/D marker, INF-g, TNF-
a and IL-2 (LAMP1 was already labeled with fluorophore).  
6.19 In vitro generation of regulatory T cells from CD4+CD25- T cells 
The experiment was done following the protocol from Natire Protocols paper (In vitro 
generation of CD4+CD25+ regulatory cells from murine naïve T cells) and the 
procedure was as described below. 6 to 8 week old mice from B6 wt and Cor1-/- mice 
were sacrifice and the spleen was harvested from each mouse following the procedure 
described in point 5 (Organ harvesting). The red cells were lysed using ACK buffer 
for 1min at room temperature. Then PBS was added to the cell suspension and the 
cells were centrifuged for 10min at 400g, 40C. The pellet was resuspended and cells 
were counted as described before. The cells were enriched for CD4+ T cells using 
StemCell Enrichment Kit (negative selection described before). As a recommended 
medium RPMI supplemented with 10% FCS was used. Afterwards the CD25+ cells 
were depleted using magnetic sorting with anti-CD25-biotin (50µg/ml cells 
Biolegend, Ref. No 102004) labeled antibodies and streptavidin-magnetic beads. The 
samples were incubated with beads for 15min at 40C and 2.5min with beads at room 
temperature. The negative fraction was kept from each sample and the cells were 
counted. 4x105 cell/well was plated in 96-well plate coated with anti-CD3 antibody 
(described before) with addition of anti-CD28 (2µg/ml), TGF-β1 (5ng/ml, R&D 
Systems, Ref. No 7666-MB) and IL-2 (20ng/ml, recombinant mouse IL-2 CF, 
Biolegend, Ref. No 575406) in X-Vivo15 serum-free medium (Lonza, Ref. No BE04-
744Q) in the absence of antibiotics. The cells were cultured in the humidified 37oC, 
5% CO2 incubator for 2 to 5 days. At the day of analysis the cells were stained as 
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described in intracellular FACS staining of cells (point 6) for L/D marker, CD3, CD8, 
CD8, CD25 and Foxp3.  
6.20 Mixed lymphocyte reaction (MLR) 
Stimulators preparation: spleen from Balb/c, bm12 or 6.25% Balb/c in BL/6 mouse 
was harvested as described before. Cells were counted and resuspended in PBS 2% 
FCS and 2mM EDTA at concentration 20x106 cells/ml. Splenocytes were depleted of 
CD3+ cells and erythrocytes by adding anti-CD3-biotin and anti-TER119-biotin 
antibodies (50µg/ml), incubating 10min at room temperature. Then streptavidin-
coated beads were added and the protocol from StemCell Enrichment Kit (EasySep, 
StemCell technologies) was followed. Obtained cells were treated with mitomycin C 
(50µg/ml, Sigma- Aldrich, Ref. No M4287-2MG) for 1h at 370C. The cells were 
washed twice with plain RPMI 1640 medium (R8758) and resuspended at the 
concentration of 8x106 cells/ml in complete RPMI media for T cells. 200µl of cells 
suspension was plated per well in 96-well plate and then serial dilution were done in 
order to get 800 000, 400 000, 200 000, 100 000, 50 000 and 25 000 cells/well.  
Responders preparation: spleens from either B6 wt or Cor1-/- mice were harvested as 
described before in PBS supplemented with 2% FCS and 2mM EDTA. The cell 
numbers were counted and cells were sorted for CD4+, CD8+ or total T cells using 
negative selection T Cell Enrichment Kit (EasySep, StemCell technologies). 
Afterwards, enriched CD4+ T cells were labeled with CTV as described above 
(Section 6.16). Washed cells were resuspended at the concentration of 1x 10^6 or 
2x10^6 cells/ml in complete RPMI media for T cells. Responder T cells were plated 
at the concentration of 1x10^5 or 2x105 cells/well. The cells were incubated in the 
humidified incubator at 370C with 5% of CO2 for 48 - 120h. 
After incubation cells were stained and analyzed with the FACS analyzer by 
acquiring every sample for 1.5min at the same speed. 
For thymidine incorporation analysis: 52h after plating the cells, thymidine 
(1υCi/well) was added and the cells were further incubated for 20 hours. The 
incorporation of radioactive label was stopped by freezing and thawing the sample at -
 	
	
Materials and Methods 
	
	 	
132	
200C and the DNA incorporated label was assessed by harvesting the lysates on a 
GF/C filters and counting with a scintillation counter (TopCount, Packard). 
6.21 In vitro suppression assays 
In vitro suppression assay followed the MLR protocol with the exceptions: - B6 Ly5.2 cells were used as stimulators - Anti-CD3 (10µg/ml) antibody was added to the culture - The cells were enriched with StemCell enrichment kit for CD4+ cells and sorted 
with FACS sorter for CD4+CD25- cells (both methods described before) - B6 wt Ly5.1 CD4+CD25- were use as responders and Cor1-/- Ly5.2 CD4+CD25- 
cells were use as suppressors. Suppressor Cor1-/- CD4+ CD25- T cells were 
added to responder cells at two concentrations: 2x105 and 4x105 cells/well.  
 
6.22 In vivo suppression assay 
Spleens from either B6 wt Ly5.1 or Cor1-/- Ly5.2 mice were harvested in PBS 
supplemented with 2% FCS and 2mM EDTA and proceed as described before. The 
cells were sorted for CD4+ T cells using negative selection CD4+ T StemCell 
Enrichment Kit as described before. Cells were counted and sorted with FACS sorted 
for CD4+CD25- cells (point 8). After sorting the cells were counted, washed and 
resuspended at the concentration of 10 x106 cells per ml in plain RPMI 1640 without 
phenol red. For the co-transfer of B6 wt (Ly5.1) CD4+CD25- with Cor1-/- (Ly5.2) 
CD4+CD25- cells were diluted 1:1. 200ul of cell suspension was injected into tail veil 
of Rag2-/- mice. All mice were sacrificed two weeks after injection and spleen and 
lymph nodes (axillary, brachial, inguinal) were analyzed by flow cytometry staining.  
6.23 Statistical analysis  
The significance in a difference between samples was assessed by multiple t test 
analysis. P value lower than 0.05 was marked as significantly different with *; p value 
lower than 0.01 as ** and p value lower than 0.001 as ***. 
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6.24 Software used 
To analyze data and write the thesis several softwares were used: - BD FACSDiva for flow cytometry acquisition and analysis - FlowJo for cell staining analysis acquired by FACS analyzer - GraphPad Prism for graph preparation and statistical calculations - Microsoft Office for writing - Adobe (Photoshop, Illustrator) – figures preparation - Zotero - bibliography 
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7 Appendix 
 
7.1 Supplementary Figures 
 
	
Supplementary Fig. 1. Major histocompatibility complexes (MHC) staining for 6.25% Balb/c in 
BL/6 mice. Blood cells were processed following the blood staining protocol, stained with anti- I-Ab, 
H2-Db, H2-Kb, I-Ad, H2-Dd and H2-Kd antibodies and analyzed with FACS. Five mice were used per 
group; the experiment was repeated two times. A. An antibody staining for Balb/c specific MHC 
complexes: I-Ad (MHC class II), H2-Dd and H2-Kd (MHC class I). B. An antibody staining for BL/6 
specific MHC complexes: I-Ab (MHC class II), H2-Db and H2-Kb (MHC class I). Each plot shows 
blood staining of five mice from Balb/c, BL/6 and 6.25% Balb/c in BL/6 for all antibodies. MHC 
molecules expressed by BL/6 are positive in BL/6 and 6.25% Balb/c in BL/6 mice strains when Balb/c 
specific MHC molecules are expressed only in Balb/c mice strains and negative in 6.25% Balb/c in 
BL/6 mice.  
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Supplementary Fig. 2. Analysis of CD8+ T cells in a mixed lymphocyte reaction (MLR) for total T 
cells from BL/6 wild type and coronin 1-deficient mice as responders and Balb/c splenocytes as 
stimulators (plated in different concentrations). Total T cells were purified as described in Materials 
and Methods (chapter 4.20). Stimulators – Balb/c splenocytes were depleted of CD3 positive cells and 
erythrocytes (with anti-CD3 and anti-TER119 antibody, respectively). The cells were treated with 
mitomycin c to eliminate background proliferation of stimulators. Then both cells were plated together, 
in numbers indicated on each graph, in 96-well plate and cultured for 48, 72, 96 and 120h. The cells 
were analyzed by FACS using the same sample volume, time and speed of acquisition. A – F. Analysis 
of CD8+ T cells proliferation in a culture of 100 000 T cells with different numbers of Balb/c 
stimulators. An asterisk always shows the significance in the difference between BL/6 wt and Cor1-/- 
sample. Each time point shows a mean of 3 replicates. B6 – BL/6 wild type; Cor1-/- - coronin 1-
deficient.
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Supplementary Fig. 3. Analysis of CD8+ T cells in a mixed lymphocyte reaction (MLR) for total T 
cells from BL/6 wild type and coronin 1-deficient mice as responders and Balb/c splenocytes as 
stimulators (plated in different concentrations). Total T cells were purified as described in Materials 
and Methods (chapter 4.20). Stimulators – Balb/c splenocytes were depleted of CD3 positive cells and 
erythrocytes (with anti-CD3 and anti-TER119 antibody, respectively). The cells were treated with 
mitomycin c to eliminate background proliferation of stimulators. Then both cells were plated together, 
in numbers indicated on each graph, in 96-well plate and cultured for 48, 72, 96 and 120h. The cells 
were analyzed by FACS using the same sample volume, time and speed of acquisition. A – F. Analysis 
of CD8+ T cells proliferation an a culture of 200 000 T cells with different numbers of Balb/c 
stimulators. An asterisk always shows the significance in the difference between BL/6 wt and Cor1-/- 
sample. Each time point shows a mean of 3 replicates. B6 – BL/6 wild type; Cor1-/- - coronin 1-
deficient. 
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Supplementary Fig. 4. CD8+ T cells from BL/6 wild type and coronin 1-deficient mice analyzed for 
cytokine secretion in a culture without (medium) and with stimulation with dendritic cells (DC), 
anti-CD3 and anti-CD28 (CD3/CD28), and PMA and ionomycin (PMA/I). A. Production of IFN-
gamma (IFNγ). B. Secretion of TNF-alpha. C. IL-2 secretion and expression of Lamp-1 (D). Dendritic 
cells were obtained from bone marrow of BL/6 wt mice after one week of culture in the presence of 
GM-CSF (as described in Materials and Methods). Then the cells were plated in 96-well plate at the 
concentration of 30 000 cells/well one day before CD8+ T cells culture started. CD8+ T cells were 
purified following the protocol. The cells were plated in 96-well plate at the concentration of 200 000 
cells/well and cultured for 5, 15, 30, 60, 120 and 300min. The cells were analyzed by FACS staining. 
Each time point shows a mean of 3 separate experiments where three individual mice were used per 
sample. 
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Supplementary Fig. 5. CD4+ T cells from BL/6 wild type and coronin 1-deficient mice analyzed for 
cytokine secretion in a culture without (medium) and with stimulation with dendritic cells (DC), 
anti-CD3 and anti-CD28 (CD3/CD28), and PMA and ionomycin (PMA/I). A. Production of IFN-
gamma (IFNγ) B. Secretion of TNF-alpha. C. IL-2 secretion and expression of Lamp-1 (D). Dendritic 
cells were obtained from bone marrow of BL/6 wt mice after one week of culture in the presence of 
GM-CSF (as described in Materials and Methods). Then the cells were plated in 96-well plate at the 
concentration of 30 000 cells/well one day before CD4+ T cells culture started. CD4+ T cells were 
purified following the protocol. The cells were plated in 96-well plate at the concentration of 200 000 
cells/well and cultured for 5, 15, 30, 60, 120 and 300min. The cells were analyzed using FACS. Each 
time point shows a mean of three individual mice used per sample. 
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Supplementary Fig. 6. Expression of different cell markers in BL/6 wild type compared to coronin 
1-deficient T cells from spleens. A. Intracellular expression of Ki67 (proliferation marker) in BL/6 wt 
and Cor1-/- CD4+ and CD8+ T cells. B. PD1 (immune exhaustion marker) expression. C. Surface 
expression of IL-7 receptor. D. Expression of CD5 (marker of strong activation of T cells). E. 
Expression of Bcl-2 (pro-survival marker). F. Surface levels of FasL on wild type compared to coronin 
1-deficient T cells. G - I. Expression of PD1, IL-7R and CD5 in different subsets of T cells. The cells 
from spleen were harvested and processed following the protocol described in Materials and Methods 
(Chapter 4.5). Then they were FACS stained as described in the protocol for surface or intracellular 
FACS staining in the Material and Methods (Chapter 4.6). Each graph shows a mean from at least one 
to three separate experiments where up to 5 individual mice were used per staining. Wt – BL/6 wild 
type; Cor1-/- - coronin 1-deficient. 
 
0
10
20
30
40
%
 K
i6
7+
 T
 c
el
ls
Ki67 spleen
wt
Cor1-/-
CD4+ T cells CD8+ T cells CD4+ T cells CD8+ T cells
0
10
20
30
40
%
 P
D
1+
 T
 c
el
ls
PD1 spleen
Cor1-/-
wt
CD4+ T cells CD8+ T cells
0
500
1000
1500
2000
M
FI
IL-7R spleen
wt
Cor1-/-
naive CD4 memory CD4
0
20
40
60
80
%
 P
D
1+
 C
D
4+
 T
 c
el
ls
PD1 spleen
Cor1-/-
wt
***
**
***
***
***
**
***
naive CD4 memory CD4
12000
14000
16000
18000
20000
22000
24000
M
FI
CD5 spleen
wt
Cor1-/-
naive CD4 memory CD4
0
500
1000
1500
2000
M
FI
IL-7R spleen
Cor1-/-
wt
**
******
**
CD4+ T cells CD8+ T cells
0
5000
10000
15000
20000
%
 C
D
5+
 T
 c
el
ls
CD5 spleen wt
Cor1-/-
*** *
CD4+ T cells CD8+ T cells
0.0
0.5
1.0
1.5
%
 F
as
L+
 T
 c
el
ls
FasL spleen
wt
Cor1-/-*
CD4+ T cells CD8+ T cells
0
2000
4000
6000
8000
M
FI
Bcl2 spleen
Cor1-/-
wt
***
A B C
D E F
G H I
 	
	
Appendix 
	
	 	
141	
	
Supplementary Fig. 7. Expression of different cell markers in BL/6 wild type compared to coronin 
1-deficient T cells from lymph nodes. A. Intracellular expression of Ki67 (proliferation marker) in 
BL/6 wt and Cor1-/- CD4+ and CD8+ T cells. B. PD1 (immune exhaustion marker) expression. C. 
Surface expression of IL-7 receptor. D. Expression of CD5 (marker of strong activation of T cells). E. 
Expression of Bcl-2 (pro-survival marker). F. Surface levels of FasL on wild type compared to coronin 
1-deficient T cells. G and H. Expression of PD1and Ki67 in different subsets of T cells. The cells from 
lymph nodes (axillary, brachial and inguinal) were harvested and processed following the protocol 
described in Materials and Methods (Chapter 4.5). Then they were FACS stained as described in the 
protocol for surface or intracellular FACS staining in the Material and Methods (Chapter 4.6). Each 
graph shows a mean from at least one to three separate experiments where up to 5 individual mice 
were used per staining. Wt – BL/6 wild type; Cor1-/- - coronin 1-deficient. 
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Supplementary Fig. 8. Expression of different cell markers in BL/6 wild type compared to coronin 
1-deficient T cells from thymus. A. Intracellular expression of Ki67 (proliferation marker) in BL/6 wt 
and Cor1-/- CD4+ and CD8+ T cells. B. PD1 (immune exhaustion marker) expression. C. Surface 
expression of IL-7 receptor. D. Expression of CD5 (marker of strong activation of T cells). E. 
Expression of Bcl-2 (pro-survival marker). F. Surface levels of FasL on wild type compared to coronin 
1-deficient T cells. G and H. Expression of PD1and Ki67 in different subsets of T cells. The cells from 
thymi were harvested and processed following the protocol described in Materials and Methods 
(Chapter 4.5). Then they were FACS stained as described in the protocol for surface or intracellular 
FACS staining in the Material and Methods (Chapter 4.6). Each graph shows a mean from at least one 
to three separate experiments where up to 5 individual mice were used per staining. Wt – BL/6 wild 
type; Cor1-/- - coronin 1-deficient. 
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Supplementary Fig. 9. CD4+Foxp3+CD25+ (regulatory T) cells in blood of BL/6 wild type and 
Cor1-/- recipients of bm12Rag2-/- skin treated or not with PC61 antibody (CD25 depletion). The 
mice were injected with 0.5mg of PC61 antibody 5 and 3 days before and 3 days after skin 
transplantation. They were bleed 6 (A) and 1 (B) day before and 7(C) days after surgery and the 
CD4+Foxp3+CD25+ T cells rates were define by antibody staining and flow cytometry analysis 
(following the protocol for Blood Staining).  
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Supplementary Fig. 10. Regulatory T cells studies. A. Suppression assay comparing Tregs from 
BL/6 wt and Cor1-/- mice. Tregs and responders were obtained from spleens after T cells negative sort 
with the STEM Cell Kit and additional FACS sorting for CD4+ CD25+ (Tregs) and CD4+CD25- 
(responders) cells. As stimulators BL6/ wt splenocytes depleted of CD4+ and CD8+ cells and treated 
with mitonycin c were used. The cells were plated in 96-well plate in different dilutions indicated on 
the graph. The cells were cultured for 72h and the proliferation was estimated by incorporation of 
thymidine. B. MLR experiment with total T cells depleted or not of CD25+ cells from BL/6 wt and 
Cor1-/- spleens. The experiment was done following the Mixed Lymphocyte Reaction protocol 
(Chapter 4.20) and the proliferation was measured by incorporation of thymidine. There was no 
statistically significant difference in proliferation between B6 wt T cells depleted and not of CD25+ 
cells as well as between Cor1-/- T cells depleted and not of CD25+ cells. However Cor1-/- samples 
(both depleted of CD25+ and not) show statistically significant difference in proliferation compared to 
B6 wt samples (depleted of CD25+ or not) for all conditions. C. MLR of Cor1-/- T cells depleted or not 
of CD25+ cells. Experiments were repeated three times and the figure shows representative results 
from one experiment. B6 wt– BL/6 wild type; Cor1-/-  - coronin 1-deficient. 
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7.2 Contribution 
 
In part, this work was done under the supervision of Beatrice Bolinger, to whom I am 
immensely grateful for sharing the project with me.  
Experiments described in Figures 18, 23A and Supplementary Fig. 10 were performed 
by Beatrice Bolinger. 
Experiments described in section 4.3 (Figure 17) and 4.5.4 (Figure 29) were 
performed with the help of Simona Rossi Girard and Mathias Schmaler. 
Repetitions of results presented in Figures 10 and 13A and B were performed by me, 
Beatrice Bolinger, Rajesh Jayachandran and Helene Rossez.  
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